Circulating progenitor cells in atrial fibrillation : Relationship to endothelial dysfunction, thrombogenesis and inflammation by Watson, Timothy J
Original Thesis for the Degree of Doctor of Medicine 
(University of Birmingham) 
 
 
CIRCULATING PROGENITOR CELLS IN ATRIAL 
FIBRILLATION: 
Relationship to endothelial dysfunction, thrombogenesis 
and inflammation. 
 
 
Dr Timothy James Watson (MRCP) 
 
November 2010 
 
Haemostasis Thrombosis and Vascular Biology Unit 
University of Birmingham Centre for Cardiovascular Sciences, 
City Hospital, 
Birmingham. B18 7QH 
 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third parties. 
The intellectual property rights of the author or third parties in respect of this work 
are as defined by The Copyright Designs and Patents Act 1988 or as modified by 
any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission of 
the copyright holder.  
 
 
 
Abstract 
 
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice 
with rapidly rising prevalence and incidence predominantly due to advancing age in 
Western populations. Of particular concern however is the strong relationship between 
AF and stroke. This relates to a number of factors, but there is an emerging body of 
evidence to suggest that AF confers a hypercoagulable state. Disruption of endothelial 
homeostasis (damage vs. repair) is thought to be central to this process. The endothelium 
appears to be damaged both by AF and various other vascular diseases (e.g. 
hypertension) that frequently co-exist with the arrhythmia, with similar disruption to 
endothelial repair (normally effected by endothelial progenitor cells). Endothelial damage 
seems to be an essential prerequisite to thrombogenesis in AF. Significantly, the 
endothelium also links a number of processes including inflammation, growth factors, the 
renin-angiotensin-aldosterone system among others, which may directly or indirectly lead 
to activation of the coagulation cascade. 
 
This thesis investigates the relationship between the temporal pattern of AF (paroxysmal, 
persistent, permanent) and established markers of endothelial dysfunction 
(vonWillebrand factor, vWf; soluble E-selectin, sEsel), angiogenesis (vascular 
Endothelial Growth Factor, VEGF), apoptosis (soluble Fas/Fas ligand, sFas/sFasL) and 
inflammation (C-reactive protein, CRP; Interleukin-6, IL-6) in AF with particular 
reference to circulating progenitor cells (CPCs) as a novel marker of endothelial 
health/angiogenesis. Additionally the impact of restoration of sinus rhythm using 
electrical cardioversion on these indices and the relevance of the AF arrhythmia burden 
in influencing these markers is investigated. 
 
In conclusion, the endothelium seems to be a central link through which all three 
components of Virchow’s triad interact in AF. This thesis finds a possible link for CPCs 
to interact with various other reported aberrancies of the hypercoagulable state in this 
process. Also reported is a modest alteration in CPC counts following restoration of sinus 
rhythm, however, only limited numbers of patients were assessed and this requires 
examination with a more in depth study. Finally, the thesis has also examined the role of 
paroxysmal AF in influencing surrogate markers of the hypercoagulable state, but failed 
to find any significant differences on the basis of the arrhythmia burden. These findings 
must however been considered in light of numerous study limitations, the most notable of 
which is limited statistical power. 
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Section I: Literature Appraisal 
1.1 Atrial Fibrillation: An Overview 
 
1.1.1 Introduction 
Atrial Fibrillation (AF) is the commonest arrhythmia encountered in clinical practice 
and is increasingly considered as an emerging health epidemic. Despite rapidly 
evolving treatment strategies, AF presents a complex management challenge to the 
physician and is now attracting substantial clinical and academic interest because of a 
strong association with substantial mortality and morbidity. Imortantly, AF And direct 
complications (primarily stroke) leads to considerable expenditure, at present 
amounting to approximately 1% of the United Kingdom National Health Service 
(NHS) expenditure1. 
 
Cross-sectional studies have shown that the prevalence and incidence of AF continues 
to surge, correlating in particular with the advancing age of Western populations. In 
those over 65, approximately 5% have AF, while in those aged over 80 years, this 
figure rises to around 10%2. For those over 40 years of age, approximately 1 in 4 will 
develop AF at some point during the remainder of their lives3, 4. 
 
This chapter provides an overview of the management of AF, with reference to 
published literature and to evidence-based clinical guidelines5, 6. 
 
1.1.2 Risk factors for AF 
Many risk factors for AF have been identified. As well as advancing age, there is a 
strong link with hypertension, ischaemic heart disease, structural/functional heart 
 15
disease, valvular heart disease and hyperadrenergic states (such as thyrotoxicosis or 
illicit drug use), to name but a few. In some patients, alcohol excess may provide an 
adequate trigger for acute AF. In fact, the array of associations with AF is enormous 
(table 1) and in part explains why a detailed knowledge of this condition is essential 
for both the generalist and specialist alike; not only will cardiologists frequently 
encounter AF, but so will colleagues in other specialties. 
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Table 1. Common risk factors for developing Atrial Fibrillation 
 
• Age 
• Male sex 
• Body mass index 
• Excess alcohol 
• Hyperthyroidism 
• Respiratory disease (e.g. chronic lung disease, carcinomatosis, pulmonary 
embolus) 
• Diabetes 
• Cardiovascular (e.g. ischaemic heart disease, hypertensive heart disease, 
valvular/structural heart disease, heart failure and cor pulmonale, intracardiac 
masses/tumours, pericardial disease, cerebrovascular disease, peripheral 
vascular disease) 
• Recent surgery 
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1.1.3 Symptoms and presentation 
The incidental finding of asymptomatic AF remains relatively common, often 
detected during medical attendance for unrelated matters, e.g. during preoperative 
assessment or simply following pulse palpation. Increasingly though, AF is diagnosed 
during investigation for symptoms such as palpitations, dyspnoea, dizziness or 
syncope. This list is by no means exhaustive and it is frequently argued that AF may 
contribute to or exacerbate numerous complaints, including lethargy, fatigue and 
anxiety. Additionally, it is important to remember that other conductive or 
atrioventricular nodal diseases may coexist with AF and in those who complain of 
syncopal episodes this should be considered as a co-diagnosis. Table 2 illustrates the 
most common symptoms reported in association with AF. 
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Table 2. Common symptoms reported in Atrial Fibrillation. 
 
• Palpitations 
• Dyspnoea 
• Poor exercise capacity 
• Dizziness/syncope 
• Fatigue 
• Anxiety 
 19
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1.1.4 Classification 
The classification of AF has been through a period of flux. Most are now agreed on a 
clinical classification system, based on the temporal patterns of AF, summarized as 
follows7: The treatment implications for each AF subtype is outlined in table 3. 
 
•Recent / Acute onset AF (i.e. within the preceding 48 hours) 
•Paroxysmal AF (bouts of AF less than 7 days duration with interceding sinus 
rhythm) 
•Persistent AF (lasting seven days or more, but potentially cardiovertable to sinus 
rhythm) 
•Permanent AF (Duration greater than 1 year or refractory to cardioversion 
attempts). 
 
Regardless of classification, the management of patients with AF should be guided by 
many considerations, including symptoms, the presence or absence of haemodynamic 
compromise, and associated co-morbidities. The (sometimes artificial) classification 
system purely gives an idea of the time course of the AF but not the ultimate clinical 
outcome, and re-emphasizes the fact that the management of AF should be guided by 
assessment of the individual patient. 
Terminology Clinical Features Arrhythmia pattern Therapeutic implications 
Initial event 
(first detected episode) 
Symptomatic 
Asymptomatic (first detected) 
Onset unknown (first detected) 
May or may not recur Antiarrhythmic therapy for prevention is not 
needed except if severe symptoms. 
Paroxysmal Spontaneous termination (<7 
days) and most often <48 hours 
Recurrent Prevention of recurrences. 
Rate control and anticoagulation if needed 
Persistent Not self terminating 
Lasting >7 days or prior 
cardioversion 
Recurrent Rate control and anticoagulation if needed and/or 
cardioversion and prophylactic antiarrhythmic 
therapy 
Permanent Not terminated 
Terminated but relapsed 
No cardioversion attempt 
Established Rate control and anticoagulation as needed 
Table 3. Treatment Implications by Temporal Pattern of Atrial Fibrillation. 
21
Adapted from Levy S et al.7 
 
 
The clinical subtypes of AF can help define the objectives of management and 
therapeutic strategies8. For example, the management objective in paroxysmal AF is 
the reduction of paroxysms and the long-term maintenance of sinus rhythm, and hence 
antiarrhythmic drugs (or increasingly non-pharmacological approaches such as 
radiofrequency ablation) are used. In persistent AF, the management objective is 
usually sinus rhythm restoration, and hence cardioversion is generally attempted at an 
appropriate point (i.e. after adequate anticoagulation). In permanent AF, the objective 
is heart rate control. This is generally achieved with antiarrhythmic drugs, however, 
non-pharmacological approaches may be required in some patients – usually where 
the support of a permanent pacemaker is required to protect from bradycardia whilst 
allowing pharmacotherapy at adequate dose to limit tachycardia. In all patients with 
AF, appropriate antithrombotic therapy use is mandatory, and is normally based on 
assessment of risk factors for stroke and thromboembolism. 
 
1.1.5 Investigation of the patient with atrial fibrillation 
As discussed, the potential causes for AF are many and the symptom profile is 
potentially complex. Thus, assessment of the patient with AF needs to be methodical. 
A thorough history taking and clinical examination are essential, as they will not only 
help alert the physician to any potential trigger for AF, but it will also help guide any 
further investigation and the treatment strategy to be pursued. 
 
A 12-lead electrocardiogram (ECG), blood investigations (including full blood count, 
electrolytes and thyroid function tests), chest X-ray and echocardiogram are essential. 
Other tests such as 24-hour (or sometimes, seven-day) Holter monitoring or exercise 
testing may be required in certain patients – often for those where a diagnosis of 
 22
paroxysmal AF is suspected but not initially apparent or to assess the AF burden as 
part of risk assessment for anticoagulation. Table 4 summarizes relevant 
investigations for AF. 
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Table 4. Investigating the patient with atrial fibrillation. 
History 
• Symptoms and severity 
• Risk factors for AF (including symptoms of thyroid disease) 
• Drugs (and alcohol) 
Examination 
• Pulse (rate is better assessed apically in AF) 
• Abnormal cardiac or respiratory findings 
12-lead electrocardiogram 
• Confirmation of rhythm 
• Rate (at rest) 
• Detection of pre-excitation arrhythmias 
• Evidence of left ventricular hypertrophy (usually secondary to hypertension or 
aortic stenosis) 
• Signs of ischaemic heart disease 
Chest X-ray 
• Screen for carcinomatosis and chronic lung disease 
Blood investigations 
• Full blood count 
• Electrolyte profile 
• Thyroid function tests 
Echocardiogram (not always necessary) 
• Structural/hypertensive/valvular heart disease 
• Left atrial size 
• Left ventricular size and function 
• Pericardium 
The following may be useful in some patients: 
Holter monitor 
• Useful to assess rate control 
• Assessment of AF burden in paroxysmal AF 
Exercise test 
• Exercise/ischaemia induced AF 
Assessment of rate control during exercise 
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1.1.6 Rate control or rhythm control 
Much of the current dilemma for the physician is deciding whether to pursue a ‘rate 
control’ or ‘rhythm control’ strategy. Theoretically, restoration of sinus rhythm in all 
patients seems ideal, as this should allow improved haemodynamics and provide 
symptom relief while potentially reducing the thromboembolic tendency and stroke 
risk. However, the trend in many patients with AF is towards recurrence (often 
asymptomatic), even if a rhythm control strategy initially succeeds. Despite the use of 
potent antiarrhythmics and an aggressive serial cardioversion strategy for early 
relapse, for example, only approximately 50% of patients remain in sinus rhythm at 
one year9. At five years, the figures are dire, with only 25% remaining free of AF9, 
bringing into question whether it is ever appropriate to stop thromboembolic 
prophylaxis even if rhythm control seemingly succeeds. 
 
This knowledge presents a dilemma. Should all patients be offered rhythm control, or 
would it be more prudent to accept that many patients will eventually succumb to 
permanent AF, and adopt a rate control strategy for all? This subject has been 
addressed by several randomized controlled trials. The largest of these, the Atrial 
Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial, 
investigated 4,060 participants with recurrent AF and one or more risk factors for 
stroke10; this trial showed no difference in the primary endpoint of overall mortality at 
five years in those randomized to rate or rhythm control strategies. Furthermore, there 
was no significant difference in the composite secondary outcome measure of death, 
disabling stroke, disabling anoxic encephalopathy, major bleeding and cardiac arrest 
between the two study arms. Notably, a rhythm control strategy was associated with a 
higher rate of hospitalisation and more frequent adverse drug reactions associated 
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with antiarrhythmic drug use. In a, post hoc, analysis, both anticoagulation use and 
sinus rhythm emerged as significant predictors of survival. However, a higher 
mortality was associated with the use of antiarrhythmic drugs which offset the 
survival advantage of being in sinus rhythm10. Nonetheless, some caution should be 
exercised before extrapolating the data from the rate control versus rhythm control 
trials to the entire AF population. This is particularly important giventhat many 
participants in the AFFIRM study were elderly and thus important degenerative 
changes within the structure of the atrial tissue may have occurred (e.g. atrial 
dilatation) limitng the potential for sinus rhythm maintenance. 
 
In this and other trials, a large proportion of patients in the rhythm control arms did 
not maintain sinus rhythm, but were continued in that arm of the trial for the 
‘intention to treat’ analysis. Most participants were older patients with risk factors for 
stroke and more than likely other comorbidities as well, or who had previous failed 
attempts at rhythm control. Crossing over from rhythm control to rate control 
treatment was also common. 
 
The United Kingdom National Institute for Health and Clinical Excellence (NICE) 
has systematically reviewed the evidence and provided guidance for which treatment 
strategy (rhythm control or rate control) is most appropriate (Table 5)5. These 
indications are not mutually exclusive, and in appropriate circumstances, the 
possibility of restoring sinus rhythm (e.g. using catheter ablation) can be considered, 
especially in symptomatic patients. Recommendations remain as guidance for 
appropriate treatment strategies for the majority of patients with AF. Some patients 
will have different requirements and will require a tailored treatment strategy. 
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Table 5. Rate or Rhythm Control for Atrial Fibrillation? 
 
A rate control strategy should be the preferred initial option in the 
following patients with persistent AF: 
• over 65 
• with coronary artery disease 
• with contraindications to antiarrhythmic drugs 
• unsuitable for cardioversion 
• without congestive heart failure. 
 
A rhythm control strategy should be the preferred initial option in 
the following patients with persistent AF: 
• symptomatic 
• younger 
• presenting for the first time with lone AF 
• AF secondary to a treated/corrected precipitant 
• congestive heart failure. 
Adapted from UK NICE guideline on AF management5. 
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1.1.7 Pharmacological Management of Atrial Fibrillation 
 
Acute atrial fibrillation 
The strategy for management of acute AF owes much to an accurate assessment of the 
patient’s haemodynamic status and cardiac stability, as well as any associated 
complications such as angina or heart failure. In patients with life-threatening 
features, emergency electrical cardioversion should always be considered, irrespective 
of duration of AF. Some patients with AF and an uncontrolled ventricular response 
develop acute decompensation with peripheral or pulmonary oedema. Although the 
rapid ventricular response clearly plays a major role, these patients often have 
underlying cardiac disease and rapid clinical improvement can be achieved by 
reducing ventricular rate. These patients may include those with recent onset AF, 
those with paroxysmal AF who present with a fast paroxysm, and those with 
previously stable persistent/permanent AF who have become tachycardic. In the latter 
group this may be due to a hyperadrenergic state (e.g. sepsis) or hypovolaemia and so 
complete assessment of the patient is mandatory. 
 
Until relatively recently, the mainstay of drug therapy for AF was the cardiac 
glycoside, digoxin (Vaughan Williams class V); however, this drug is of limited 
efficacy in the context of thyrotoxicosis, fever, perioperatively and most importantly 
during exercise11. As such, it is only in the elderly sedentary patient that digoxin 
monotherapy is likely to offer adequate rate control. A rate-limiting calcium 
antagonist (Vaughan Williams class IV) or beta-blocker (Vaughan Williams class II) 
should be tried as first line in stable patients, but where these are inappropriate (e.g. 
pulmonary oedema and hypotension), intravenous amiodarone (Vaughan Williams 
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class III) should be considered. This drug is a potent irritant and should ideally be 
administered through central venous access. In other patients, particularly those who 
are younger without any structural heart disease, it is important to consider Wolff-
Parkinson-White syndrome, as fast AF may be the initial presenting rhythm in this 
condition. Atrioventricular node blocking agents (such as diltiazem, verapamil, or 
digoxin) should not be used in this circumstanceas these may exacerbate the 
ventricular rate by accelerating conduction through the accessory pathway and could 
be dangerous. Here it would be appropriate to consider intravenous flecainide 
(Vaughan Williams class 1c) for attempting pharmacological cardioversion. This drug 
is also helpful in restoring sinus rhythm in younger patients in the absence of 
structural or ischaemic heart disease. 
 
Rate control in atrial fibrillation 
Clearly optimal cardiovascular status is best achieved by restoration of sinus rhythm; 
however, this is not always feasible or successful and in these circumstances the 
ventricular rate should be controlled to that where cardiac output is optimal and the 
patient’s symptoms are adequately controlled. It is generally accepted that a resting 
heart rate below 90 bpm is optimal, while on exertion the heart rate should not exceed 
110 bpm in the sedentary patient or ‘200 minus age’ in the ambulatory patient12. Beta-
blockers are effective at controlling ventricular rate and are increasingly being used as 
first-line agents. Beta-blockers also offer some protection against recurrence 
following successful cardioversion (be it spontaneous, pharmacological or electrical) 
and are often used as first-line prophylactic agents in paroxysmal AF. They are also 
useful in the perioperative setting, to reduce the likelihood of developing AF in those 
deemed at risk. As AF commonly coexists with ischaemic heart disease, hypertension 
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or heart failure due to systolic dysfunction, beta-blockers may also be part of the 
therapeutic management in such patients. The rate-limiting, non-dihydropyridine 
calcium channel blockers (diltiazem, verapamil) are also frequently used to optimise 
rate control in those unable to take or tolerate a betablocker. Although digoxin is no 
longer considered first line in most patients, it remains a useful adjunct in those who 
remain tachycardic at rest and can be used in combination with either a beta-blocker 
or calcium channel blockers (the so-called ‘hybrid’ approach). Despite such strategies, 
a small minority of patients continue to have poor control of ventricular rate, or in the 
case of paroxysmal AF, may suffer frequent distressing relapses. This sub-group of 
patients tend to be very symptomatic and other agents such as amiodarone are 
sometimes useful. Side effects with this drug are, however, common, particularly with 
prolonged exposure, when hepatic, ophthalmic, pulmonary, thyroid and 
dermatological complications may occur. Thus, it is important to keep these patients 
under long-term follow-up with regular assessment usually under the care of a 
cardiologist. Alternative non-pharmacological strategies may also be employed in this 
setting (see section 1.1.8). 
 
Rhythm control in atrial fibrillation 
Rhythm control aims to restore, and achieve long-term maintenance of sinus rhythm. 
Potential candidates for a rhythm control strategy are: younger patients; those with 
lone AF, or AF secondary to a corrected precipitant (e.g. alcohol); patients with 
symptoms despite optimal rate control; patients with heart failure. In persistent AF, 
cardioversion can be performed electrically or pharmacologically. Electrical 
cardioversion may be successful in 75–93% of patients, but success rate depends on 
duration of AF, left atrial size and coexisting structural heart disease13. The outcome 
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is significantly lower in patients with AF duration of more than one year. The rate of 
recurrence of AF after electrical cardioversion is high and maintenance of sinus 
rhythm may be improved by concomitant administration of antiarrhythmic drugs, such 
as amiodarone or sometimes beta-blockers. Pharmacological cardioversion can be 
achieved using a number of drugs including: disopyramide (Vaughan Williams class 
IA), flecainide and propafenone (Vaughan Williams class IC), dofetilide, ibutilide, 
sotalol and amiodarone (Vaughan Williams class III). Those most commonly 
prescribed in the UK are flecainide, sotalol and amiodarone. As with electrical 
cardioversion, earlier administration improves the chance of success, with (generally) 
little to choose between oral and intravenous administration, except speed of 
conversion. In fact, successful cardioversion is reported in up to 80% with oral 
antiarrhythmic drugs, rising only to approximately 90% with intravenous 
administration14. 
 
As relapse following cardioversion is common, antiarrhythmic drugs are used in both 
persistent and paroxysmal AF to enhance long-term maintenance of sinus rhythm. The 
class IC and III drugs are preferred to class IA drugs, in view of their better safety 
profile (table 6)15. A number of studies have demonstrated that flecainide and 
propafenone are effective for preventing recurrence of AF16-18. The effectiveness of 
flecainide is comparable to quinidine, but with fewer side effects. Propafenone is 
more effective at maintaining sinus rhythm than quinidine, and is as effective as 
sotalol. Given the relatively high risk of proarrhythmia, class IC drugs should not be 
used in patients with ischaemic heart disease or left ventricular dysfunction. All 
current class IA, IC, and III antiarrhythmic drugs have potential for significant side 
effects. Major complications include proarrhythmia and non-cardiovascular effects. 
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Most antiarrhythmic medicines prevent or terminate AF by alteration of function of 
potassium or sodium channels of atrial cells. Blocking of potassium channels prolongs 
repolarisation and the refractory period that may cause QT and QRS prolongation. QT 
prolongation with potassium-channel blockers (e.g. sotalol) may result in the life-
threatening proarrhythmia (such as torsades de pointes) in up to 5% of patients19. 
Factors known to enhance risk for development of torsades de pointes are 
hypokalaemia or hypomagnesaemia, congenitally prolonged QT intervals, 
bradycardia, congestive heart failure, female gender, and pauses associated with the 
conversion of AF to sinus rhythm. The risk of QT prolongation and torsades de 
pointes may be further increased by concomitant use of wide range of medications, 
especially ones, which interfere with the hepatic metabolism of antiarrhythmic drugs. 
It is therefore advisable that these drugs are not prescribed to patients taking other 
substances known to promote QT prolongation (such as erythromycin) and that a 12-
lead ECG be requested after starting treatment. In some, particularly in the presence 
of renal impairment, class IC drugs can turn AF into atrial flutter with 1:1 
atrioventricular nodal conduction and haemodynamic instability. For this reason, the 
concomitant use of atrioventricular nodal blocking agents, such as beta-blockers and 
rate-reducing calcium antagonists, is recommended. 
Vaughan-Willams Examples Rate Control Rhythm Control Side Effects 
Ia Quinidine 
Disopyramide 
- +++ 
Ib  - ++ 
Ic Flecainide 
Propafenone 
- +++ 
Potential for multiple side-effects across drug 
class. Most importantly is risk of pro-
arrhythmia or atrial flutter with 1:1 
conduction. Procainamide can induce lupus 
like syndrome. Side effects least with class IC 
II Atenolol 
Bisoprolol 
Sotalol 
+++ + Bradycardia; lethargy; exacerbation of asthma; 
impotence 
III Amiodarone 
Sotalol* 
++ +++ Potential for multiple side-effects with 
amiodarone (thyroid / liver / pulmonary / 
ophthalmic / neurological / dermatological. 
IV Verapamil 
Diltiazem 
+++ - Bradycardia; gum hyperplasia; pedal oedema 
V [Miscellaneous] Digoxin +++ - Gastrointestinal upset - nausea, vomiting 
     
Table 6. Pharmacological Therapy in Atrial Fibrillation by Vaughan-Williams Classification 
* Low-dose sotalol primarily has class II actions, at higher dosages, class III effects predominate. 
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1.1.8 Non-pharmacological approaches 
For those who continue to be heavily symptomatic or where antiarrhythmic drugs are 
ineffective or not tolerated, non-pharmacological options can be considered. It has 
long been recognized that the pulmonary veins appear to have a crucial role in the 
aetiology of AF20. This has led to the emergence of non-pharmacological approaches 
to AF management. 
 
Catheter approaches 
Ablation of the atrioventricular (AV) node with permanent pacemaker implantation is 
an established and effective option that ensures good rate control, alleviates symptoms 
and improves quality of life21. This technique is particularly useful in those with poor 
rate control despite multi-drug therapy. In some, AV node modification rather than 
ablation may be attempted. This technique involves preferential ablation of the 
electrical inputs to the AV node with the shortest refractory period, thereby implying 
an upper limit to ventricular rate response22. Of course, there is a significant incidence 
of complete heart block requiring subsequent pacing and also risk of AF recurrence, 
limiting the feasibility of this approach. 
 
Pulmonary vein isolation has been used as first-line management for recurrent AF, 
with impressive results. Häissaguerre et al. reported that 94% of ectopic triggers for 
AF were located in the myocardial tissue around the pulmonary veins23. Ablation of 
these foci prevented AF recurrence in 62% of patients. Unfortunately, the procedures 
remain long and arduous, and often two or more attempts are required to achieve 
long-term success. Furthermore, complications (e.g. pulmonary vein stenosis) remain 
relatively common and can occur in up to 6% of patients24. In addition, some go on to 
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have recurrent episodes of AF, which may be asymptomatic and difficult to detect 
clinically, thus making an absolute assessment of stroke risk difficult25, 26. More 
recently, Pappone et al demonstrated that robotic magnetic navigation was feasible for 
AF ablation27. This allowed circumferential pulmonary vein ablation from a remote 
operator and illustrates the potential for expansion of catheter techniques. 
 
Surgery. 
Prior to the expansion of ablation techniques, surgical procedures allowed the 
potential to offer a ‘cure’ for recurrent AF. The ‘corridor’ procedure, introduced in 
1985, involves surgical isolation of the atrial-free walls from the septum through a 
series of sutures28. In the remaining corridor, a conduction pathway between the sinus 
and AV nodes is maintained. Unfortunately, later development of other atrial 
arrhythmias was common and affected up to 27% after five years29. Subsequent work 
by Cox et al. led to the development of the ‘maze’ procedure which involves a series 
of incisions within the atria with subsequent fibrosis, thereby creating lines of 
conduction block30. This later evolved into the Maze-III operation, which involves 
excision of the left and right atrial appendages, isolation of the pulmonary veins and 
several additional incisions to prevent atrial re-entry. This is now the surgical 
procedure of choice for medically refractory AF. However, because of the 
requirement for an invasive approach, these techniques are probably best reserved for 
those undergoing thoracotomy for other reasons, for example, those requiring 
coronary artery bypass grafting or valve surgery. 
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1.1.9 Antithrombotic therapy 
The presence of AF increases the risk of stroke by up to five-fold across all age 
groups; indeed, AF accounts for up to 10–15% of all ischaemic strokes31. This 
association continues to strengthen with age and in those over 80, AF accounts for 
nearly 35% of strokes, especially in the presence of comorbidities31. Of greater 
concern is that those with AF who have a stroke have a significantly worse outcome 
in terms of both morbidity and mortality. 
 
Warfarin vs. placebo 
6 randomized trials (n=2,900 participants) have assessed the efficacy of warfarin vs. 
placebo or no treatment. Meta-analysis of this data demonstrated that adjusted-dose 
warfarin offered a significant reduction in risk of ischaemic stroke or systemic 
embolism (67%, 95% CI 54 to 77%)32. As expected, the absolute risk reduction for all 
stroke was far greater for secondary prevention (8.4% per year, number needed to 
treat (NNT) for one year to prevent one stroke 12) when compared with primary 
prevention (2.7% per year, NNT=37)32. A target INR (international normalized ratio) 
of 2.0–2.5 should be maintained in most patients, as the risk of stroke increases two-
fold in those with INR 1.5–2.0, and is even higher with INRs <1.533. 
 
Antiplatelet therapy vs. placebo 
Eight trials (n=4,876 participants) have investigated the efficacy of antiplatelet 
therapy compared to placebo of which seven (n=3,990 participants) specifically 
investigated aspirin (at various dosages). Meta-analysis of this data reveals that 
aspirin confers only a modest reduction in stroke compared to placebo of around 19% 
(95% CI -1 to 35%)32. This figure is similar to that seen for stroke reduction with 
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antiplatelet therapy for patients with vascular disease in sinus rhythm, and thus the 
aspirin effect may simply reflect this. In fact, much of the evidence supporting the use 
of aspirin for stroke prevention in AF stems from the Stroke Prevention in Atrial 
Fibrillation (SPAF I clinical trial, where inconsistencies in the randomization process 
are evident34. Notably patients eligible to receive anticoagulants (arm I) were 
randomized to warfarin, aspirin or placebo whereas those deemed ineligible for 
anticoagulants (based on safety grounds or patient preference) received either aspirin 
or placebo (arm II). By pooling data from both groups, the trialists were able to report 
a headline 42% stroke risk reduction with aspirin vs. placebo, although analysis of 
data from arm II alone revealed only a modest 8% reduction. 
 
Warfarin vs. Antiplatelet agents 
12 trials (n=11,748 participants) have compared adjusted-dose warfarin to antiplatelet 
therapy (predominantly aspirin and at varying dosages). Meta-analysis of pooled data 
from these trials demonstrates that adjusted-dose warfarin is associated with a 37% 
(95% CI 23 to 48%) reduction in stroke32. Combination of antiplatelet agents (e.g. 
aspirin plus clopidogrel), although of some benefit compared to aspirin alone, is also 
inferior to warfarin for stroke prevention35. 
 
The benefits of anticoagulation are further underlined in a recent Cochrane review of 
antithrombotic therapy in AF, which concluded that aspirin only provided a modest 
reduction in stroke risk, at best approaching 25% compared to no treatment, whereas 
adjusted-dose warfarin reduced risk of stroke by about one third when compared to 
antiplatelet therapy36. Thus, antiplatelet agents should therefore be considered an 
inferior substitute in terms of stroke prevention among high-risk subjects with AF. 
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 Despite the evidence, there is a tendency for physicians to shy away from prescribing 
anticoagulation – the main concern being that of significant haemorrhage. In 
particular, anticoagulation is less likely to be offered to the elderly and those with a 
history of falls, recent history of bleeding, or poor compliance. Each of these patient 
factors is more common in the elderly, but it is this very patient group that is also at 
the highest risk from thromboembolic events. The recent Birmingham Atrial 
Fibrillation Treatment of the Aged (BAFTA) study has been able in part to address 
this very issue37. In agreement with other AF anticoagulation trials, this study again 
demonstrated the superior efficacy of warfarin over aspirin for stroke prevention. The 
focus in this trial however, was the over 75s (mean age 81·5 years, SD 4·2) and it is 
notable the observed stroke risk reduction was not at the expense of excess 
haemorrhagic stroke or major bleeding events. Thereby providing at least some 
reassurance that age alone should not be a bar to anticoagulation prescription. 
However, one important caveat is that entry to this trial was General Practionar 
assessment that warfarin would not be unsafe and thus caution should be exercised in 
extrapolating this data to the broader population. 
 
Some further reassurance is provided by new data from the AnTicoagulation and Risk 
Factors In Atrial Fibrillation (ATRIA) study where the net clinical benefit of warfarin 
anticoagulation (i.e. the rate of ischaemic stroke / systemic embolus prevention whilst 
also accounting for harm due warfarin in relation to excess haemorrhagic stroke) was 
assessed38. The investigators report an overall net benefit of warfarin for the overall 
cohort of 0.68% per annum (95% CI, 0.34% to 0.87%). The net benefit was greater 
still when assessing subgroups of advancing age and higher untreated stroke risk. The 
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criteria for calculation of net benefit were not simple and based upon calculation of 
benefit/harm using a complex algorithm which again is unlikely to be applicable 
outside the setting of a clinical trial. 
 
The requirement for regular therapeutic monitoring, lifestyle restrictions (especially 
alcohol and various foodstuffs) and compliance all play a role in the decision whether 
or not to anticoagulate. Of note, up to 40% of patients would prefer not to receive 
warfarin39 and thus may pressurize the doctor advocating the (often inappropriate) use 
of aspirin, however many patients see a moderate–severe stroke as a fate worse than 
death40. Indeed, the importance of compliance should be stressed to each patient, as an 
erratic INR leads to an excessive risk of bleeding events. Furthermore, a 10% increase 
in time out of the therapeutic INR range can be associated with an increased risk of 
mortality, ischaemic stroke and hospitalisation among those patients anticoagulated 
for AF41. 
 
Other important considerations relate to the onset of AF. In fact, there appears to be a 
clustering of embolic events around the time of AF onset in some patients and 
therefore a decision regarding anticoagulation should not be excessively delayed. In 
addition, the greater application of percutaneous coronary intervention (PCI) for 
ischaemic heart disease has led to debate regarding the optimal choice for 
anticoagulation in this setting and indeed, many patients with AF have co-existing 
coronary artery disease. 
 
For PCI, generally aspirin and clopidogrel are recommended, to reduce the risk of 
stent thrombosis, however, the efficacy of these drugs for stroke prevention in AF is 
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questionable, while triple therapy with aspirin, clopidogrel, and warfarin is associated 
with more bleeding events42. Various suggestions regarding treatment have been 
made, however these are based upon assumptions regarding risk of stroke and 
subsequent cardiac events. It is clear that for this common clinical scenario, guidelines 
formulated from evidence based on clinical trials are urgently required. 
 
A number of novel anticoagulants are under development or being assessed in clinical 
trials. Much interest has been focused on the potential for factor Xa and direct 
thrombin inhibition. The recently reported Randomized Evaluation of Long-Term 
Anticoagulation Therapy (RELY) trial investigated the efficacy of dabigatran – a 
direct thrombin inhibitor – in comparison to open-label warfarin43. The trial reports 
that dabigatran 110mg b.d. was associated with rates of stroke and systemic embolism 
similar to those seen with warfarin but with a lower rate of major haemorrhage. At a 
higher dose of 150mg b.d., dabigatran was associated with a lower stroke and 
systemic embolism rate than warfarin, with similar rate of major haemorrhage. This 
trial was a non-inferiority study and although therefore it cannot be claimed that 
dabigatran is more efficacious than warfarin, the results are very encouraging. It is 
hoped that with the evolution of safe efficacious drugs that do not require regular 
therapeutic monitoring, the stranglehold of warfarin on the anticoagulation market in 
AF may soon be at an end. In theory, this may encourage more appropriate 
prescribing. 
 
Numerous risk stratification schema have been proposed in an effort to identify high-
risk patients with AF who should be targeted for anticoagulation – some derived 
directly from event rate analyses, others based on expert consensus. None of the 
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published schemes are ideal, with marked variability in terms of both complexity and 
patient categorisation as low-, medium-, or high-risk leading to inconsistencies in 
recommendations for thromboprohylaxis. Almost all schema include previous stroke 
or TIA, age, hypertension and diabetes mellitus as consistent independent clinical 
predictors for stroke44. It is recognized that AF commonly associates with other risk 
factors for stroke and investigators have proposed combining these to form a scoring 
system. For example, in the CHADS2 scoring system, one point is assigned for the 
presence of congestive heart failure, hypertension, age >75 years and diabetes 
mellitus, while two points are assigned for a history of stroke or transient ischaemic 
attack. The stroke risk per 100 patient years in this schema increased by a factor of 1.5 
for each one-point increase in the score, highlighting the importance of accurate risk 
stratification45. Whilst no direct comparison of the predictive accuracy of all available 
schema is available, it is also recognized that the usefulness of a particular score 
relates to the composition of the patient cohort to which it is applied – i.e. the 
proportion of elderly patients with multiple risk factors when compared to younger 
patients with fewer risk factors and to the ratio of primary to secondary prevention. In 
the UK, the current NICE guideline favours a more practical and pragmatic algorithm-
based risk stratification approach, which is shown in figure 1. The CHADS2 score and 
NICE risk stratification schema (the latter based on the Birmingham risk stratification 
schema31) have a similar predictive value for stroke and vascular events, when tested 
in a prospective cohort of AF patients. 
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Figure 1. UK Practical guidelines for antithrombotic therapy in non-valvular 
AF. 
 
(1) The risk factors are not mutually exclusive, and are additive to each other in 
producing a composite risk. Since the incidence of stroke and thromboembolic events 
in patients with thyrotoxicosis appears similar to other aetiologies of atrial fibrillation 
(AF), antithrombotic treatments should be chosen based on the presence of validated 
stroke risk factors. (2) Owing to lack of sufficient clear-cut evidence, treatment may 
be decided on an individual basis, and the physician must balance the risk and benefits 
of warfarin versus aspirin. As stroke risk factors are cumulative, warfarin may, for 
example, be used in the presence of two or more risk factors. Referral and 
echocardiography may help in cases of uncertainty. *Coronary artery disease or 
peripheral artery disease. **An echocardiogram is not needed for routine assessment, 
but refines clinical risk stratification in the case of moderate or severe left ventricular 
dysfunction and valve disease. INR = international normalized ratio; TIA = transient 
ischaemic attack. Adapted from UK NICE guideline on AF management5 
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1.1.10 Data Appraisal 
Much of the data presented in this chapter regarding the epidemiology of AF and the 
strong assosciation with stroke has been derived from highly regarded studies. 
Although some relevant publications are now historical, the populations concerned 
remain under active follow-up and close scrutiny. Importantly more contemporary 
data is also available and has broadly reiterated previous findings. 
 
Guidelines for the management of AF have been formulated by consensus expert 
opinion following review of the available literature. Studies considered have been of 
variable design and quality and thus it is not always easy to make straightforward 
comparisons between treatment strategies. For example, data concerning the safety of 
class I antiarrhythmic drugs has been extrapolated from investigation of these drugs in 
other settings. Similarly, inconsistent study design has also led to some controvery as 
to the true value of aspirin for thromboprophylaxis in AF, whereas the efficacy of 
warfarin is less contentious. Further evidence of disparity in the literature is evident 
with consideration of the various stroke rosk stratification models that are currently 
available. 
 
Finally, the role of catheter ablation for AF will continue to evolve – particularly with 
enhanced techniques and equipment and also with improved operator availability. 
Thus the available contemporary data may not truly reflect current clinical practice 
and merits further exploration particularly as these techniques may have some impact 
in patient selection regarding rate vs. rhythm control 
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1.1.11 Summary 
AF is a common arrhythmia, with increasing frequency of diagnosis – both in 
asymptomatic and symptomatic patients. The are numerous risk factors and co-
morbidities which associate with AF, in particular advancing age, hypertension, 
ischaemic heart disease, diabetes mellitus and heart failure. Importantly each of these 
also enhances risk of stroke and all are more frequent in a population advancing in 
age. Thus the burden of AF on healthcare systems is rising – both in relation to the 
arrhythmia itself and due to direct complications (e.g. stroke). 
 
The mechanisms that enhance stroke risk in AF are complex and remain poorly 
understood and thus merit in depth exploration in chapter 1.2. 
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1.2 Mechanisms of Thrombogenesis in Atrial Fibrillation 
 
1.2.1 Introduction 
The association between atrial fibrillation (AF) and the risk of stroke and 
thromboembolism has long been recognized and has already been described in section 
1.1. However, the pathogenesis of thrombus formation (thrombogenesis) in AF is 
multi-factorial and is not only related to stasis in a poorly contractile left atrium (LA). 
Indeed, there is an increasing body of evidence to support the presence of a 
‘prothrombotic’ or ‘hypercoagulable’ state in AF46. 
 
1.2.2 Virchow’s Triad for Thrombogenesis 
Over 150 years ago, Rudolf Virchow proposed a triad of events needed for thrombus 
formation - i.e. abnormal changes of the vessel wall, blood flow, and blood 
constituents47. In the 21st century, we now recognize Virchow’s triad as: endothelial 
or endocardial damage or dysfunction (and related structural abnormalities); abnormal 
blood stasis; and abnormal haemostasis, platelets, and fibrinolysis. Extensive 
alterations in these variables are clearly evident in AF. Thus, AF could, in fact, drive a 
prothrombotic or hypercoagulable state, by virtue of its fulfillment of Virchow’s triad 
for thrombogenesis48. 
 
1.2.3 Anatomical and Structural Considerations 
Attached to each atria is a blind-ended passage known as an appendage. The left atrial 
appendage (LAA) is long with a narrow inlet, thereby predisposing to blood stasis. 
Thus, the LAA is the most common site of intra-atrial thrombus formation, not only in 
AF, but also in patients in sinus rhythm49, 50. Changes in the dimensions of the LA and 
LAA occur as a consequence of AF, with some correlation to subsequent 
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thromboembolism. Detailed descriptions of endothelial damage in the context of AF 
are well described and can be visualized by scanning electron microscopy, especially 
within the appendages. Goldsmith et al. reported more severe endocardial changes in 
the LAA than in the right-atrial appendage51 especially in subjects in AF (compared 
with sinus rhythm) and in mitral stenosis (compared with mitral regurgitation). This 
data seems to be very reproducible and Masawa et al. later described a ’rough 
endocardium’ with a wrinkled appearance attributable to oedema and fibrinous 
transformation; small areas of endothelial denudation and thrombotic aggregation 
have also been noted in patients with AF and cerebral embolism52. However, the 
populations analyzed in these two studies were clearly highly selected in that they 
were undergoing cardio-pulmonary bypass – often for valvular heart disease. 
 
However, subsequent work has confirmed that these changes are present, even in 
those without valvular heart disease53. Other changes, including myocytic hypertrophy 
or necrosis and a mononuclear cell infiltrate, are also evident54. These structural 
changes (with or without electrical changes) could explain the delay in return of atrial 
(mechanical) systole after successful cardioversion55, 56. The occurrence of such 
cardiac stunning highlights the importance of adequate anticoagulation even after 
successful restoration of sinus rhythm57. 
 
Not all structural changes in AF are cardiac. Complex aortic plaque identified by 
transoesophageal echocardiography (TOE) is common and occurs in up to 57% of 
patients with AF, of whom about 25% have complex plaque (i.e., thicker than 4 mm 
and with ulceration, pedunculation, or mobile elements)58. Oddly, the presence of 
complex plaque on the descending (rather than ascending) aorta is a risk factor for 
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stroke59. Thus it is likely that aortic plaque simply aids identification of patients who 
are at high stroke risk by virtue of the presence of associated vascular risk factors or 
atherothrombotic disease, in addition to AF. 
 
Altered extracellular matrix turnover could also be implicated in the structural 
changes associated with AF. The extracellular matrix provides support scaffolding for 
myocytes, maintaining the structural and geometrical integrity of the heart60. 
Disruption of the extracellular matrix therefore, has the potential not only to result in 
conduction defects (perpetuating AF), but also to induce fibrosis and infiltration of the 
endocardium, and thereby promote thrombogenesis by activation of the coagulation 
cascade. Several studies have shown that patients with AF have altered amounts of 
collagen degradation products and impaired matrix degradation, with abnormal 
plasma concentrations of various matrix metalloproteinases (MMPs), their inhibitors 
(tissue inhibitor of MMPs (TIMPs), and various growth factors (e.g., transforming 
growth factor β1) reported61-63. These proteins are important in the breakdown of 
various collagens and hence their regulation is key to ensuring healthy matrix 
turnover. Evidence suggests that abnormal changes in the extracellular matrix are not 
related to the presence of AF itself, but are probably a consequence of various 
coexisting co-morbidities (e.g. hypertension). Nevertheless, MMPs and TIMPs could 
have a link with the prothrombotic state, as exemplified by a correlation with 
prothrombin fragments 1 and 2, markers of thrombogenesis62. Further studies have 
identified disruption of other extracellular matrix components, although most have 
focused on these factors as a cause for the arrhythmia or explanation for remodeling 
and chamber dilatation64-67. One study suggested that some of the changes in MMPs 
were due to concomitant mitral valve disease66, whereas another reported changes in 
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the ventricular myocardium, albeit to a lesser extent67. Similarly, in patients with 
ventricular dysfunction (a potent risk factor for AF), various studies have also shown 
striking atrial structural changes68, 69. This may relate to diastolic dysfunction or to 
back pressure through functional mitral regurgitation. 
 
1.2.4 Abnormal Blood Stasis 
In addition to stasis consequent on the failure of atrial systole, the presence of non-
valvular AF seems to promote progressive left atrial (LA) dilatation70, thus further 
amplifying the potential for stasis. In the presence of mitral stenosis, LA dilatation is 
increased and leads to further stasis and propensity to thrombosis71. The contribution 
of LA dilatation to thrombogenesis (at least, in non-valvular AF) is indicated by the 
finding that atrial size corrected for body surface area is an independent risk factor for 
stroke 72, 73. Valvular heart disease is also an important contributory factor to 
thrombogenesis in AF and cannot be ignored. In mitral stenosis, up to 75% of patients 
with cerebral emboli on computed tomography or autopsy are identified to have AF, 
presumably due to alterations in LA emptying and transmitral flow74. However, this 
data must be interpreted with caution given that ‘stroke’ was defined on the basis of 
radiological, rather than clinical findings. In contrast to this, moderate to severe (non-
rheumatic) mitral regurgitation seems to reduce the risk of stroke with AF75. Defining 
patients with AF and mitral valve disease who are at the greatest risk of stroke has 
proved complex. The risk of emboli increases with age and in individuals with a lower 
cardiac index (a measure of cardiac output corrected for body surface area), but seems 
to correlate poorly with clinical classification or mitral valve area. Studies assessing 
the degree of LA dilatation have also proven inconsistent. However, an initial embolic 
event is highly predictive for subsequent or recurrent thromboemboli76. 
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Abnormal stasis in the LA and LAA can be visualized on TOE with spontaneous echo 
contrast (SEC) or pulsed-wave Doppler during paroxysms of AF50, 77-79. In sinus 
rhythm, a quadriphasic pattern of blood flow can be seen in the LAA, affording 
minimal blood stasis80. This pattern of blood flow is thought to be related to the 
intimate, yet slightly delayed, relationship between atrial and ventricular passive and 
active filling. In AF, SEC has been shown to independently predict increased risk of 
thromboembolism59. SEC is thought to be related to increased interaction between 
fibrinogen and erythrocytes and seems to relate to the relative concentrations of each, 
with more fibrinogen needed to induce the same effect at lower haematocrits81-83. 
Since some patients with AF can be intravascularly deplete (for example, as a result of 
co-prescription of diuretics), this finding could contribute to the increased stroke rate 
seen in this patient population84. Crucially, SEC is also highly dependent on flow rate 
and thus more likely to occur in patients predisposed to stasis and in AF, can also be 
seen after restoration of sinus rhythm and can still occur in up to 37% of this cohort at 
3 months85. With additional stroke risk factors, this proportion is higher still, 
illustrating the need for continuing anticoagulation despite apparent maintenance of 
sinus rhythm. This data again must be interpreted with some caution, as SEC is highly 
operator dependent and as with a number of other echocardiographic phenomena, may 
have become more notable with improved resolution available with modern digital 
equipment. 
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1.2.5 Abnormal Blood Constituents 
The main intravascular promoters of thrombogenesis are platelets and the various 
proteins of the coagulation cascade. In AF, abnormal changes in all these parameters 
and numerous other blood constituents (e.g. inflammatory cytokines, growth factors) 
are evident, thereby completing Virchow’s triad. 
 
Abnormal changes in coagulation 
Abnormal haemostasis and coagulation are well described in AF (figure 2 and table 
7). In particular, increased fibrin turnover has been reported in patients with acute 
onset or chronic AF86-92. These changes initially seemed to be unrelated to the cause 
of AF or structural heart disease91, 92. However, abnormal concentrations of 
prothrombotic indices (e.g., prothrombin fragments 1 and 2 and thrombin-
antithrombin complexes) are more prominent in patients with stroke who have AF 
than in those who have sinus rhythm93, as well as in patients with AF and many stroke 
risk factors (e.g., diabetes plus heart failure) compared with either risk factor alone94-
96. Furthermore, some prothrombotic indices are abnormal in the patients with AF 
only97, 98 and in those with paroxysmal AF99 in the absence of detectable risk factors. 
The data for some markers has been considered reasonable robust and they have been 
proposed as suitable candidates to refine various stroke risk stratification schema, 
many of which are reasonably able to identify patients at low risk or high risk of 
stroke, but poor at identifying patients at moderate risk100. 
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Figure 2 Components of Virchow’s triad for thrombogenesis in AF 
 
 
 
Abnormal changes shown in the vessel wall (e.g. atrial tissue changes, endothelial 
damage and dysfunction), in flow (e.g. stasis in the left atrial appendage), and in 
blood constituents (e.g. haemoconcentration, platelets, coagulation cascade activation, 
inflammation); all factors contribute to propensity for thrombus formation 
(thrombogenesis) in atrial fibrillation. vWf=von Willebrand factor. 
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An association between various prothrombotic indices, stasis, and intra-cardiac 
thrombus has been described101, 102. In one study, congestive cardiac failure, a history 
of recent embolus, and fibrin D-dimer were both shown to independently predict the 
presence of LAA thrombi on TOE, leading the researchers to conclude that D-dimer 
could be useful in predicting the absence of LAA thrombi102. This is of potential 
importance when considering whether to offer cardioversion for recent onset AF in 
the absence of therapeutic anticoagulation. However, this has not been translated into 
a change in clinical practice – perhaps reflecting the relatively small size of this study. 
 
The prothrombotic state also correlates with the degree of LAA dysfunction 103, 104. 
Furthermore, a relation to TOE indices of stroke risk has been described. For 
example, SEC that is visible during TOE shows a significant correlation to 
prothrombin fragments 1 and 2, fibrinopeptide A, and thrombin-antithrombin III 
complex in non-valvular AF105, 106. Patients with atrial flutter and impaired LAA 
function (shown by pulsed-wave Doppler) have increased amounts of D-dimer and β-
thromboglobulin106. In accordance with clinical data suggesting that mitral 
regurgitation protects against stroke in AF, a greater degree of mitral regurgitation is 
associated with reduced coagulation activity as estimated by fibrin D-dimer 
amounts107, again highlighting the important contribution of stasis. Again, such 
echocardiographic parameters are notoriously operator dependent (see above). 
Additonally, echocardiographic assessment of the severity of mitral regurgitation can 
also depend on many factors including heart rate, blood pressure and intravascular 
volume etc. Thus the correlations observed here may not be as robust if applied to 
other populations or by other researchers. 
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Anticoagulant treatment has been shown to reduce concentrations of some 
prothrombotic markers 92, 108, 109. This finding is true even with low-intensity 
anticoagulation (international normalized ratio [INR] 1·5–1·9), which has been shown 
to suppress prothombin fragments 1 and 2 and D-dimer110. Notably, some indices of 
hypercoagulability could be useful in investigating the efficacy of antithrombotic 
treatment for AF. For example, the Atrial Fibrillation, Aspirin, AntiCoagulation 
(AFASAK-2) substudy reported that only dose-adjusted warfarin (INR 2–3) had an 
effect on the amounts of prothrombin fragments 1 and 2 after 3 months of treatment. 
Fixed low-dose warfarin, combined low-dose warfarin and aspirin, or aspirin alone 
had little effect111. Similarly, fixed low-dose warfarin or aspirin-warfarin combination 
treatment did not substantially reduce other markers of thrombogenesis in AF, 
whereas dose-adjusted warfarin did112. Additionally, warfarin greatly decreased 
plasma concentrations of coagulation factor-related prothrombotic indices (more so 
than platelet-related indices), which implies that activation of the coagulation cascade, 
rather than platelets, is key to the excess thromboembolic risk in AF113, 114. These 
findings should come as little surprise and are consistent with reports that warfarin (as 
a modulator of the coagulation cascade) is more efficacious than aspirin (a platelet 
inhibitor) in thromboembolic prophylaxis in AF (section 1.1.9). 
 
In chronic AF, D-dimer amounts remain in broadly the same range over time and 
seem to be a useful parameter for assessing the degree of hypercoagulability 
irrespective of patient age87. Combined with clinical risk factors, D-dimer has also 
been shown to predict subsequent thromboembolic events in patients with non-
valvular AF, including those already receiving treatment with warfarin115-117. The 
application of D-dimer seemed to be especially important in patients without 
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conventional risk factors for stroke (e.g., age, cardiomyopathy, previous stroke), 
where a low D-dimer implied a low risk of stroke (0.7% per year). Conversely, in the 
same patient group, the stroke rate rose to 3.8% per year when D-dimer was elevated. 
In patients with clinical risk factors for stroke, the event rate was less than 5% per 
annum, irrespective of D-dimer concentration. In another study of patients with 
chronic AF, both D-dimer and age were important predictors of mortality. High 
amounts of D-dimer during treatment with oral anticoagulants was also a predictor of 
combined cardiovascular events115. Thus, D-dimer could be useful as a screening 
method to identify those patients with AF at low risk of intra-cardiac thrombus who 
can then be safely cardioverted without anticoagulation. Notably, Somlói et al. have 
suggested that D-dimer measurements compare favourably with the use of a TOE-
guided strategy with a negative predictive value of 98%118. However, discrepancies 
between these small studies have limited application of this strategy in clinical 
practice. 
 
von Willebrand factor (vWf) 
Further insight into the hypercoagulable state in AF is provided by studies of vWf, 
which is a well-established index of endothelial damage and dysfunction. Raised vWf 
concentrations independently predict presence of LAA thrombus in AF101. 
Furthermore, increased LAA endocardial expression of vWf has been described119, 
especially in those with an overloaded appendage, which seems to correlate with the 
presence of adherent platelet thrombus. Furthermore, increased expression of vWf in 
the endocardium has been shown to associate with enlarged LA dimensions in mitral 
valve disease and increased myocyte diameter120. Both vWf and tissue factor are over-
expressed in the atrial endothelium in patients with AF who have a history of 
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cardiogenic thromboembolism—specifically in the endothelial sites containing 
inflammatory cells and denuded endocardium, which indicate features of persistent 
myocarditis121. 
 
Plasma vWf and D-dimer are also positively correlated in patients receiving either 
aspirin or no antithrombotic treatment, but not in those receiving warfarin92, further 
indicating the ability of warfarin to modulate the thrombogenic process. Furthermore, 
a positive association between AF and plasma vWf was seen in the Rotterdam 
study122. This relation was most apparent in female patients, which could explain the 
excess risk of stroke due to AF in women compared with men. Furthermore, plasma 
vWf amounts were associated with the presence of four independent risk factors for 
stroke (heart failure, previous stroke, age, and diabetes) and stroke risk stratification 
schema123, 124. Follow-up data from this study suggests that vWf concentrations might 
independently predict subsequent stroke and vascular events124, 125. However, such 
applications will probably be hampered by the non-specificity of vWf, concentrations 
of which are also increased in various other disorders 126, 127. Many of the studies 
investigating vWf have been of substantial size and the data is broadly consistent and 
generally considered robust. Some smaller studies studies have been contradictory and 
further discussion is reserved for later in this thesis (section 4.1.5). 
 
Abnormal changes in fibrinolysis 
Few studies have focused on fibrinolytic function in atrial fibrillation. Enhanced 
fibrinolysis, shown by increased concentrations of tissue-plaminogen activator (t-PA) 
antigen and t-PA inhibitor (PAI)-1 and reduced amounts of plasmin-antiplasmin 
complex can be attributable to a pathophysiological response to the prothrombotic 
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state128, 129. However, the available data are not consistent and conflicting results have 
also been reported88. In the Stroke Prevention in Atrial Fibrillation (SPAF) III study, 
increased concentrations of plasmin-antiplasmin complexes were independently 
associated with thromboembolic risk factors such as older age (>75 years), recent 
congestive heart failure, decreased fractional shortening, and recent onset of AF130. A 
significant correlation can be also shown between t-PA amounts and left-atrial 
diameter in AF88. Predictably, anticoagulation leads to some improvement in 
fibrinolytic markers in rheumatic AF131. Increased amounts of t-PA and PAI-1 can 
indicate the coexistence of confounders, such as hypertension, heart failure, or 
ischaemic heart disease, all of which can cause endothelial dysfunction, damage, and 
inflammation. However, studies in patients with AF only confirm that presence of the 
disorder does modulate these markers88, 131. Thus, the high amounts of t-PA and PAI-1 
in AF could be a consequence of endothelial damage and dysfunction or represent 
systemic inflammation132, 133. Lower PAI-1 concentrations are also predictive of 
successful cardioversion134, and are independent predictors of the development of AF 
after cardiopulmonary bypass135. 
 
It is unclear whether increased amounts of t-PA or PAI-1 in AF are due to endothelial 
dysfunction, inflammation, fibrinolysis, or vascular disease, or a combination as none 
of these studies has been large enough or broad enough to fully address the impact of 
confounding variables. Nevertheless, abnormal changes in the fibrinolytic system 
might relate not only to thrombogenesis but also to structural remodeling of the atria, 
in view of the strong links to extracellular matrix turnover. 
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Platelets 
Many studies indicate a potential role for platelets in the hypercoagulable state (table 
8). However, the results of the majority of these studies have been conflicting, 
representing the diverse aspects of platelet physiology that have been measured. 
Additional limitations that apply to all platelet studies relate directly to the various 
assays available, each of which allows for assessment of diverse aspects of platelet 
function and (patho) physiology and thereby demonstrate little agreement. 
Nonetheless, the available data support the notion that abnormal changes of platelets 
in AF do exist, but the relation between these measures and increased thrombotic risk 
remains uncertain, and many of such abnormal changes could simply indicate 
underlying vascular co-morbidities. 
 
For example, Choudhury and colleagues136 recently showed that patients with AF had 
far higher amounts of platelet microparticles and soluble P-selectin than healthy 
controls in sinus rhythm, but no difference was seen between patients with AF and 
disease-matched controls, implying that the abnormal changes detected were a 
consequence of the underlying co-morbidities rather than AF itself. Increased amounts 
of β-thromboglobulin, a platelet-specific protein that indicates platelet activation and 
is released from α-granules during platelet aggregation and subsequent thrombus 
formation, have been shown in patients with both valvular and non-valvular AF 
compared with controls in sinus rhythm84, 104, 114, 137-140. Substantially higher β-
thromboglobulin amounts have been measured in patients with the lowest LAA flow 
velocities, who had greater left-atrial dimensions104 suggesting that platelet activation 
could be enhanced in patients with a greater degree of intra-atrial stasis. Notably, 
antithrombotic treatment modulates only some of these abnormal changes, and 
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Kamath and co-workers did not show a beneficial effect of warfarin on plasma β-
thromboglobulin concentrations113. In the same study, in vitro measures of platelet 
aggregation were not significantly increased in AF, once again questioning the 
importance of platelets in enhancing the thrombogenic tendency in this setting. 
 
In other studies, oral anticoagulation also did not reduce platelet activation in AF, 
despite pronounced inhibition of other coagulation variables141, 142. By contrast, 
aspirin reduced concentrations of soluble P-selectin compared with warfarin in AF143. 
Notably, some patients given aspirin 325 mg per day still do not show complete 
inhibition of platelet aggregation, whereas others have hyper-aggregable platelets144. 
In view of recent interest in aspirin resistance, these findings raise the possibility of 
platelet-dependent mechanisms for aspirin and warfarin failure to prevent stroke in 
patients with AF. 
 
Although combined antiplatelet treatment with aspirin and clopidogrel is more 
effective than aspirin monotherapy in inhibiting platelet function145, this strategy does 
not substantially modulate the various markers of the coagulation cascade (e.g. 
platelet-dependent thrombin generation, antithrombin III, thrombin-antithrombin III 
complex, prothrombin fragments 1 and 2) in patients with AF. Such data accord with 
clinical trials, in which combined antiplatelet treatment with aspirin plus clopidogrel 
was shown to be less effective than warfarin for stroke prevention in AF35. These 
findings are also supported by data showing that patients show changes in plasma 
markers of platelet function but not platelet aggregation, which are unaffected by 
anticoagulation with warfarin113. 
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The use of digoxin in patients with AF seems to be associated with platelet activation, 
with increased amounts of CD62P (P-selectin) expression on platelets and platelet-
leucocyte conjugates, which could predispose to thrombosis and vascular events142. 
Enhancement of platelet activity and coagulability occur within 12 h of onset of 
AF146, whereas after restoration of sinus rhythm, substantial reduction in platelet 
activity is seen compared with controls at 24 h after cardioversion147. During 
radiofrequency ablation of AF, persistent platelet activation is reported, but is not 
apparent during cryoablation148. Despite the presence of enhanced platelet activation 
in AF, any firm clinical evidence indicating that it directly enhances thrombotic risk is 
lacking. A substudy from the Stroke Prevention in Atrial Fibrillation III (SPAF-III) 
trial149 recorded no association between plasma β-thromboglobulin amounts and 
subsequent thromboembolic events. By contrast, the population-based Rotterdam 
study150 showed that plasma concentrations of soluble P-selectin were predictive of 
adverse clinical outcomes in elderly patients with AF. In view of the close links 
between platelet activation and the atherothrombotic vascular co-morbidities related 
to AF, the platelet activation seen in this arrhythmia could contribute to 
thrombogenesis indirectly. For example, increased expression of P-selectin on 
platelets associated with reduced concentrations of nitric oxide has also been shown to 
be a risk factor for silent cerebral infarction in patients with AF151. Moreover, raised 
amounts of P-selectin and CD63 have both been associated with the embolic and pre-
embolic status of patients with non-rheumatic AF152. 
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Restoration of sinus rhythm 
Some evidence suggests that the coagulation system could be activated by 
cardioversion of AF153. Electrical cardioversion has been associated with more 
prominent activation of the coagulation system than a pharmacological strategy154. 
One study found a positive correlation between the energy delivered for cardioversion 
to sinus rhythm and plasma D-dimer values on day 7154. However, it could equally be 
argued that if more energy is required to restore sinus rhythm, the worse the ‘state of 
AF’. An extended duration of AF could also lead to a more prominent 
hypercoagulable state (estimated by D-dimer value) after cardioversion155, which of 
course may relate to delayed restoration of mechanical systole (section 1.1.6). The 
hypercoagulable state after cardioversion has even been seen despite optimum 
anticoagulation with warfarin156. Nevertheless, patients receiving therapeutic low-
molecular-weight heparin (LMWH) before cardioversion seem to have reduced 
hypercoagulability157. In atrial flutter, limited data suggest that plasma amounts of D-
dimer, platelet factor 4, β-thromboglobulin, thrombin-antithrombin III complex, and 
prothrombin fragments 1 and 2 remain raised, but do not seem to increase further with 
cardioversion of this arrhythmia158. Atrial flutter however is generally less 
thrombogenic than AF and so direct comparison needs particular caution. 
 
1.2.6 What drives the prothrombotic state in AF? 
Several mechanisms have been purported to drive the prothrombotic state in AF 
(figure 3), but recent evidence has focused on the potential role of inflammation and 
the release of various growth factors. 
 60
Figure 3 Abnormal changes in coagulation during Atrial Fibrillation 
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Inflammation 
In AF, inflammation might not only result in endothelial damage, dysfunction, or 
activation, but also be linked directly to thrombogenesis. Increasing evidence has 
supported a link between inflammation and the initiation and perpetuation of AF159-
163. Furthermore, abnormal changes in systemic inflammation have been related to 
prothrombotic indices in AF, suggesting that inflammation could drive the 
prothrombotic state in AF159. 
 
Although most cases of AF are associated with various co-morbidities, many of which 
could also enhance the baseline inflammatory state, there may be an underlying direct 
link between AF and inflammation. Interleukin-6 (IL-6) concentrations are abnormal 
in AF, with some prognostic implications shown in one study164. Many studies have 
also shown that amounts of high-sensitivity C-reactive protein (hs-CRP) are greater in 
patients with AF than in controls in sinus rhythm, with a stepwise increase in hs-CRP 
with the transition from patient groups with an increasing arrhythmia burden (sinus 
rhythm to paroxysmal then persistent AF)132. 
 
Raised hs-CRP amounts consistently correlate with cardiovascular risk, although not 
with future AF159. Also, reduced concentrations of both hs-CRP and E-selectin at 
baseline are associated with an increased probability of maintenance of sinus rhythm 
at 6 months after electrical cardioversion for AF, although the maintenance of sinus 
rhythm seems to have no effect on hs-CRP165. More recently, high hs-CRP amounts 
were shown to be predictive of mortality and vascular death in AF, but not stroke 
itself166. 
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Both CRP and IL-6 stimulate tissue factor production from monocytes in vitro167, 168. 
Furthermore, IL-6 increases platelet production and sensitivity to thrombin169, 
stimulates transcription of fibrinogen170, and is linked to both endothelial activation 
and damage171, 172. However, no link seems to exist between hs-CRP and thrombin-
antithrombin complexes173. Tissue factor and high stroke risk are also independent 
associates of IL-6, whereas fibrinogen and plasma viscosity are independent 
associates of hs-CRP amounts174. 
 
Growth factors 
Another potential driver for thrombogenesis could be growth factors. In cancer 
biology, various pro-angiogenic factors, in particular vascular endothelial growth 
factor (VEGF), act as potent stimulants for tissue factor expression175. This activity 
could partly explain the enhanced thrombogenic risk often associated with cancer. 
Various pro-angiogenic factors have been identified; concentrations of some of these 
factors have been shown to alter in AF176-178. VEGF is largely produced by activated 
platelets179 and results in up-regulation of tissue factor mRNA production and 
subsequent expression of this compound on the endothelial membrane180. 
 
VEGF amounts are substantially increased in both persistent and permanent AF, with 
a corresponding increase in tissue factor176. Additionally, raised serum concentrations 
of transforming growth factor-β1177, and angiopoietin 2 (but not angiopoetin 1)178 are 
also recorded in AF, showing the depth and complexity of modulation of growth 
factor amounts. Although the requirements for enhanced angiogenesis in AF are 
unknown, in view of the intimate association between VEGF and tissue factor, 
enhanced growth factors could be a crucial driving force behind the hypercoagulable 
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state. Notably, tissue factor acts as a cofactor to factor VIIa and is widely regarded as 
the physiological trigger to thrombin formation181. 
 
Why are factors such as the angiopoietins involved? Angiopoietin 1 and 2 are natural 
co-antagonists and both compete for the same binding site on Tie-2, an endothelial 
tyrosine kinase receptor. With an excess of angiopoietin 1, stability of the 
endothelium is favoured, whereas the converse is true with an excess of angiopoietin 
2178. In these circumstances, the balance could ultimately favour endothelial 
destabilization and therefore the action of cytokines such as VEGF. 
 
Extracellular matrix turnover 
The extracellular matrix is a dynamic structure, which continually undergoes a 
process of structural remodeling182. Atrial remodeling has already been discussed 
(section1.2.3), and this process could contribute to the hypercoagulable state, by 
virtue of both enhanced blood stasis and an abnormal endocardium. Impaired matrix 
degradation in AF is well documented61-67, 183. These changes could, therefore, be 
important in atrial remodeling and therefore indirectly contribute to thrombogenesis. 
Perhaps more importantly, MMPs could be directly implicated in thrombogenesis by 
virtue of several known interactions with the coagulation cascade, most notably with 
plasmin184. 
 
The first matrix proteins studied were MMP-1 and TIMP-1 in patients with non-
valvular AF, not receiving anticoagulation62. This study demonstrated evidence of 
impaired matrix degradation in patients with AF, but this finding was not 
independently associated with the presence of AF on multivariate analysis. However, 
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a significant correlation was seen between the MMP/TIMP system and 
echocardiographic measures of left-ventricular hypertrophy and ventricular 
remodeling, but with no relation to atrial dimension or function. Notably, an 
independent relationship was also shown between the MMP/TIMP system and the 
prothrombotic state, as assessed by prothrombin fragments 1 and 2. Similarly 
enhanced MMP-2 and MMP-9 are also associated with reduced PAI-1 activity, 
offering further links with thrombogenesis185. Other MMPs have also been 
investigated - e.g. up-regulation of myocardial MMP-9 and TIMP-3 shown in the left 
atrium of explanted hearts from patients with AF undergoing heart transplantation67. 
Additionally, MMP-14 concentrations in the right atrium were reduced. These results 
should be interpreted with caution since all patients had advanced heart failure; 
however, AF could be associated with chamber-specific alterations in myocardial 
collagen content and MMP and TIMP amounts, indicative of differential remodeling 
and altered collagen metabolism. 
 
Nitric oxide 
Nitric oxide is synthesized by nitric oxide synthase, which is present in large 
concentrations in the endothelium. The expression of nitric oxide synthase is 
regulated by flow-mediated shear stress and is consequently downregulated at sites 
with low flow velocity186. Nitric oxide shows potent antithrombotic effects in arterial 
endothelium, and nitric oxide released from activated platelets inhibits platelet 
recruitment to the growing thrombus187, while also inhibiting expression of PAI-1188. 
 
In animal models of AF, the loss of atrial contraction and consequent reduction in 
shear stress seems to reduce LA expression of nitric oxide synthase with a 
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corresponding decrease in nitric oxide bioavailability and increase in PAI-1 
expression189. In the LAA, nitric oxide concentrations were also significantly reduced 
compared with control animals, but this finding did not indicate decreased expression 
of nitric oxide synthase at this site. Since atrial thrombus is frequently formed in the 
LAA, this finding still has no adequate explanation. 
 
Renin-angiotensin-aldosterone System (RAAS) 
The RAAS is now appreciated as key to the pathophysiology of various 
cardiovascular disease states, related predominantly to the reduction in angiotensin-II 
amounts. Atrial tissue has the capacity to produce and use this hormone with local 
expression of acetylcholinesterase and angiotensin-II receptors, both of which could 
be up-regulated in AF190. RAAS could be mechanistically implicated in initiation and 
perpetuation of AF190-192, as well as providing the link to other mechanisms promoting 
the prothrombotic state in AF. Angiotensin II has been shown to possess several pro-
inflammatory properties and increases the production of pro-inflammatory cytokines 
(e.g., IL-6 and tumour necrosis factor α [TNFα]), adhesion molecules (e.g., vascular-
cell adhesion molecule 1), monocyte chemoattractant protein 1, and selectins (e.g., P-
selectin)193-195. Similarly, through release of various chemokines (e.g. cytokine-
induced neutrophil chemoattractant), angiotensin II can initiate neutrophil 
recruitment195. Expression of angiotensin-II receptors has also been linked with 
increased atrial cell death and leucocyte infiltration196. These data potentially support 
a complex relation between RAAS, inflammation, and AF. 
 
Additionally, RAAS has been implicated in the activation of various MMPs and 
thromboxane A2 (a prothrombotic signaling molecule produced by activated 
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platelets). These processes could occur both as a direct effect of angiotensin II and 
also through induction of interleukin 6197. Furthermore, angiotensin II could 
accelerate degradation of nitric oxide through production of reactive oxygen species 
and thereby impair endothelium dependent vasodilatation198. Likewise, activation of 
RAAS increases synthesis of PAI-1, possibly indicating either enhanced endothelial 
damage or impaired fibrinolysis in AF199. Unsurprisingly, modulation of the RAAS 
cascade has beneficial clinical outcomes191, 192. 
 
A substudy of the Losartan Intervention For Endpoint reduction in hypertension 
(LIFE) trial assessed a cohort of patients with AF and ECG left-ventricular 
hypertrophy assigned to either losartan or atenolol200. The rate of cardiovascular 
morbidity, mortality, and stroke was significantly reduced in patients receiving 
losartan despite similar reductions in blood pressure between the two trial groups. 
Thus, RAAS modulatory drugs are often considered in patients with AF for both 
stroke reduction and rhythm suppression. 
 
1.2.7 Data Appraisal 
The literature investigating the hypercoagulable state in AF is vast. Whilst some 
studies are of reasonable power – e.g. where laboratory indices have been measured in 
patients recruited for large trials, many studies are small and have recruited only 
limited numbers of patients. AF is not a discrete entity and generally associates with 
one or more co-morbidites (section 1.1). In studies with low power, this has led to 
inevitable difficulties in establishing precisely whether the abnormalities detected are 
more likely a consequence of the arrhythmia or to co-morbidities and thus some links 
(e.g. between markers) remain speculative. This has been noted within the text where 
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this is of particuar concern. 
 
Similar difficulties arise when the nature of the various laboratory indices are 
considered. Many molecules do not reflect a single process in isolation – e.g. 
inflammation is mediated through numerous interleukins and cytokines, some of 
which also interact with other pathways – potentially amplifying the effect. Thus 
alterations observed in, for example, IL-6 levels might not translate into similar 
alterations in hs-CRP. Many of the studies reported have only assessed a small 
handful of markers relevant to one particular process, rather than assessing the full 
complement. This is somewhat inevitable – assays are expensive and supply of 
patient’s blood finite and therefore laboratory assessment is usually confined to 
markers deemed of direct relevance to the hypotheses being immediately tested. 
 
Additionally, many small studies have relied upon multivariate analyses to test for 
association. However, with multiple variables and low power in some studies this 
form of statistical analysis needs to be interpreted with caution as only limited 
conclusions may be drawn. This process is further hampered in some studies, by 
suboptimal study design leading to later difficulty in data interpretation. For example, 
some studies have tried to compare healthy controls to a cohort of patients with AF 
and co-morbidities thus automatically limiting the feasibility of establishing whether a 
finding is due to the presence / absence of AF or due to the presence / absence of co-
morbidities. 
  
Finally, not all studies referenced in this section are of clear, logical design. For 
example, some have tried to compare healthy controls to patients with AF and co-
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morbidities, whilst others have not included a chorort of controls at all. For reference, 
the most important studies, their design and findings have been listed in tables 7 and 
8. 
 
1.2.8 Future directions 
There is increasingly strong evidence for the presence of a prothrombotic or 
hypercoagulable state in AF. The presence of various flow and structural defects has 
been used to refine clinical risk stratification models for stroke and thromboembolism, 
or to help predict the likelihood of success for cardioversion and the long-term 
maintenance of sinus rhythm201. However, the clinical role of indices of the 
prothrombotic or hypercoagulable state is emerging, although more data are clearly 
needed. For example, plasma vWf125 and D-dimer116, 202 have been used to refine 
clinical stroke risk stratification. The availability of these biomarkers would be of 
particular value in patients classed as moderate risk, in whom clinical guidelines state 
that the use of aspirin or warfarin is possible, but measurement of high vWf amounts, 
for example, could reclassify such patients as high risk125. Also, these biomarkers 
could serve as indices of ongoing thrombogenesis, to test antithrombotic regimens 
(e.g., warfarin plus an antiplatelet drug)112 or new antithrombotic drugs (e.g., oral 
thrombin inhibitors, oral factor Xa inhibitors), and help decision making on dose 
selection203. Application of such surrogate markers to test antithrombotic regimens 
has been evident in studies97, 145 which have suggested that oral anticoagulation would 
be better than aspirin-clopidogrel combination therapy in reducing thrombogenesis in 
AF, a finding later confirmed in clinical trials showing the effectiveness of warfarin 
for stroke prevention35. The potential of such an approach was recognized in 
recommendations from a consensus conference organized by the German Atrial 
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Fibrillation Competence NETwork and the European Heart rhythm Association on 
defining outcome parameters for trials in AF204. 
 
1.2.9 Summary 
The mechanisms underlying the tendency towards thrombogenesis in AF are clearly 
complex and remain only partly understood. That this process is related purely to 
blood stasis is no longer accepted and various abnormal changes are observed in terms 
of blood flow, the endocardium/endothelium and blood constituents such that 
Virchow’s triad for thrombogenesis is fulfilled. Many of these abnormalities are 
thought to relate directly to AF, but undoubtedly the various (often vascular) co-
morbidities that frequently co-exist with this arrhythmia are also important. Together 
there would appear to be a synergistic interaction between these processes, further 
heightening the state of hypercoagulability. This process is all too clinically evident 
through the enhanced stroke event rate seen in the context of this arrhythmia and is 
only partially remediated by the use of potent antithrombotic agents such as warfarin. 
 
Given these factors, a number of challenges need to be addressed by research both 
laboratory based and clinical. The first is to continue to develop our understanding of 
the mechanistic processes that result in the hypercoagulable state. In particular this 
requires further exploration of the interaction between the various components of the 
coagulation cascade, the endothelium, platelets and, of course, the end product 
thrombosis. In addition, further insight into the various pathways (e.g. inflammation, 
RAAS, growth factors etc) that may drive the hypercoagulable state would also prove 
invaluable. 
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Finally, the quest to identify those at greatest risk of stroke continues as does the 
struggle to develop a potent antithrombotic agent that reliably reduces stroke event 
rates, but without the cumbersome approach required with alternatives such as 
warfarin for therapeutic monitoring. Of course, such agents also need to have a 
favourable side effect profile and, in particular, a low incidence of bleeding. 
Table 7. Coagulation abnormalities in atrial fibrillation 
 
Author Study design DD PF1+2 TF s-thrombo-
modulin 
TATIII 
complex
vWf Comment 
Gustafsson 
C205 
20 AF patients with 
stroke 
20 AF patients without 
stroke 
20 stroke patients with 
SR 
40 normal controls 
+     + increased in nonvalvular AF 
patients with and with out stroke 
Kumagai K91 73 AF patients 
73 control subjects 
+       
Asakura H206 83 AF patients vs. 
normal controls 
 +   +   
Sohara H207 13 paroxysmal AF 
patients vs. normal 
subjects 
NS    NS   
Lip GY92 87 AF patients 
158 control subjects 
+     +  
Lip GY114 51 AF patients 
26 healthy controls 
+       
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Table 7. Coagulation abnormalities in atrial fibrillation (continued) 
 
Author Study design DD PF1+2 TF s-thrombo-
modulin 
TATIII 
complex
vWf Comment 
Kahn SR89 75 NV AF patients 
with or without prior 
embolic events 
42 control patients with 
or without prior 
thrombotic stroke 
     + in AF patients after stroke vWf 
was higher when compared to 
controls without stroke and 
similar to controls after stroke 
Heppell RM101 109 AF patient with or 
without thrombus in 
left atrium 
+    + + increased in patients with left 
atrial thrombus when compared to 
patients without thrombus 
Shinohara 
H104 
45 NV AF patients +    +  increased in patients with low 
LAA velocity vs. patients high 
LAA velocity 
Feinberg 
WM149 
1531 AF patients  NS     PF1+2 was not associated with 
thromboembolism 
Mondillo S98 45 AF patients 
35 healthy controls 
+   +  +  
Fukuchi M119 AF patients vs. patients 
without AF 
     + increased in atrial appendage 
tissue 
Conway D123 1321 AF patients      + increased in high-risk group for 
stroke 
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Table 7. Coagulation abnormalities in atrial fibrillation (continued) 
 
Author Study design DD PF1+2 TF s-thrombo-
modulin 
TATIII 
complex
vWf Comment 
Kamath S113 93 AF patients 
50 normal subjects 
+       
Vene N115 113 AF patients +      DD were in AF patients having 
cardiovascular events vs. not 
having ones 
Nakamura 
Y121 
LAA tissue of 7 NV 
AF patients vs. patients 
without AF 
  +   +  
Conway DS124 994 AF patients      + vWf levels were not a significant 
predictor of stroke and vascular 
events 
Kamath S129 No abstract available +      DD higher in permanent AF but 
not acute AF compared to 
controls. 
Sakurai K106 28 patients with AFL 
27 patients with SR 
+ +   +  DD levels were higher in patients 
with impaired LAA function 
Inoue H95 246 NV AF patients 
111 control subjects 
+ NS     DD levels were higher in NVAF 
patients having risk factors 
Kumagai K120 AF patient      + vWf mRNA and protein were 
increased in AF patients  with 
enlarged atrium 
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Table 7. Coagulation abnormalities in atrial fibrillation (continued) 
 
Author Study design DD PF1+2 TF s-thrombo-
modulin 
TATIII 
complex
vWf Comment 
Marin F86 24 acute onset AF 
patients 
24 chronic AF patients 
vs. 24 IHD patients in 
sinus rhythm 
24 healthy controls 
+   +  +  
Nozawa T110 509 AF patients 
111 healthy controls 
+ NS      
Freestone B178 59 AF patients 
40 healthy controls 
     +  
Nozawa T116 509 NVAF patients 
 
+ NS     Predictive significance for 
thromboembolic events was 
evaluated 
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Table 8. Studies of platelet function in atrial fibrillation 
 
Author Study design BTG PF4 sP-sel mP-sel sGPV Platelet 
aggregation 
Comment 
Yamauchi K140 26 V AF patients 
73 NV AF patients 
57 normal subjects 
+ NS      
Furui H128 20 lone AF patients 
15 normal controls 
+      after treadmill exercise the increase 
of BTG was greater in AF than in 
normals 
Gustafsson 
C205 
20 AF patients with 
stroke 
20 AF patients without 
stroke 
20 stroke patients with 
SR 
40 normal controls 
+ +     increased in nonvalvular AF patients 
with and with out stroke 
Sohara H207 13 paroxysmal AF 
patients vs. normal 
subjects 
NS NS      
Lip GY114 51 AF patients 
26 healthy controls 
+       
Heppell RM101 109 AF patient with or 
without thrombus in left 
atrium 
+ +     increased in patients with left atrial 
thrombus when compared to patients 
without thrombus 
Minamino T151 25 AF patients vs. 
healthy controls 
   +    
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Table 8. Studies of platelet function in atrial fibrillation (continued) 
 
Author Study design BTG PF4 sP-sel mP-sel sGPV Platelet 
aggregation 
Comment 
Shinohara H104 45 NV AF patients + +     increased in patients with low LAA 
velocity vs. patients high LAA 
velocity 
Feinberg 
WM149 
1531 AF patients NS      BTG was not associated with 
thromboembolism 
Minamino T139 28 AF patients +   +    
Mondillo S98 45 AF patients 
35 healthy controls 
+ +      
Kamath S113 93 AF patients 
50 normal subjects 
+    + NS  
Conway DS123 1321 AF patients   NS    was independent of risk for stroke 
Conway DS124 994 AF patients   NS    sP-sel levels were not a significant 
predictor of stroke and vascular 
events 
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Table 8. Studies of platelet function in atrial fibrillation (continued) 
 
Author Study design BTG PF4 sP-sel mP-sel sGPV Platelet 
aggregation 
Comment 
Atalar E147 15 paroxysmal atrial 
fibrillation 
14 paroxysmal 
supraventricular 
tachycardia 
25 chronic AF patients 
22 healthy controls 
+ +     BTG and PF4 were higher in chronic 
AF than in paroxysmal AF and after 
conversion to sinus rhythm 
Nozawa T110 509 AF patients 
111 healthy controls 
+ +      
Sakurai K106 28 patients with AFL 
27 patients with SR 
+ +     BTG levels were higher in patients 
with impaired LAA function 
Inoue H95 246 NV AF patients 
111 control subjects 
+ NS      
Nozawa T116 509 NVAF patients 
 
+ +     Predictive significance for 
thromboembolic events was 
evaluated 
 
 
1.3 Endothelial Progenitor Cells and Cardiovascular Disease 
 
1.3.1 Introduction 
The crucial role played by the endothelium in cardiovascular biology is becoming 
increasingly appreciated208. Indeed, endothelial injury has been implicated in 
atherosclerosis, thrombosis, and hypertension, and the balance between endothelial 
injury and endothelial recovery is of paramount importance for reducing 
cardiovascular events209. Moreover the importance of the endothelium in relation to 
the hypercoagulable state in AF has already been discussed in section 1.2. 
 
Of note, mature endothelial cells possess limited regenerative capacity210, 211. There is 
therefore growing interest into circulating endothelial progenitor cells (EPCs), 
especially into their purported role in maintenance of endothelial integrity, function, 
and postnatal neovascularization212. Other studies are also providing intriguing and 
encouraging insight into the potential use of EPCs in the clinical setting. Indeed, there 
is accumulating evidence for reduced availability and impaired EPC function in the 
presence of both cardiovascular disease and associated co-morbid risk factors. This 
chapter aims to provide an overview of data relevant to the clinical role of EPCs and 
perspectives for treatment of cardiovascular disorders as a whole.  
 
1.3.2 Definition of the Endothelial Progenitor Cell 
The precise definition of EPC has been through a period of flux and remains under 
intense debate, not least because the origin and differentiation of this cell line is 
complex. It is therefore important to understand some of the basic considerations that 
relate to this cell population. 
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Endothelial Markers 
In 1997, Asahara et al. were the first to report isolation of endothelial precursor cells 
(EPCs) from peripheral blood when they found that CD34+ hematopoietic progenitor 
cells could differentiate into cells with endothelial characteristics213. EPCs were 
defined as cells positive for both hematopoietic stem cell and endothelial cell markers, 
such as CD34 and vascular endothelial growth factor (VEGF) receptor-2, 
respectively. The latter, VEGF receptor-2, is often referred to as kinase insert domain 
receptor (KDR). 
The putative CD34+ EPC is able to proliferate and differentiate to mature endothelial 
cells with expression of different endothelial markers (Figure 4) such as KDR214, 215, 
platelet-endothelial cell adhesion molecule (CD31)214, 216, von Willebrand factor214, 215, 
217, VE-cadherin214, 215, caveolin-1216, 218, and endothelial nitric oxide synthase216, 218. 
While in vitro, EPCs can form vascular-like structures215, 218, and in vivo, incorporate 
into new vessels at sites of tissue ischaemia215, 217, 219. Of note, CD34 antigen density 
is highest on early progenitors and decreases progressively as cells mature220; 
however, CD34 is expressed not only on EPCs but on mature endothelial cells, albeit 
at a lower density221. Therefore, an early hematopoietic stem cells marker, CD133, 
was adopted as an alternative additional marker to indicate a “true” EPC222, 223. 
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Figure 4 Potential Origin and Differentiation of Endothelial Progenitor Cells 
BONE MARROW
Tissue-resident
stem cells 
c-kit+
Side population 
cells
Monocytes
CD14++ CD45+
Macrophages
CD14+++ CD45+
Myeloid Precursors
CD14+ CD45+
“Early” EPCs
CD34++ CD133++
KDR+
“More mature” EPCs
CD34+ CD133+ KDR+
Mature EPCs
CD133- CD34low
KDR+ CD31+
VE-Cadherin+
vWF+
Are these cells the same?
BLOOD VESSEL
Hematopoietic stem cells 
CD34+ CD133++ CD45+
Mesenchymal stem
cells CD34- c-kit-
 
EPC - endothelial progenitor cell; KDR - kinase insert domain receptor; VE - vascular 
endothelial; vWf - von Willebrand factor. 
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The marker CD133 (also known as prominin or AC133) is a 120-kDa transmembrane 
polypeptide with an (as yet) unknown biological function. It is expressed on 
hematopoietic stem and progenitor cells from human bone marrow, fetal liver, and 
peripheral blood224. As progenitors develop to more mature endothelium-like cells, 
CD133 is rapidly downregulated223. The CD133+ cells are able to form both early and 
late outgrowing colonies in vitro223. Thus, CD133 might provide a more reliable 
means of defining and tracking human angioblast-like EPCs and distinguishing these 
from mature endothelial or monocytic cells. The combination of CD34, CD133, and 
KDR is commonly used for this purpose, and this represents a rare subset of 
peripheral blood cells. Interestingly, the CD34−/133+ subpopulation of endothelial 
progenitors was recently found to be a possible precursor of classic CD34+/133+ 
EPCs, but to possess even more potent angioregenerative properties in vivo than on 
the latter225. 
 
Haematopoietic Markers 
Haematopoietic cell markers such as CD34, CD133, and CD117 (c-kit) and 
monocytic/macrophagic cell markers such as CD11 and CD14 are expressed by early 
immature EPCs, and are subsequently lost in the more differentiated state223, 224. 
Paradoxically, expression of endothelial markers progressively increases with EPC 
maturation215. Subtypes of these cells that do not express VE-cadherin and von 
Willebrand factor seem to be an early subpopulation of EPCs localized predominantly 
in the bone marrow or detected immediately after their migration into the systemic 
circulation226. More mature circulating CD34-positive EPCs also present CD31, 
CD146, VE-cadherin, and endothelial nitric oxide synthase, as well as begin to 
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express von Willebrand factor223, 224. Thus, the surface marker profile of EPCs seems 
to depend predominantly on their stage of differentiation227. The current most detailed 
phenotypic description of circulating EPCs proposes the co-expression of several 
common hematopoietic and endothelial antigens: CD34, CD133, CD31, CD38, CD45, 
KDR, VE-cadherin, c-kit, and Flt-1228. 
 
Cultivation of peripheral blood mononuclear cells (MNCs) in medium favoring 
endothelial growth is another approach widely used for definition and quantitative 
analysis of EPCs. Adherent cells grow colonies and have been shown to possess 
endothelial characteristics, such as expression of von Willebrand factor and staining 
for Dil-acetylated low-density lipoprotein and Fluorescein isothiocyanate (FITC)-
conjugated BS-lectin229-232. Despite the relatively low numbers of CD34+ of 
circulating endothelial precursors in peripheral blood (100 to 500/ml), relatively large 
numbers of adherent cells are found during culture (approximately 100,000 from 1 
mL blood). This raises some controversy with respect to the identification and the 
origin of isolated EPCs, as these cells seem to reflect a functional subpopulation 
within the blood MNCs that have the potential to differentiate into an endothelial 
phenotype in vivo232-236. 
 
There are at least 2 morphologically and functionally distinct endothelial cell 
populations can be grown from circulating MNCs214. The early spindle-like outgrowth 
cells possess a relatively low proliferative capacity and low ability to express mature 
endothelial proteins215. These cells presumably represent cells of different lineage, 
which include a subset of CD14+/CD34− monocytic cells, which have the potential to 
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differentiate (transdifferentiate) into endothelial-like cells under certain environmental 
condition in the presence of special growth factors (e.g., VEGF, fibroblast growth 
factor, and so on)235. Late “outgrowth cells” show a high proliferative potential and 
originate predominantly from bone marrow donors and are considered as circulating 
angioblasts214. 
 
It is important to appreciate that although monocyte-derived EPCs have a lower in 
vitro proliferation potential than hematopoietic stem cells or cord-blood-derived 
EPCs237, the different progenitor types seem to have a similar ability to enhance 
neovascularization in experimental models215, 238, 239. One may speculate that 
proliferation capacity is not the decisive factor and that the reduced proliferation of 
the monocyte-derived EPCs is likely to be attributable to increased release of growth 
factors, which may act in a paracrine manner to support angiogenesis and 
arteriogenesis240. 
 
The expression of common markers by hematopoietic and endothelial progenitor cells 
in embryonic development and transdifferentiation potential of monocytes into cells 
with endothelial characteristics would suggest a possible common origin from a bone 
marrow precursor, perhaps a putative hemangioblast241. Bone marrow also contains 
mesenchymal cells, which have been shown to differentiate into endothelial cells242, 
improve vascularization in vivo243, 244, and contribute to tissue repair245. Likewise, 
other bone-marrow-derived EPCs mesenchymal stem cells release a variety of 
angiogenic growth factors246. In addition to bone-marrow-derived cells, other cell 
populations, such as fat tissue247, 248, cardiac tissue249, neural stem cells250, and fetal 
 84
liver cells251, can give rise to endothelial cells, suggesting that tissue-resident 
stem/progenitor cells can contribute to vascular growth in the adult. 
 
In summary, a universal single or complex EPC marker still remains to be identified, 
showing the heterogeneous nature of endothelial precursors. As a result, various 
different surface markers and cell culture properties have been used by research 
workers to define EPCs. This has obvious implications when interpreting data as there 
are marked inconsistencies in cellular definition and in assessment techniques. Thus it 
is not possible to completely compare and contrast studies in a direct manner and it is 
necessary to compile a descriptive analysis of the literature. Further discussion 
regarding the definition of the putative EPC and implications for the studies to be 
conducted within this thesis is made in section 3.1. 
 
1.3.3 Physiological Considerations 
Because of the rarity of EPCs and the difficulties in identification, limited information 
is available about the normal range and functional characteristics of different types of 
EPCs in humans. 
 
Ageing associated decline in EPC number/function  
The available data suggest that age may affect the availability and function of EPCs 
and this is a broadly consistent finding across the literature regardless of antigenic 
EPC definition252-254. Ageing is associated with a reduced number of circulating EPCs 
in patients with coronary artery disease (CAD). For example, Vasa et al. reported age-
associated depression in circulating CD34/kinase insert domain receptor (KDR)-
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positive cells in a mixed group of healthy probands and CAD patients231. Scheubel et 
al. have reported an age-dependent loss of circulating EPCs in stable CAD252. 
Moreover, the number of EPCs mobilized after coronary artery bypass grafting was 
significantly decreased in older patients in this study. The ageing-associated 
impairment of cardiac angiogenic capacity in older mice, estimated as 
neovascularisation of cardiac allografts, can be restored by implantation of bone 
marrow-derived EPCs from young adult animals253. Progression of atherosclerosis in 
apolipoprotein E -/- mice with persistent hypercholesterolemia seems delayed by 
chronic administration of bone marrow-derived progenitor cells from young mice254. 
This treatment was much less effective when donors were older animals with 
atherosclerosis, indicating that progressive age-dependent reduction in EPCs may 
accelerate the development of atherosclerosis, particularly in the presence of risk 
factors (e.g., hypercholesterolemia)254. 
 
Multiple factors are thought to be involved in the ageing associated deterioration of 
EPC quantity and function with a number of mechanisms proposed (table 9). Chronic 
exposure to risk factors continuously damages endothelial cells and requires their 
intensive replacement. Conversely, risk factors may possibly affect EPC mobilization, 
integration in injured vascular sites, and angiogenic capacity. EPC dysfunction may 
also be result of their accelerated senescence and apoptosis, as well as exhaustion of 
the pool of progenitor cells available in the bone marrow232, 255, 256. Reduced levels of 
angiogenic and mobilizing cytokines have also been related to age-dependent 
impairment of EPC mobilization in vivo. Both vascular endothelial growth factor 
(VEGF) and nitric oxide (NO) production have been reported to decrease with age252, 
256-260, and these factors are thought to play synergistic roles in the mobilization, 
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migration, proliferation, and survival of endothelial cells256, 259. The alteration of 
constitutive human telomerase reverse transcriptase activity can also affect the 
regenerative capacity of EPCs261. Thus, the impaired mobility of EPCs may be a 
consequence of inadequate stimuli normally involved in their physiology. 
 
Physical Training and Exercise 
It is well known that physical training improves endothelial function, exercise 
tolerance, and collateralization in patients with CAD, chronic heart failure262, 263, and 
peripheral artery disease264, 265. Exercise upregulates circulating EPCs in patients with 
CAD266, and increases the number of EPCs in bone marrow, peripheral blood, and the 
spleen (at least in mice)267. The upregulation of EPCs by exercise may be dependent 
on endothelial NO and VEGF levels or a decreased rate of EPC apoptosis266. In a 
recent clinical study, physical exertion in patients with peripheral arterial occlusive 
disease resulted in a 5.2-fold increase in EPCs and improvement of their function. 
However, subischaemic exercise training in revascularized patients did not affect EPC 
number, although in vitro vascular tube formation was enhanced268. These data imply 
that a positive impact of regular physical training on cardiovascular performance may 
be attributable at least partly to the improved behavior of EPCs268. Many of these 
studies are small in a highly selected group of patients, using a variety of methods and 
definitions for EPC assessment leading to inconsistencies within the data. Further 
exploration of the role of exercise of EPC release is discussed in section 3.2. 
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1.3.4 Pathophysiological Considerations 
An increasing body of evidence suggests that cardiovascular risk factors affect the 
number and properties of EPCs. An inverse correlation is found between the number 
(and functional activity) of EPCs and cardiovascular risk factors among apparently 
healthy people and in patients with CAD231, 232. The number of EPCs correlates with 
endothelial function and is a better predictor for this than the patient’s combined 
Framingham risk factor score232. 
 
Lipids 
Multiple studies have consistently reported an association between lipid metabolism 
and the biology of human EPCs. The numbers of EPC colony forming units (EC-
CFUs) are significantly reduced in relatively healthy subjects with elevated serum 
cholesterol levels232. In CAD, low-density lipoprotein (LDL) cholesterol inversely 
correlates with the number of circulating EPCs231. In addition, the functional 
characteristics of isolated EPCs, such as proliferation, migration, adhesion, and in 
vitro vasculogenic capacity, are also impaired in patients with 
hypercholesterolemia231, 269. Exposure of cultured EPC to oxidized LDL induces a 
dose-dependent impairment of their functional activity, accelerates the rate of EPC 
senescence, possibly by telomerase inactivation, and can be associated with up to a 
70% reduction in EPC numbers270, 271. In addition, oxidized LDL impairs VEGF-
induced EPC differentiation via the deactivation of Akt272. Plasma levels of high-
density lipoprotein cholesterol and triglycerides positively correlate with the number 
of EPC-CFUs, but not with the number of CD34+/CD133+ progenitor cells273. 
Although this may of course represent fundamental differences between EPC 
assessment by culture and flow cytometry. 
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Hypertension. 
Among various risk factors, hypertension is the strongest and most consistent 
predictor of EPC migratory impairment231. Angiotensin-II diminishes telomerase 
activity in EPCs and accelerates the onset of EPC senescence through an increase in 
oxidative stress. Some controversy exists about the effects of angiotensin-II on in 
vitro EPC proliferation. Although angiotensin-II inhibited EPC proliferation in one 
study, it enhanced VEGF-induced EPC proliferation in another274, 275. Angiotensin II 
also potentiates VEGF-induced network formation by EPCs, probably by up-
regulation of KDR275. Both these studies originate from the same research group 
investigating the effect of various hormones on EPCs cultured in vitro in a limited 
number of samples. Consequently, results may not be directly applicable to clinical 
practice and may feasibly be influenced by the use of exogenous hormones at non-
physiological levels. 
 
Diabetes mellitus. 
Diabetes mellitus, another important cardiovascular risk factor, is a disease in which 
impairment of ischaemia-induced neo-vascularization has been described276, 277. The 
number of EPCs is reduced in both type 1 and type 2 diabetes278, 279. Furthermore, 
marked EPC dysfunction may underlie new mechanisms involved in the pathogenesis 
of vascular complications in diabetic patients. Indeed, EPC proliferation, adhesion, 
and angiogenic properties are impaired in this setting278-280. EPCs can facilitate 
angiogenesis in a paracrine fashion by secretion of angiogenic factors to mobilize 
bone-marrow progenitors and to activate mature endothelial cells281, 282. Of note, the 
media from EPC culture of type 1 diabetic patients not only possesses evidence of 
reduced angiogenic capacity, but also contains an inhibitor for in vitro tube 
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formation278. Interestingly, diabetes was not associated with enhanced apoptosis in 
this study. Similarly, Tepper et al. showed impaired ability of mature endothelial cells 
to incorporate into tubules in type 2 diabetes279. In both studies, decreased number 
and dysfunction of EPCs was inversely related to the levels of haemoglobin A1c, 
implying that the degree of glycaemic dysregulation was associated with EPC 
pathophysiology. These findings are important and may aid our understanding of why 
patients with poor glycaemic control have worse outcome. 
 
Further evidence of the negative impact of hyperglycemia on EPCs was provided by 
Kränkel et al., who showed that cultivation of peripheral blood mononuclear cells 
(MNCs) from healthy donors under hyperglycemic conditions was associated with 
significant reduction in EPC numbers, inhibition of NO production, and matrix 
metalloproteinase-9 activity, as well as an impairment of the migrational and 
integrative capacities of the cells283. 
 
Smoking 
Smoking is a significant predictor of reduced circulating and cultured endothelial 
progenitors231. The number of circulating EPCs correlates inversely with the number 
of cigarettes consumed in one study284. However, naturally, this is likely to be a 
chance finding as it is clearly difficult to prove such an association when numerous 
other risk factors are unlikely to have been fully accounted for. However, EPCs from 
heavy smokers appear to die prematurely during the early phase of culture284. 
Similarly, smoking cessation is associated with an increase of EPC numbers, and 
these changes are most marked in those who smoked the least. However, if smoking is 
resumed, EPC numbers rapidly decrease to levels seen before smoking cessation284. 
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Of note, nicotine effects on the activity and function of EPCs also seems to be dose 
dependent. Lower doses of nicotine have a positive influence on EPC numbers, 
proliferation, migration, and in vitro vasculogenesis with the peak effect at  
concentrations of nicotine 10 8 mol/l, similar to that found in the blood of smokers285. 
However, cytotoxicity was observed at higher nicotine concentrations285. 
Homocysteine, which is another common cardiovascular risk factor, was shown to 
decrease numbers and impair activity of EPCs from human peripheral blood286. 
Asymmetric dimethylarginine (ADMA), an endogenous NO synthase inhibitor, 
contributes to endothelial dysfunction and inhibition of angiogenesis and is an 
independent biomarker of future major adverse cardiovascular events or death287. Of 
note, circulating ADMA levels inversely correlate with the number of progenitor 
cells, and ADMA inhibits EPC function, at least in vitro288. 
 
1.3.5 EPCs and established cardiovascular disease 
Abnormalities in quantity and function of EPCs have been shown in a number of 
studies of various cardiovascular disorders (table 10). 
 
Stable Coronary Artery Disease 
Despite numbers of circulating CD34+ / CD45+ and CD133+ / CD34+ progenitor cells 
and EPCs in patients with severe chronic CAD being similar to those in control 
subjects, in vitro functional capacity of bone marrow MNCs is significantly reduced 
and transplantation of bone-marrow MNCs from patients with CAD into ischaemic 
nude-mice high limb showed a markedly impaired ability to restore tissue 
perfusion289, 290. 
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Unstable Coronary Artery Disease 
In patients with unstable angina, an increase in numbers of EPC-CFUs, but no change 
in adhesive properties, has been shown; however, the number of EPCs were reduced 
by almost 50%, after clinical stabilization291. Correlations were also noted between 
systemic C-reactive protein (CRP) levels and circulating EPC numbers, but not with 
their adhesive capacity, implying that systemic inflammation may play a role in the 
mobilization of EPCs in patients with unstable angina291. On the contrary, CRP was 
found to inhibit EPC proliferation, survival, differentiation, and function, suggesting a 
possible role in the development of cardiovascular disease292. These apparently 
conflicting findings may relate to the differing contexts in which these parameters 
were assessed. 
 
In myocardial infarction, the number of circulating EPCs is markedly increased from 
the early phase of the disease to peak levels on day 7289, 229. Subsequently, EPC 
numbers reduce and become similar to levels seen in control subjects within 60 
days229. Of note, plasma levels of VEGF (a growth factor associated with 
angiogenesis) are closely related to circulating EPC numbers, and levels also peak on 
day 7 229. These data show the important role for VEGF in EPC mobilization in acute 
coronary syndromes. However, given that most patients with myocardial infarction 
are treated with EPC mobilizing drugs, such as statins or angiotensin-converting 
enzyme inhibitors, the primary driving factor for peripheral EPC elevation in 
myocardial infarction is uncertain. In a rat model, the number and function of EPCs 
were depressed after myocardial infarction in those given placebo, whereas treatment 
with either an angiotensin-converting enzyme inhibitor or a statin was associated with 
significant stimulation of the amount and activity of the EPCs293. Moreover, 
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mesenchymal stem cells, which also possess the potential to differentiate to 
endothelial cells, are decreased on day 7 after acute ST segment elevation myocardial 
infarction294. 
 
The functional role of the bone marrow cells in myocardial infarction may be 
attributable not only to their angiogenic properties and release of growth factors and 
cytokines, but also to their ability to restore the population of cardiac progenitor cells 
by selective homing to specific areas of myocardial injury and conversion to the 
phenotype of cardiac side-population cells295. Bone marrow-derived hematopoietic 
cells may generate cardiomyocytes (albeit at a very low frequency) within the 
infarcted myocardium in some animal models296, although others fail to show trans-
differentiation of hematopoietic stem cells into cardiac myocytes after myocardial 
infarction297. Such data has not been reproducible in human studies. 
 
Heart Failure 
The numbers of EPCs are elevated in patients with acute heart failure, which 
significantly correlates with levels of the cytokine tumor necrosis factor alpha (TNF-
α)298. Differences in the quantity of EPCs can be related to the stage of heart failure, 
with relatively higher numbers in the early stage of heart failure (New York Heart 
Association, NYHA, functional class I and II), with levels progressively decreasing 
with NYHA functional class III and IV heart failure298. Higher levels of brain 
natriuretic peptide are associated with depression of circulating EPCs with no effect 
of medical therapy or etiology of heart failure298. 
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Other Disease States 
Reduced numbers of EPCs are found in patients with erectile dysfunction299, those 
with instent restenosis300, and in cardiac transplantation patients with vasculopathy301. 
The number of EPCs does not seem to be associated with the degree of 
cerebrovascular atherosclerosis per se302. However, EPC levels are significantly 
decreased in patients after stroke303 and in those with atherosclerotic patients 
(including ones without clinical stroke) in whom areas of cerebral infarction as 
determined by positron emission tomography were found302. In the latter study, EPC 
numbers also correlated with regional blood flow in areas of chronic hypoperfusion of 
the brain302. Each of these studies has assessed limited numbers of patients in a 
somewhat unstructured manner and thus interpretation should be made with caution. 
 
1.3.6 Effects of Drug Therapies 
Drug therapies may influence EPC physiology, as summarized in table 11. These 
changes need to be placed in context to explain the possible therapeutic benefit(s) of 
these drugs, and to justify the effects on clinical outcomes, good or bad. 
 
3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase inhibitors. 
Many primary and secondary prevention trials have suggested that statins possess 
favorable (pleiotropic) effects, which include the improvement of endothelial function 
and an anti-thrombotic effect, independent of their impact on cholesterol reduction304, 
305. Along with direct effects on endothelial cells, stimulation of EPC activity may be 
an additional mechanism of the beneficial influence of statins on endothelial 
performance. Indeed, different statins have been shown to enhance the proliferative 
capacity of EPCs in vitro255, 306, 307. Moreover, the effect of statins seems to be 
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comparable with VEGF306, which is known to augment the number of EPCs213, 308. 
 
Statins stimulate EPC proliferation through the cell cycle regulatory genes255. 
Additionally, statins induce EPC differentiation via the PI 3-kinase/Akt pathway306, 
307, as well as enhance adhesiveness by increased integrin expression309, and improve 
migratory activity by upregulation of the telomere repeat-binding factor TRF2 in 
EPCs230, 310. As previously mentioned, the pleiotropic effects of statins on EPC 
activity are independent of their impact on reduction in LDL cholesterol, as shown by 
comparison of simvastatin and ezetimibe311. Finally, atorvastatin or mevastatin dose 
dependently inhibit the onset of EPC senescence in culture255. Thus, one may 
potentially consider the use statins to augment the functional potential of EPCs for 
transplantation therapy. 
 
The renin-angiotensin-aldosterone system 
The renin-angiotensin-aldosterone system [RAAS] is an important pathophysiological 
mechanism related to many cardiovascular disorders, and may also be involved in 
EPC (dys)function274, 275. Indeed, treatment with the angiotensin II receptor 
antagonists, olmesartan or irbesartan, has been shown to significantly increase the 
number of EPCs312. Also, valsartan was reported to reduce angiotensin II accelerated 
senescence of EPCs via upregulation of telomerase activity275. The administration of 
ramipril, an angiotensin-converting enzyme inhibitor, increases the number and 
improves the functional capacity of EPCs in patients with CAD, independent of any 
impact on blood pressure313. Importantly, RAAS may be implicated in the 
thormbogenic state in AF (section 1.2.6) 
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Oestrogens 
No direct studies of effect of oestrogen therapy on EPCs in humans are available, but 
increased blood oestrogen levels in women do correlate with numbers of circulating 
EPCs314. In an animal carotid injury model, oestradiol treatment showed stimulatory 
effects on EPC mobilization, proliferation, mitogenic activity, and migration activity, 
as well as inhibited EPC apoptosis315. These findings require further investigation 
with larger structured studies. 
 
Miscellaneous drugs. 
Enhancement of EPC activity has been shown with treatment with vardenafil (a 
phosphodiesterase inhibitor)299, puerarin316, and Ginkgo biloba extract317. In contrast, 
rapamycin inhibits proliferation and differentiation of human EPCs in vitro318. The 
administration of rosiglitazone, a peroxisome proliferator activated receptor gamma 
agonist, in patients with type 2 diabetes not only increases the number and migratory 
activity of cultured EPCs280, but also can attenuate the detrimental effects of C-
reactive protein on endothelial progenitors292. Finally a correlation between 
erythropoietin levels and EPC numbers, as well as functional activity, has been 
reported319, 320. The administration of erythropoietin also increases the number of 
functionally active EPCs in patients with renal anemia, as well as in healthy 
subjects321. Of course, each of these effects may simply be a consequence of altering 
underlying pathophysiology – e.g. by optimizing glycaemic control. 
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1.3.7 EPC Transplantation 
Many pre-clinical studies have shown therapeutic efficacy of EPCs in ischaemic 
disorders and vascular injury in animal models239, 322, 323. Several small-scale phase 1 
trials of bone marrow MNC transplantation in treatment of myocardial infarction, 
peripheral limb ischaemia, severe stable CAD, and heart failure providing preliminary 
evidence of feasibility and safety of EPC transplantation have been performed. 
However, many clinical studies have yielded disappointing results despite such early 
theoretical promise. A Full discussion of this topic is out of the scope of this thesis. 
 
1.3.8 Summary 
The endothelium would appear to be of central importance in various purported 
mechanisms leading to cardiovascular events. Endothelial injury evidenced by a wide 
variety of investigative techniques is documented in numerous disease states and 
vascular processes, including but not limited to hypertension, diabetes mellitus, 
atherosclerosis, thrombosis, coronary artery disease and stroke. Notably endothelial 
damage is clearly evident in patients with AF (section 1.2) and may provide a key link 
between this arrhythmia and the hypercoagulable state. Moreover, various processes 
which may provide a central drive to the hypercoagulable state (e.g. RAAS, 
inflammation) may also link directly to EPC release / activity. 
 
Of further importance, EPCs may provide a novel (albeit thus far untapped) 
therapeutic avenue and thus it is vital that research be continued into this exciting cell 
line. 
Table 9  Cardiovascular Risk Factors and Endothelial Progenitor Cells 
Study Risk factor Patients Effects on EPC number Effect on function 
Vasa M231 LDL 
hypertension 
smoking 
 
CAD ↓CD34+/KDR+ cells, NE CFU 
NE 
↓circulating CD34+/KDR+ cells, 
↓in culture 
↓migration 
↓migration 
NE on migration 
Hill JM232 total 
cholesterol, 
LDL 
Healthy ↓CFU ND 
Chen JZ269 total 
cholesterol 
CAD ↓in culture ↓proliferation, migration, adhesion, 
in vitro vasculogenic capacity 
 
Pellegatta F273 HDL, 
triglycerides 
 
Healthy ↓CFU ND 
Loomans CJM278 Diabetes 
 
Type I diabetes mellitus ↓in culture ↓ in vitro vasculogenic capacity 
Tepper OM279 Diabetes 
 
Type II diabetes mellitus ↓in culture ↓ in vitro vasculogenic capacity 
Pistrosch F280 Diabetes 
 
Type II diabetes mellitus NE ↓ adhesion 
Kondo T284 Smoking 
 
Healthy ↓circulating 
CD45low/CD34+/CD133+/KDR+ 
 
ND 
CFU – colony-forming units of EPCs; NE – no effect; ND – no data 
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Table 10 Cardiovascular Disorders and Endothelial Progenitor Cells 
Study Patients Effects on EPC number Effect on function 
Heeschen C290  Stable CAD ↓CFU ↓migration, in vivo  
vasculogenic capacity 
George J291 Unstable angina ↑CFU NE adhesion 
 
Massa M289 Myocardial infarction 
Stable CAD 
↑ CD34+/KDR+ cells 
NE 
 
ND 
Shintani S229 Myocardial infarction ↑circulating CD34+ cells, ↑CFU 
 
ND 
Valgimigli M298 Heart failure  CFU and CD34+/CD133+/KDR+ cells 
↑ in NYHA class I,  
↓ in NYHA class III-IV 
 
ND 
Foresta C299 Erectile dysfunction ↓circulating EPCs 
 
ND 
George J300 Diffuse in-stent restenosis ↓CFU 
 
ND 
Simper D301 Transplant arteriopathy ↓CFU 
 
ND 
Taguchi A302 Cerebrovascular 
atherosclerosis 
CD34+/CD133+ cells 
↓ in cerebral infarction 
No correlation with the degree of atherosclerosis 
 
ND 
Ghani U303 Stroke ↓CFU 
 
ND 
CFU – colony-forming units of EPCs, ND – no data 
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Table 11  Drug Therapies and Endothelial Progenitor Cells 
Study Risk factor Patients Effects on EPC number Effect on EPC function 
Llevadot J307 ND simvastatin ↑proliferation ↑ migration 
Dimmeler S306 healthy simvastatin, mevastatin, 
atorvastatin 
↑proliferation ND 
Vasa M231 CAD atorvastatin ↑EPC number ↑migration 
Assmus B255 healthy atorvastatin 
mevastatin 
↑proliferation 
NE 
↓senescence 
↓senescence 
Walter DH309 ND simvastatin ND ↑adhesion 
Spyridopoulos I310 healthy atorvastatin, mevastatin ND ↑migration 
Landmesser U311 heart failure atorvastatin 
ezetimibe 
↑in culture 
NE 
ND 
Bahlmann FH312 Diabetes 
melitus 
olmesartan, irbesartan ↑in culture ND 
Imanishi T270 healthy valsartan ND ↓senescence 
Min TQ313 CAD ramipril ↑in culture ↑proliferation, migration, 
adhesion, in vitro 
vasculogenic capacity 
Bahlmann FH321 renal anaemia, 
healthy 
erythropoietin ↑circulating CD34+/CD45+ cells,  
↑in culture 
 
↑ in vitro vasculogenic 
capacity 
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Table 11  Drug Therapies and Endothelial Progenitor Cells (continued) 
 
Study Risk factor Patients Effects on EPC number Effect on EPC function 
Pistrosch F280 diabetes  rosiglitazone ↑in culture ↑ migration 
Foresta C299 healthy vardenafil ↑circulating EPCs ND 
Zhu JH316 ND puerarin 
 
↑in culture ↑migration, adhesion, in 
vitro vasculogenic capacity 
Chen J317 ND Ginkgo biloba 
 
↑in culture ↑ migration, adhesion, in 
vitro vasculogenic capacity 
Butzal M318 ND rapamycin ↓in culture ↓differentiation, adhesion, 
↑apoptosis 
CFU – colony-forming units of EPCs, NE- no effect, ND – no data 
 
 
Section II: Study Rationale, Hypotheses and Study Design 
2.1 Study Rationale and Hypotheses 
 
2.1.1 Introduction 
The importance of AF as a clinical entity has been discussed in detail in the preceding 
section. It is clear that this arrhythmia, which previously was once assumed to be 
relatively benign, does, in fact, have an important impact on healthcare. 
 
Although AF may be directly implicated to and may exacerbate a number of 
symptoms, the most important consideration is the high risk of stroke and 
thromboembolism. As discussed earlier, it seems increasingly clear that AF may in 
fact drive or co-exist with a hypercoagulable state, thereby fulfilling Virchow’s triad 
for thrombogenesis with endothelial damage / dysfunction being a central theme or 
hallmark of this process. Whether this relates to the arrhythmia per se or to associated 
co-morbidities remains unclear. Markers and models of endothelial function continue 
to evolve and many have been tested in AF with various abnormalities reported. 
EPCs, however, hold potential to reflect two co-existing processes – not only may 
these cells reflect underlying vascular health, but in addition, but they may alter in 
number/function depending upon the extent of associated endothelial damage. Thus it 
is planned to investigate the role of EPCs, inflammation and apoptosis in AF. 
 
2.1.2 Aim 
To investigate the inter-relationships between EPCs in AF and various 
pathophysiological mechanisms (endothelial perturbation, inflammation, apoptosis 
and angiogenesis) potentially leading to thrombogenesis in this arrhythmia. 
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 2.1.3 Original Hypotheses 
1. Abnormalities of endothelial activation/dysfunction and EPCs (quantity, 
functionality) are present in permanent AF compared to controls (both ‘disease 
matched controls’ and ‘healthy controls’, in sinus rhythm) 
2. EPCs correlate with plasma markers of endothelial perturbation (E-selectin, 
vWf), angiogenesis (VEGF), apoptosis (Fas/Fas ligand) and inflammation 
(IL6) in AF. 
3. Similar abnormalities are present in lone AF patients, compared to matched 
‘healthy controls’ in sinus rhythm. 
4. The numbers of circulating EPCs may predict the outcome following 
cardioversion of AF. 
5. That in paroxysmal AF, levels of surrogate markers for the hypercoagulable 
state (hs-CRP, E-selectin, vWf) are enhanced with a greater AF arrhythmia 
burden. 
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2.2 Study Design 
 
2.2.1 Cross-sectional Study 
50 patients with permanent AF were studied, and compared to 50 ‘disease controls’ in 
sinus rhythm [matched for associated cardiovascular disease and risk factors (age/sex, 
prior vascular disease, hypertension, diabetes, etc)] and 50 age/sex matched healthy 
controls in sinus rhythm. 
 
In addition, 30 subjects with ‘lone AF’ (normotensive patients with no risk factors for 
AF and normal chest X-ray and echocardiogram) were studied, and compared to 30 
age-matched healthy controls in sinus rhythm. 
  
Exclusion criteria were haemodynamically significant valvular disease, or other 
conditions which may adversely affect the endothelium, such as severe uncontrolled 
hypertension, carcinomatosis, recent (i.e. <3 months) stroke, myocardial infarction or 
surgery. 
 
2.2.2 Effects of Cardioversion: 
20 patients with newly diagnosed non-rheumatic AF lasting > 4 weeks of either sex, 
aged 18-85 years old planned for elective cardioversion were recruited. Blood 
sampling was performed at baseline, immediately after cardioversion and at 4 weeks 
after successful cardioversion. 
 
Exclusion criteria were as per study (a), plus any contraindication to cardioversion 
(e.g. known permanent AF) 
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 2.2.3 AF Arrhythmia Burden Study 
Consecutive patients (n=100) aged 18-85 with permanent pacemakers incorporating 
advanced AF detection algorithms (Vitatron ‘T70’ or Selection 9000) were recruited 
from routine pacemaker follow-up clinics. These devices are able to accurately record 
episodes of AF and allow calculation of an exact atrial fibrillation arrhythmia burden 
(AFB), without the need for an extended period of ambulatory monitoring. Suitable 
patients were identified as those who had previous documented evidence of 
paroxysmal AF with at least two episodes within the last three months. Anti-
arrhythmic therapy had been stable in all patients for at least five half-lives prior to 
study entry. 
 
Exclusion criteria included any condition that may adversely affect the endothelium 
(e.g. recent (<3 months) stroke, thromboembolism, myocardial infarction, 
uncontrolled hypertension etc.) or activate or suppress the inflammatory cascade (e.g. 
concurrent infection, vasculitis, malignancy, corticosteroid usage etc.). Similarly 
patients with significant structural cardiac abnormalities (e.g. significant valvular 
disease, hypertrophic cardiomyopathy or left ventricular ejection fraction < 40%) 
were also excluded. 
 
2.2.4 Validation Studies 
The two commonest techniques used for assessing EPCs are flow cytometry and cell 
culture. Each technique has its relative merits, although the primary advantage of the 
latter is the ability to assess cellular function. There is no international consensus on 
either the best method for assessing EPCs, or their precise antigenic definition. 
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Various technical considerations in identifying rare cells and their heterogenous 
nature (with flux in their antigenic profile with maturation) are also important 
considerations. 
 
The initial work for this thesis will therefore involve a comparison of laboratory 
assays for EPC enumeration by cell culture and flow cytometry. Concurrently, various 
physiological properties of EPCs will be assessed, including temporal decline once 
samples are held ex vivo, diurnal variation and response to short burst exercise. 
 
2.2.5 Ethical Approval and Consent 
The Sandwell and West Birmingham research Ethics Committee evaluated this study 
and offered a favourable opinion. Consent for the study was sought from the Sandwell 
and West Birmingham Hospitals NHS Trust Research and Development Department. 
Written informed consent was obtained from all patients who enrolled in the study. 
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2.3 Power Calculation, Data Analysis and Statistical Methods 
 
2.3.1 Power Calculation. 
In the cross-sectional study, the number of patients to be recruited was calculated 
from the hypothesized difference in EPCs/plasma markers between the groups (e.g. 
0.25 of a standard deviation in a normally-distributed index such as vWf, or a 25% 
difference in a non-normally distributed index such as EPCs). Anticipated levels for 
EPCs was taken from a pilot feasibility study run by our sister laboratory in Hong 
Kong. They found the following using a similar flow cytometer protocol to ours: AF – 
mean 150 (90-331) cells/mL; coronary artery disease – mean 90 (60-125) cells/mL; 
healthy control subjects – mean 424 (185-673) cells/mL324. Also previous work from 
our laboratory investigating vWf had required a sample size of between 20-40 
patients, with a lower sample size still when circulating endothelial cells (CECs – an 
equally rare cell) were investigated. We therefore calculated that 40 patients per group 
would be required – although planned to recruit 50.  
 
Similarly in the longitudinal study, previous work within the department had shown a 
significant fall in both vWf and CECs at 4-weeks following cardioversion in a cohort 
of 20 patients325. Based on these parameters, we calculated that a similar number of 
patients would be required. Although it was acknowledged that new guidelines aimed 
at stratifying who underwent cardioversion may have some impact on numbers we 
would be able to recruit (section 1.1.6). Power criteria are a minimum of 0.05 for 
alpha error and 0.8 for 1-beta error. 
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In the AF burden study, the number of patients to be recruited was calculated from the 
hypothesized difference in plasma markers between groups (i.e. 0.25 of a standard 
deviation in a normally distributed index (vWf) and a 25% difference in a non-
normally distributed index (IL-6).  Data were taken from previously published work 
comparing sinus rhythm (with co-morbidities) vs. permanent AF326. Power criteria 
were a minimum of 0.05 for alpha error and 0.8 for 1-beta error. Based on these 
parameters we hypothesized that 100 patients (25 per group) would be required. 
 
2.3.2 Data Analysis 
General 
Following a test of statistical normality (Kolmogorov-Smirnov test), data were 
expressed as mean with standard deviation (SD) or as median with inter-quartile range 
(IQR) for the normally distributed data and non-parametrically distributed data 
respectively. Comparisons between groups were analysed by 2-way repeated ANOVA 
or Kruskal–Wallis test, as appropriate. Repeated measures were tested using 
Friedman’s method. For paired data, the Wilcoxon matched-pairs signed-ranks or 
paired t-test were used. A P value <0.05 was considered as statistically significant. 
 
Correlations and Multivariable Regression 
Correlations between indices were performed by Spearman's or Pearson’s method as 
appropriate. Additionally, a step-wise multi-variate analysis will be performed to 
assess for potential inter-relationships. Naturally, with large numbers of statistical 
comparisons, the probability of chance findings becomes important. To minimize this, 
for these analyses a P value <0.01 will be considered statistically significant. 
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Inter / intra-assay coefficient of variation 
The inter-assay and intra-assay co-efficients of variability are calculated for all 
ELISA laboratory indices are generally <5% and <10% respectively. Data are 
collected on a regular basis and analyzed in-house by the laboratory head to ensure 
each assays remains robust. For the flow cytometric analysis, the inter-assay and 
intra-assay co-efficients of variability were both <10%327. 
 
All analyses were performed using SPSS version 17.0 for Windows©. Graphpad 
Prism version 5.00 for Windows© was used for graphical illustrations.. 
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2.4 Methodology 
 
2.4.1 General 
In all participants, a detailed history, physical examination, resting 12 lead 
electrocardiogram (ECG) and surface echocardiogram was obtained. 
 
2.4.2 Venesection 
A 20ml blood sample was drawn from each participant. Blood samples were collected 
from a single puncture to a large antecubital vein using a 21-gauge needle directly 
into Vacutainer® tubes (Becton Dickinson, UK) containing 7.2mg tri-potassium (K3) 
Ethylene Diamine Triacetic Acid (EDTA), 0.5mL 3.2% sodium citrate or Z serum 
clot activator. The Vacutainer® system ensures that moderate standardized negative 
pressure was used for each sample, thereby preventing venous collapse and thus 
minimizing endothelial activation / damage due to trauma. In those patients where 
serial sampling was required, care was taken not to re-enter the previous point of 
venepuncture. 
 
For enzyme-linked immunosorbent assay (ELISA) blood samples were centrifuged 
within 30 minutes from collection at 1,500g for 20 minutes at 4°C. The resultant 
supernatant (plasma/serum) was then collected and stored at -70°C until later batch 
processing. For endothelial cell measurements, samples were processed as below. 
 110
2.4.3 Endothelial Progenitor Cell Quantification 
Flow Cytemetry 
For flow cytometry, 1 ml of freshly drawn K3 EDTA anticoagulated venous blood 
was used for enumerating EPCs by flow cytometry. Red blood cells were lysed with 
10 mL of BD lysing solution® (Becton Dickinson, UK). The sample was gently 
inverted continually for 10 minutes followed centrifugation at 700g for 5 minutes. 
The resultant cell pellet was then washed with 10mL of buffer solution [phosphate 
buffered saline (PBS), 5% bovine serum albumin BSA)] and then centrifuged again at 
700g for 5 minutes. This washing step was repeated twice. The resulting pellet was re-
suspended and the white cells blocked with 20μL of the Fc-receptor blocking 
antibody Octagam® (Octapharma, Lachen, Switzerland) and 200μL 10% mouse 
blocking serum (Sigma-Aldrich, Gillingham, UK) for a minimum of 20 minutes at 
room temperature. Next, the sample was incubated with 10μL each of CD133-PE 
(PhycoErythrin), CD45-FITC (Fluorescein IsoThioCyanate) and CD34-PECy5 
(PhycoErythrin Cy5) fluorochrome-labelled monoclonal antibodies for 20 minutes in 
the dark at room temperature. The sample was then washed with buffer solution and 
centrifuged as before. The resulting cell pellet was re-suspended and fixed in 200μL 
of 2% paraformaldehyde solution for 20 minutes at 4°C and then made up to a final 
volume of 1mL with buffer solution, ready for immediate flow cytometric analysis. 
 
Each sample was analysed using a 3-colour FACScan™ flow cytometer (Becton 
Dickinson, Oxford, UK) for a minimum of 500,000 mononuclear cellular events and a 
pre-determined time period, corresponding to a known volume of sample. The latter 
was determined from previous validation studies (data not shown). Cells were plotted 
according to forward scatter (FSC) and side scatter (SSC) profiles (each a measure of 
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size and granularity respectively) and gated to include only mono- and polymorpho-
nuclear events, thereby excluding cell doublets, platelets and cellular debris. EPCs 
were enumerated as a count of CD34+, CD133+, CD45- events per mL of blood. 
 
The gating strategy used was based upon a modified version of the ISHAGE protocol 
for haematopoietic progenitor / stem cell enumeration which is well established and 
has international consensus. In the initial plot all events are plotted according to 
CD45-FITC vs. SSC. The primary acquisition gate (R, region 1) is centred on all 
leukocytes, thereby excluding debris and other cell lines. Events from R1 are then 
sorted as CD34-PE Cy5 vs. SSC. The secondary acquisition gate (R2) is set around 
the CD34+ population of cells with a low SSC. The third plot is of cells gated through 
R1 and then R2, with R3 selecting those cells which are CD45- and CD133+ (CD133-
PE). The final gate (R4) displays cells from additive regions 1-3 with boundaries set 
by identifying the lymphocyte population. This method was designed to ensure that 
only cells with a FSC compatible with lymphocytes were included in the final 
analysis thereby providing a further point at which to exclude debris, dead cells and 
platelets etc. (figure 5). Fluorochrome-matched isotype controls (FITC-IgG1, PE-
IgG1, Pe-CY5-IgG1, BD, Abingdon, UK) and unstained samples were used to set 
various gate parameters and also served as negative controls. A simplified summary 
of this protocol is illustrated in Figure 6. 
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Figure 5. Flow Cytometry Gating Strategy for Endothelial Progenitor Cell 
Capture 
 
Image courtesy of Mr PKY Goon. 
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Figure 6. Simplified Flow Cytometry Gating Strategy for Endothelial Progenitor 
Cell Capture. 
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Cell Culture 
12 ml of freshly drawn K3 EDTA anticoagulated venous blood was transferred 
directly to the laboratory for processing. All work was performed in a ‘clean 
environment’ using appropriate sterile techniques and a negative pressure extraction 
hood designed specifically for cell culture. 
 
In brief, Mononuclear cells (MNCs) were isolated by density gradient centrifugation. 
4 mL of peripheral blood was diluted with an equal volume of Hank’s balanced salt 
solution (Sigma-Aldrich, Gillingham, UK). This was then carefully layered on to 3 
mL Ficoll® (GE-Healthcare, Little Chalfont, UK) in a 15 mL centrifuge tube, 
ensuring that the two solutions did not mix. The tube was centrifuged at 400 g for 40 
minutes at 18°C with no brake. The resultant buffy cell layer was removed and 
washed twice with 6 mL Hank’s balanced salt solution, followed by centrifugation at 
100 g for 10 minutes at 18°C to remove excess Ficoll®, serum and platelets. The 
resultant cell fraction was then re-suspended in 1 mL endothelium specific culture 
medium and, following an initial cell count, was plated on 24-well culture plates 
precoated with human fibronectin (Sigma-Aldrich). This process was repeated three 
times for each patient. 
 
The endothelium-specific culture medium used was Medium M199 (Gibco 
(Invitrogen), Paisley, UK) supplemented with 5 mg/100 mL endothelial growth 
supplement (Upstate, Buckinghamshire, UK), 15% foetal bovine serum (Sigma-
Aldrich) and penicillin/streptomycin (Sigma-Aldrich, Gillingham, UK). At 48 hours 
media were changed. 
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After 6 days in culture, media and non-adherent cells were removed and adherent 
cells underwent cytochemical analysis. Cells were consequently incubated with 
DiLDL (Invitrogen, Paisley, UK) (2.4 mg/mL) for 2 hours and with FITC-labelled 
lectin Ulex europaeus (Sigma-Aldrich) (10 mg/mL) for 1 hour and then fixed with 2% 
paraformaldehyde for 20 minutes. Dual-staining cells positive for both lectin and 
DiLDL were considered as EPCs. Additionally, expression of vascular endothelial 
(VE) cadherin was measured. Adherent cells were detached from the culture plate 
using 1 mmol/L EDTA diluted in phosphate buffered saline. Following a wash, cells 
were then incubated first with 10 μL Octagam® (Octapharma) and 200 μL 10% 
mouse serum (Sigma-Aldrich), and then in the dark for 20 minutes with 10 μL 
phycoerythrin (PE)-conjugated VE cadherin (Becton-Dickinson, Oxford, UK). 
Following a cell wash to remove excess antibody, the sample was immediately run on 
a Becton Dickinson (BD) FACScan flow cytometer.  
 
2.4.4 Enzyme-linked Immunosorbent Assays (ELISA) 
The ELISA assays all used commercially available antibodies and each has been fully 
validated in-house. ELISAs to be used in this thesis include: vWf, VEGF, Soluble 
Fas, Soluble Fas ligand, Soluble E-selectin and IL-6. 
 
In addition, hs-CRP was measured for the AFB study using an automated analyser 
from Roche Diagnostics. Brief standard operating procedures for each ELISA are 
included within the appendix for reference. 
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Section III: Laboratory Studies 
3.1 Investigating the biology of Progenitor Cells 
 
3.1.1 Introduction 
EPCs make up only about 0.0001% of circulating mononuclear cells328. Their rarity in 
peripheral bloods presents a challenge to researchers, many of whom prefer a pre-
enrichment phase or their reproduction through cell culture techniques prior to 
enumeration. In addition, the definition of EPCs relies upon a precise phenotypic 
definition. This antigen profile however varies widely across the literature. This in 
part relates to similarities between EPCs and other progenitor cell populations (e.g. 
haematopoietic stem cells, HSCs) which may also demonstrate similar functional 
characteristics or even cross-differentiate. Profiling is further hampered by a process 
of antigenic shift during the process of maturation (section 1.3.2). However, given the 
exciting potential for EPCs (particularly in view of their as yet unrealized therapeutic 
potential), it is vital that these cells are defined accurately and that our understanding 
of basic biological functions be enhanced. 
 
3.1.2 Antibody Selection 
EPCs are believed to predominantly originate from haematopoietic stem cells in bone 
marrow and, indeed, recent evidence suggests that the haemangioblast is a common 
progenitor for both haematopoietic and endothelial cells329. However, the definition of 
EPCs continues to evolve and has shifted significantly following their initial 
characterization by Asahara et al. in 1997213. EPCs were first identified and 
enumerated by their expression of both haematopoietic stem cell and endothelial cell 
markers, such as CD34, CD133 and vascular endothelial growth factor receptor-2 
 117
(KDR)213. Later expression of other endothelial markers (e.g. vascular endothelial 
(VE) cadherin, von Willebrand factor (vWf), CD146) in the process of maturation of 
endothelial progenitors was demonstrated214. However, given the heterogeneity of the 
EPC population, a robust definition still does not yet exist225. The situation is further 
complicated as expression of cell surface markers changes with EPC maturation221-224. 
There is also some evidence that cells of other lineages can cross-differentiate in to 
EPCs234, 242, 247. These markers are easily detected using flow cytometry, which 
essentially estimates the number of cells from peripheral blood, bone marrow, or other 
tissues that possess a specific cell type profile of surface markers. The expression of 
common markers by haematopoietic and endothelial progenitor cells in embryonic 
development and the trans-differentiation potential of monocytes into cells with 
endothelial characteristics would suggest a possible common origin from a bone 
marrow precursor, perhaps a putative haemangioblast329. Bone marrow also contains 
mesenchymal cells, which can differentiate into endothelial cells242 and improve 
vascularization in vivo243, 244, as well as release a variety of angiogenic growth 
factors246 and contribute to tissue repair245. In addition to bone marrow-derived cells, 
other cell populations, such as fat tissue247, 248, cardiac tissue249, and neural stem 
cells250 can also give rise to endothelial cells, suggesting that tissue-resident 
stem/progenitor cells can contribute to vascular growth in the adult. Table 12 
summarizes the various phenotypic profiles currently employed for EPC enumeration. 
 
Given the lack of universal agreement on the definition of true EPCs and the difficulty 
in reliably identifying a subpopulation with ongoing antigenic shift, it was decided 
that the term circulating progenitor cell (CPC) would best reflect these characteristics. 
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It was considered important that the antibody panel in flow cytometry reflect potential 
of CPCs for angiogenesis. Some reports indicate that most EPCs are a very early 
subset of progenitor cells and could therefore be defined as CD45dim/CD133+/CD34+ 
CPCs244, 284, 330. Other investigators have shown that CD45dim/CD34+ progenitor cells 
evolve into mature endothelial cells with a mature endothelial cell phenotype (CD45-
/CD31+/CD105+/KDR+/CD34+)331, 332. Additionally, most EPCs are CD34+ 333, and 
nearly all CD133+ cells are also CD34+ 224. The CD133 antigen appears to be shed 
during maturation thereby reliably identifying the earliest progenitors 334. 
 
3.1.3 Conclusion 
On the basis of this data, we opted to investigate CPCs as an early precursor of the 
EPC using the definition: CD133+/CD34+/CD45dim. Although the addition of a fourth 
marker (e.g. KDR/VEGF-R2) may be considered preferable, this could still not be 
viewed as definitive definition for a progenitor committed to endothelial 
differentiation as this too is non-specific. Additionally, further complexity of the 
antibody profiling was not possible given that the BD FACScan flow cytomter allows 
for only 3 colour channels. 
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Table 12 Flux of antigenic markers used to distinguish endothelial progenitor 
cells with maturation. 
 HSCs CPCs (early) CPCs (late) 
CD133 ++ - - 
CD117 ++ - - 
Sca-1 ++ + + 
CD34 ++ + + 
CXCR-4 + + + 
VEGFR-2/KDR + + + 
CD31 + + + 
VE-cadherin - + + 
vWf - + + 
E-selectin - + + 
ENOS - + + 
DiLDL + + + 
Lectin + + + 
CD105 - + + 
CD45 - + - 
CD14 - + - 
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3.2 Assessment of Cell Culture 
 
Abstract  
Background Flow cytometry and cell culture, the two main laboratory techniques 
employed for counting Circulating Progenitor Cells (CPCs), both have serious 
limitations. Mononuclear cells cultured in media favouring endothelial growth allow 
cells to replicate and differentiate/mature. CPCs under these circumstances tend to 
form groups of cells called endothelial colony forming units (EC-CFUs). EC-CFUs 
are widely accepted as a surrogate estimate of CPC number and function. However, 
some important limitations may restrict the assumption that EC-CFUs reflect CPC 
numbers accurately. Similarly, flow cytometry allows for a CPC count, using a panel 
predetermined markers. However, assessment of CPCs by this method alone litis 
complete assessment of CPCs by an inability to gauge their ability for replication and 
differentiation. The purpose of this study was to compare and contrast flow cytometry 
and cell culture for CPC enumeration and report our early findings. 
 
Methods 60 patients (62% male, mean age 67.5 ± 6.8 years) were recruited, 42% 
of whom had coronary artery disease were recruited. 20mL of blood was taken 
through a large antecubital vein and samples processed immediately in the laboratory. 
In brief, the mononuclear cell layer was isolated using density centrifugation. Cells 
were resuspended in a medium designed to enhance growth of endothelial progenitors 
(Medium M199 (Gibco), enhanced with Endothlial Growth Supplement (Upstate)) 
and then plated on to cell culture plates precoated in human fibronectin. Non-adherent 
cells were removed at 24 hours and media changed every 48 hours. At Day 5, EC-
CFUs were counted per plate. CPCs were confirmed by dual staining for Dil-
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acetylated low-density lipoprotein and fluorescein isothiocyanate-labelled lectin from 
Bandeiraea simplicifolia. Adherent cells were then detached from the cell culture 
plate using EDTA and stainined with VE-cadherin conjugated to FITC for 20 minutes 
in the dark. Following a washing stage to remove excess fluorochrome, samples 
underwent immediate flow cytometric analysis to assess the overall cell count. 
 
Results  Across the entire cohort recruited, there was a median of 14 (12-16) 
EC-CFUs per plate. In contrast, flow cytometry of the same samples returned a 
median of 285 (201-416) CD144+ detached cells per mL. Spearman’s correlation 
method was applied and did not demonstrate any correlation between EC-CFU per 
plate and CD144+ CPCs (r=0.011, P=0.931). Additionally, we observed that the size 
and number of EC-CFUs appeared to greatly fluctuate - even on the same cell culture 
plate - varying from only a few individual cells to large colonies. We also noted that, 
thin, spindle shaped endothelial-like cells are often located separately from EC-CFUs 
within the same plate. 
 
Conclusions EC-CFU counts represent the cumulative assessment of CPC quantity 
and their functional characteristics, including rate of differentiation, proliferation and 
senescence, and migrational activity. However, in the present analysis we observed 
large discrepancies between EC-CFU counts between samples on the same patient 
and a clear lack of correlation between EC-CFUs and cell counts from flow 
cytomtery. We therefore suggest that EC-CFU counts may not be reliably used for the 
estimation of CPC numbers in peripheral blood and until stronger definitions of CPCs 
emerge, flow cytometry may be the more optimal assessment modality, although this 
does not allow assessment of CPC functionality. 
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3.2.1 Introduction 
Flow cytometry and cell culture are the two main laboratory techniques employed for 
counting and functional assessment of CPCs (section 2.4.3). Both of these techniques, 
however, have serious limitations, often overlooked by the scientific community. This 
chapter explores the potential pitfalls encountered in counting CPCs following cell 
culture. 
 
Cultivation of peripheral blood mononuclear cells (MNCs) in media favouring 
endothelial growth is a widely used approach for the definition and quantitative 
analysis of CPCs 232, 234, 281. Adherent cells have been shown to possess endothelial 
characteristics, such as the expression of vWf and staining for Dil-acetylated low-
density lipoprotein (DiLDL) and fluorescein isothiocyanate-labelled lectin from 
Bandeiraea simplicifolia (FITC-BS-lectin) 229-232. Despite the relatively low numbers 
of CD34+ of circulating endothelial precursors in peripheral blood (100–500 per mL), 
relatively large numbers of adherent cells are found during culture (<100,000 from 1 
mL of blood). This raises some controversy with respect to the identification and the 
origin of isolated CPCs, as these cells appear to reflect a functional subpopulation 
within the blood MNC pool that have the potential to differentiate into an endothelial 
phenotype in vivo 222, 232, 233, 235, 236, 281. Indeed, early endothelial-like cells are often 
derived from peripheral blood monocytes281. Nonetheless, a clear advantage then of 
the cell culture approach is that it permits quantification of all cells capable 
differentiating into endothelial cells. Differentiated endothelial cells tend to form 
groups of cells, which are called endothelial cell colony forming units (EC-CFUs). As 
the number of single endothelial cells in culture is too large to count under light or 
fluorescent microscopy, the number of EC-CFUs is a widely accepted surrogate 
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estimate for the quantity of CPCs in cell culture. However, do EC-CFUs really reflect 
the number of CPCs following cell culture? The purpose of this work was to compare 
and contrast flow cytometry and cell culture for CPC enumeration and report our 
early experiences. 
 
3.2.2 Methods 
We investigated whether EC-CFUs were truly reflective of the number of CPCs 
following cell culture in patients with different temporal patterns of AF, recruited 
consecutively from the AF clinic. As the main focus of the present study was to 
compare and contrast methods for CPC enumeration, AF represented an ideal disease 
group choice due to the frequent association of this arrhythmia with various 
cardiovascular co-morbidities. 
 
Cell Culture and Flow Cytometric Analysis of Circulating Progenitor Cells 
The technique for cell culture and flow cytometric analysis has been discussed in 
depth previously (section 2.4.3). For each patient, samples were plated on at least two 
separate culture plates and the mean EC-CFU count taken. 
 
Flow Cytometry 
Following cell culture and EC-CFU counts on day 5, adherent cells were detached 
from the cell culture plate as per section 2.4.3 and stainined with VE-cadherin. 
Following this, samples underwent immediate flow cytometric analysis to assess the 
overall cell count. 
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3.2.3 Results 
60 patients (62% male, mean age 67.5 ± 6.8 years) were recruited, 42% of whom had 
coronary artery disease (table 13). Across the entire cohort recruited, there was a 
median of 14 (12-16) EC-CFUs per plate. In contrast, flow cytometry of the same 
samples returned a median of 286 (201-416) CD144+ detached cells per mL (table 
14). 
 
Data for EC-CFUs and CPCs were both non-parametric in distribution (kolmogorov-
smirnov). Spearman’s correlation method was applied to mean EC-CFU per plate and 
mean CD144+ CPCs (r=0.011, P=0.931), whilst logarithmic correlation is illustrated 
in figure 7. 
 
Additionally, we observed that the size and number of EC-CFUs appeared to greatly 
fluctuate - even on the same cell culture plate - varying from only a few cells (Figure 
8(a)) to large colonies (Figures 8(b) and 8(c)). We also noted that, thin, spindle 
shaped endothelial-like cells are often located separately from EC-CFUs within the 
same plate (Figure 8(d)). 
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Table 13 Baseline Demographics of cell culture patients 
 
Characteristics  
n 60 
Age 67.5 ± 9.8  
Male 37 (62%) 
Diabetes 6 (10%) 
Hypertension 51 (85%) 
Hyperlipidaemia 33 (55%) 
Known IHD 25 (42%) 
Previous stroke 3 (5%) 
Smoker 34 (57%) 
Aspirin 21 (38%) 
Warfarin 29 (48%) 
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Table 14. Comparison of median cell counts during cell culture and subsequent 
flow cytometry. 
 
 Number per sample Correlation 
n 60 
EC-CFUs 14 (12.4 – 16) 
CPCs 286 (201-416) 
 
r 
 
P 
0.011 
 
0.931 
 
EC-CFU – Endothelial Cell Colony Forming Units; CPC – Circulating Progenitor 
Cells. Data refers to median (InterQuartile Range). Correlation Co-efficient by 
Spearman’s method. 
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Figure 7 Correlation of cell counts by cell culture and flow cytometry. 
 
 
 
 
Scatterplot of mean EC-CFU per plate vs. mean CD144+ CPCs following logarithmic 
transformation. Correlation by Spearman’s method, r=0.011, P=0.931. 
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Figure 8 Endothelial Progenitor cells and endothelial colony forming units under 
light microscopy. 
 
 
 
Note that the size of endothelial cell colony forming units (EC-CFUs) varies widely. 
(a): small CFUs consisting of a few cells (40x); (b) and (c): bigger CFUs (40x, 100x); 
(d):  predominantly single located endothelial cells without accumulation in EC-CFUs 
(40x). 
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Figure 9 Progenitor cell migration and colony forming units (EC-CFUs). 
 
 
 
(a): Migration of EPCs to each other before forming CFUs (40x); (b). b: This process 
may be impaired in some patients (40x). 
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3.2.4 Discussion 
Large EC-CFUs are often demonstrated on research publications, and sometimes 
represent very large cell accumulations. Indeed, variations in the size of EC-CFUs 
amongst different samples are common, and the migratory capacity of CPCs can be 
changed in different pathological states231, 269, 290. The ability of CPCs to migrate to 
each other to form a colony may significantly affect the number of EC-CFUs formed 
in culture experiments, despite a similar number of CPCs. The importance of culture 
cell migration for colony forming can be proven visibly by the poor EC-CFU forming 
capacity of MNCs before their differentiation into endothelial cells (Figure 9) and the 
fact that EC-CFUs can include different proportions of total CPCs (Figure 8). The 
subjectivity regarding which clusters should be considered as EC-CFUs may make 
this approach less reliable. Furthermore, recent studies have demonstrated that EC-
CFUs have limited differentiation capacity into endothelial cells and may retain some 
myeloid progenitor activity335. 
 
Most researchers perform CPC counts (based on numbers of EC-CFUs) relative to the 
day of initiation of cell culture (generally between day 4 and day 7). The rate of CPC 
differentiation depends on the functional condition of CPCs, culture media used, and 
endothelial growth supplements. Simultaneous with CPC differentiation, the process 
of cell proliferation (another functional characteristic of CPCs) begins. Thus, the 
number of EC-CFUs depends not only on CPC counts and migratory activity, but also 
on the rate of CPC proliferation and differentiation. Amongst adherent MNCs, there 
may also be some mature circulating endothelial cells (CECs), and thus some 
researchers prefer to perform pre-plating of MNCs to reduce contamination with 
CECs, which also express endothelial markers, including CD34 225. How effective this 
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approach is remains unclear, but the loss of some CPCs during the pre-plating stage 
may significantly affect total PC counts. 
 
There are alternatives to EC-CFU counts. A count of the total number of cultured 
endothelial cells (single cells plus cells inside the EC-CFU) may be more accurate in 
terms of CPC quantification, but numbers of single CPCs in cell culture are too great 
for an accurate manual count under light microscope. As an alternative, the count of 
differentiated cultured CPCs by flow cytometry can be used, with specific mature 
endothelial markers (e.g. CD146, CD144 (VE cadherin) or vWf). This approach has 
been tested in our department (with VE cadherin as a marker) and permits count of 
both single CPCs and those CPCs grouped in EC-CFUs together. CD146 is expressed 
on non-differentiated endothelial progenitors, although in small amounts336. The rate 
of vWf expression is slower, and its use can thus underestimate the true CPC count. 
Thus, VE cadherin may be the optimal marker, from those currently available for use 
in this setting. Indeed, VE cadherin is an adhesion molecule that plays a fundamental 
role in microvascular permeability and in the morphogenic/proliferative events 
associated with angiogenesis, suggesting its importance for endothelial integrity. VE 
cadherin is exclusively expressed by endothelial cells in adults 337-339. In addition, 
embryo yolk sac cells with haemoangiogenic potential have been shown to lose VE 
cadherin expression when differentiating to haematopoietic progenitor cells340. This 
analytical approach permits the exclusion of the effect of migratory activity on CPC 
counts, but cannot exclude the effect of CPC proliferation and CEC numbers. 
 
It is impossible to fully eliminate the contamination of peripheral blood MNCs with 
CECs, but we can estimate the proportion of CECs by flow cytometric count of cells 
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with pure markers of mature endothelial cells (e.g. CD146 or VE cadherin) after the 
first media change (in 24–48 hours), when non-adherent MNCs are removed and 
CPCs have still not differentiated into mature endothelial cells. At this stage, CD146 
or VE cadherin+ cells will reflect CEC contamination. Any increase in VE cadherin+ 
or CD146+ cells will mainly represent differentiated ECs, as CECs proliferation seems 
to be relatively low or rare. As there is no marker which can reliably distinguish 
mature CPCs from their generic endothelial cells as a result of CPC proliferation, it 
seems reasonable to standardize the day of the PC count (e.g. days 4–7) and use 
media/supplement to make the impact of CPC proliferation less significant. 
 
It can be argued that one of the major characteristics of CPCs is their ability to 
proliferate, differentiate and integrate within the endothelium. These characteristics 
however, cannot be assessed by flow cytometry alone and require supplemental data – 
usually from cell culture experiments. The apparent lack of agreement observed 
within the present analysis is clearly of concern if the two techniques are to be used in 
parallel. Other researchers have also reported their concern regarding discrepancies 
observed between cell culture and cell counts returned following flow cytometry, 
using similar techniques to those employed here341. However, there is again 
inconsistency and other groups have suggested a strong correlation between the two 
techniques, albeit using alternative cell marker profiles342. Such discrepancies may 
have numerous explanations. This includes variable techniques for culture and 
inconsistencies within the antigenic profile used for flow cytometry. The latter is 
unlikely to be resolved until a universal definition for CPCs becomes established 
It is therefore feasible that cells undergoing proliferation on the cell culture plate are 
predominantly of a different subset compared to those cells that are being enumerated 
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by flow cytometry. 
 
Sample contamination with yeasts and bacteria can also inhibit cellular proliferation – 
thus necessitating meticulous attention to sterility and the addition of anti-fungal and 
bactericidal to cell culture media. Nonetheless, despite these steps the release of 
various substances by bacteria into the cell culture media, does offer the potential to 
imply variable inhibition of proliferation of CPCs. 
 
One further methodoligcal consideration that merits discussion is the effect of cell 
loss by sequential handling. This is important, as each time a sample is handled, 
transferred to an alternative transport tube or washed, there will be loss of a number of 
cells of interest. This can be due to failure to transfer the entire sample – cells may 
adhere to the walls of the transport tube, or preparation tubes during centrifugation. 
Similarly during media changes and washing steps, partially adherent cells may be 
lost. Alternatively cells may be destroyed following detachment with EDTA and 
subsequent transfer from the culture plates, although this is likely to be particularly 
evident with flow cytometry samples as these have undergone additional processing 
steps after the initial cell count for EC-CFUs, thereby introducing further potential for 
inconsistencies. 
 
Finally, one pragmatic solution to these methodolgical limitations would be to first 
count and sort CPCs using flow cytometric methods and then take the same cells and 
culture these in a standard way. However, it is likely that the processing involved in 
preparation of a sample for flow analysis may well alter the physical properties of the 
cells or their ability to differentiate – particularly if chemical such as 
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paraformaldehyde are used to ‘fix’ cells as in our protocol (section 2.4.3). More 
recently, cells have been partially pre-selected and then cultured (with some success) 
using magnetic sorting techniques that entail the use of an antibody conjugated to 
magnetic beads. The advent of further technological advances are awaited. 
 
3.2.5 Conclusion 
EC-CFU counts represent the cumulative assessment of CPC quantity and their 
functional characteristics, including rate of differentiation, proliferation and 
senescence, and migrational activity. However, in the present analysis we observed 
large discrepancies between EC-CFU counts between samples on the same patient 
and a clear lack of correlation between EC-CFUs and cell counts from flow 
cytomtery. We therefore suggest that EC-CFU counts cannot be reliably used in the 
setting of the present study for the estimation of CPC numbers in peripheral blood. 
Therefore until stronger definition(s) of bone marrow or peripheral blood 
population(s) of CPCs are developed, flow cytometry may be the more optimal 
technique for CPC quantification, despite a clear inability to assess for functional 
capacity of these cells. Given these findings, it was decided to base CPC enumeration 
for the remainder of this thesis on assessment by flow cytometry rather than use cell 
culture. 
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3.3 Physiology of Circulating Progenitor Cells 
 
Abstract 
Background Circulating progenitor cells (CPCs) are thought to help to maintain 
endothelial homeostasis. However, our knowledge of CPC physiology remains 
immature. This study aimed to define the influence of exercise treadmill testing (ETT) 
on CPC levels; to assess the diurnal variation of CPCs; and to investigate the rate of 
temporal decline in CPCs once ex-vivo.  
 
Methods The dynamics of CPC count changes following an ETT were assessed 
on 20 patients (70% male, age 69.9±7.8 years) with suspected angina pectoris. 
Venous blood samples were taken pre-exercise, immediately post-exercise and at 30 
minutes post-exercise. Diurnal variation in CPCs was assessed in 13 stable in-hospital 
patients (46% male, age 69.1±7.5 years). Blood samples were taken 5 times – once 
every 6 hours for a complete 24-hour cycle. To investigate the temporal decline, 
blood samples from 12 patients with chronic atrial fibrillation (58.3% male, age 
69.9±7.9 years) were reprocessed for CPC counts at 4 and 24 hours after sample 
collection. Plasma levels of von Willebrand factor (vWf), soluble E-selectin (sE-
selectin) were assessed by ELISA. CPCs were enumerated by flow cytometry as 
CD34+, CD133+, CD45dim events. 
 
Results  Exercise led to significant increases in systolic blood pressure, heart 
rate, vWF and sE-selectin levels, but no significant influence on CPC counts were 
observed. Baseline CPC numbers demonstrated a negative correlation with vWf (r=-
0.551, p=0.012). Baseline CPC numbers also correlated significantly with their levels 
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immediately post, and 30 minutes post exercise (r=0.968 and r=0.955 respectively, 
both P<0.001). Similar observations applied to vWf (r=0.720, P<0.001 and r=0.471, 
P=0.036 respectively) and sEselectin (r=0.772 and r=0.874 respectively, both 
P<0.001). An exploratory subgroup analysis assessed patients with a negative ETT 
(n=9) vs. those unable complete the protocol (positive or inconclusive ETT, n=11). 
The cohort with a positive ETT had higher median CPC counts across all three 
timepoints, although the ΔCPC (from rest to peak exercise) were similar. None of 
these differences reached statistical significance. There were no major differences in 
sE-selectin or Vwf levels across the three timepoints, although patients with a positive 
test had borderline significantly lower vWf levels immediately after the test. 
 
Median CPC counts showed significant diurnal variation (P=0.011), being 
significantly higher at 12am compared to 12pm (150 [90-237] vs. 142 [38-167]; 
p=0.046) and 12pm compared to 6pm (150 [90-237] vs. 96 [79-188]; p=0.023). 
Delayed sample preparation by 4 hours did not significantly affect the number of 
CPCs detected, compared to baseline, but there was a significant decline in CPC 
recovery observed when sample processing was delayed by 24 hours (P=0.019). 
 
Conclusions Routine exercise stress testing does not appear to significantly affect 
CPC counts and usual physical activity prior blood sample collection is unlikely to 
affect their levels. Peripheral CPC levels showed a degree of diurnal variation and 
delays in sample preparation for CPC counts should be avoided as they may influence 
the accuracy of the test by resulting in a significant decline in CPC recovery. 
However data needs to be considered in light of low sample numbers and broad data 
spread, hence larger studies are required for confirmation of these findings. 
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3.3.1 Introduction 
As with CECs, CPCs would appear to reflect vascular health with numerous studies 
demonstrating fewer numbers in patients with multiple cardiovascular risk factors or 
overt cardiovascular disease231, 232. Conversely, during periods of tissue ischaemia, 
CPC numbers generally seem to increase – presumably to effect repair to the vascular 
endothelium 343, 344. Natural physiological processes also seem to have an impact on 
CPCs, for example, ageing has been shown to reduce both CPC numbers and 
function252, 254. Conversely during physical exercise, circulating CPC numbers rise – 
both in healthy patients and those with cardiovascular disease266, 345. The explanations 
for these and many other observations are varied and may relate to aberrations in CPC 
production, release, destruction or endothelial integration232, 255, 344. In addition, the 
role of various chemokines including endothelial nitric oxide or Vascular Endothelial 
Growth Factor [VEGF] may be important. 
 
Physical training has consistently been shown to improve endothelial function, 
exercise tolerance and collateralization of blood supply to patients with coronary 
artery disease, heart failure and peripheral vascular disease263, 265, 346. Similarly, during 
exercise, circulating CPC numbers also rise – both in healthy patients or subjects with 
cardiovascular risk factors or overt cardiovascular disease and it has been speculated 
that this effect may relate to enhanced release of endothelial nitric oxide or VEGF or 
even due to reduced EPC apoptosis347-349. This effect may also be mediated through 
enhanced endothelial sheer stress or due to enhanced stimulation of growth factors or 
inflammatory mediators. 
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It is vital that CPCs are accurately defined in terms of origin, basic biological function 
and kinetics if we are to appreciate their full potential.  In this study, we examined the 
influence of exercise treadmill testing (an established screening tool to identify 
patients likely to have flow-limiting coronary artery disease) on peripheral CPC 
numbers. In addition, we assess the diurnal variation of peripheral CPC counts in 
patients with risk factors for cardiovascular disease and investigate the rate of 
temporal decline in CPCs once ex-vivo.  We hypothesized that exercise might provoke 
a rise in CPC counts. Secondly, we hypothesized significant diurnal aberrations in 
CPC counts throughout the 24-hour period studied. Thirdly, we hypothesized that 
there would be a steady temporal decline in CPC counts once the cells were 
held/stored ex vivo. 
 
3.3.2 Methods 
Effects of physical exercise on CPC count 
The dynamics of CPC counts following an exercise treadmill test (ETT) were 
assessed on 20 consecutive patients referred to our ‘rapid-access’ chest pain clinic 
with suspected angina pectoris, who satisfied study criteria. The ETT was performed 
according to the Bruce protocol (an established screening tool used to identify patients 
likely to have flow-limiting coronary artery disease) as previously described350, 351. 
Real-time 12-lead and computer-averaged Electrocardiogram [ECG] recordings were 
taken during and after exercise testing. Blood pressure was measured immediately 
pre-procedure and at 3-minute intervals thereafter until complete recovery following 
the ETT. The ETT was considered positive in patients with exercise-related ECG 
changes diagnostic of ischaemia (>1 mm horizontal or down-sloping ST-segment 
depression or elevation for >60–80 ms after the end of the QRS, significant 
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arrhythmia, systolic blood pressure decrease of >10 mmHg or significant 
symptoms352. Venous blood samples were taken from supine patients immediately 
pre-exercise, immediately post-exercise and at 30 minutes post-exercise.  
 
Exclusion criteria included recent (<3 months) stroke, thromboembolism, acute 
coronary syndrome, myocardial infarction, uncontrolled hypertension (BP ≥140/90 
mm Hg), left or right bundle branch block on resting ECG, presence of structural 
cardiac abnormalities (e.g. significant valvular disease, hypertrophic cardiomyopathy 
or left ventricular ejection fraction <40%), and inflammation-related conditions 
(active infection, rheumatoid arthritis, connective tissue disorders, vasculitis, 
malignancy, corticosteroid usage). 
 
Diurnal CPC variation 
13 patients were studied for assessment of diurnal variation in CPCs. All patients 
were hospital in-patients who had been stable for at least 1 week following their initial 
admission and were similar in terms of age, gender and co-morbidities to participants 
of the exercise test arm. Blood samples were taken 5 times every 6 hours starting from 
at 12pm and finishing 12pm following day [5 sampling points per patient].  
 
Effects of delay of sample preparation on CPC count 
In a subset of 12 patients, the blood sample was reprocessed for CPC counts at 4 
hours and 24 hours after collection in order to assess for temporal decline of CPC 
counts once ex vivo. During this time, samples were kept in a controlled environment 
at 4◦C. 
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Laboratory processing for circulating progenitor cells 
The technique for blood sampling and enumeration of CPCs by flow cytometry has 
been previously described (section 2.4.3) 
 
Statistical analysis 
The statistical methods used have been previously described (section 2.3.2) 
 
3.3.3 Results 
Effects of exercise   
20 patients were recruited into this arm of the study (age 69.9±7.8 [range 51-80], 70% 
male) years (table 15). The ETT was negative in 9 patients, positive in 8 cases and 
was considered sub-maximal or inconclusive in 3 subjects. Exercise led to significant 
increases in systolic blood pressure, heart rate, vWF, and sE-selectin, but no 
significant dynamics on CPC count were observed in relation to exercise (table 16). 
 
Baseline CPC numbers demonstrated a negative correlation with baseline vWf (r=-
0.551, p=0.012). Baseline CPC numbers also correlated significantly with their levels 
immediately post, and 30 minutes post exercise (r=0.968 and r=0.955 respectively, 
both P<0.001). Similar observations applied to vWf (r=0.720, P<0.001 and r=0.471, 
P=0.036 respectively) and sE-selectin (r=0.772 and r=0.874 respectively, both 
P<0.001) (table 17). No baseline risk factors were predictive of exercise induced 
alterations in research indices on multiple linear regression analysis (table 18)). 
 
An exploratory subgroup analysis assessed patients with a negative ETT (n=9) versus 
those unable complete the protocol (positive or inconclusive ETT, n=11). Baseline 
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demographic data revealed no major differences between the two cohorts aside from a 
higher number of smokers amongst the latter group (11% vs. 54%, P=0.001, table 19). 
Those with a negative test had a peak blood pressure 17mmHg higher than those with 
a positive test, although this did not reach statistical significance. The cohort with a 
positive ETT had higher median CPC counts across all three timepoints, although the 
ΔCPC (from rest to peak exercise) were similar. None of these differences reached 
statistical significance. There were no major differences in sE-selectin or Vwf levels 
across the three timepoints, although patients with a positive test had borderline 
significantly lower vWf levels immediately after the test (table 19). 
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Table 15. Characteristics of the patient participating in the exercise study 
 
Characteristics  
n 20 
Age 69.9±7.88 
Male 14 (70%) 
Diabetes 2 (10%) 
Hypertension 17 (85%) 
Hyperlipidaemia 12 (60%) 
Known IHD 5 (25%) 
Atrial fibrillation 1 (5%) 
Previous stroke 2 (10%) 
Aspirin 12 (60%) 
Beta-blockers 10 (50%) 
Calcium antagonists 6 (30%) 
Statins 8 (40%) 
ACEI/ARB 12 (60%) 
Current smokers 7 (35%) 
Haemoglobin 14.1±1.41 
Leukocytes 7.42±2.14 
Platelets 235±77.6 
Creatinine 93.4±19.2 
 
IHD – Ischaemic Heart Disease; ACE-I – Angiotensin Converting Enzyme inhibitor; 
ARB – Angiotensin-2 receptor blocker. Values are expressed as mean ± standard 
deviation or No. (%) 
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Table 16. Effects of exercise on Haemodynamic Parameters and marker levels 
 
Parameter Before test Immediately 30 min after test P-value 
HR 
(beats/min) 
70.4 ± 16.52 145.1 ± 19.03 70.4 ± 9.96 <0.01a,c 
BP (mmHg) 136.3 ± 18.53 170.6 ± 16.03 134.0 ± 11.3 <0.01a,c 
CPC (mL-1) 117.5 (36-172) 132 (64-165) 102 (61-142) 0.279 
vWf (IU/dL) 116.9±27.2 131.4±23.3 123.5±19.8 0.014a,b 
sE-selectin 
(ng/mL) 
52.0 (28.0-
66.0) 
59.0 (41.0-
71.0) 
55.0 (30.5-59.5) 0.004a,c 
 
HR – Heart Rate; BP – Blood Pressure; CPC – Circulating Progenitor Cells; vWf – 
von Willebrand factor; sE-selectin – soluble E-selectin. Values are expressed as mean 
± standard deviation, Median (Interquartile Range). P-value refers to the results of 
repeated measures ANOVA. For significant differences (Tukey post hoc P<0.05): apre 
and immediate post; bpre and 30 minutes post; cimmediate post and 30 minutes post. 
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Table 17. Spearman Correlation of test variables 
 
   Baseline Immediate post 30 minutes post 
 Variables  vWf sEsel CPCs vWf sEsel CPCs vWf sEsel 
r -.551 -.501 .968 -.456 -.262 .955 -.202 -.328 CPCs 
p .012 .024 .000 .043 .265 .000 .394 .158 
r .106 -.509 .720 .069 -.555 .471 .010 vWf 
p 
 
.656 .022 .000 .773 .011 .036 .966 
r  -.499 -.076 .772 -.454 -.063 .874 
B
as
el
in
e 
sEsel 
p  
 
.025 .749 .000 .044 .791 .000 
r   -.424 -.274 .963 -.109 -.332 CPCs 
p   
 
.062 .242 .000 .648 .153 
r    -.090 -.411 .205 -.084 vWf 
p    
 
 .705 .072 .387 .725 
r     -.270 .205 .791 
Im
m
ed
ia
te
 p
os
t 
sEsel 
p     
 
.250 .387 .000 
r       -.203 -.314 CPCs 
p       .390 .177 
r        -.214 
30
-m
in
ut
es
 
vWf 
p        .365 
 
CPC- Circulating Progenitor cells; vWf – vonWillebrand factor; sEsel – soluble E-
selectin; Data refers to Spearman correlation of test variables at baseline. A P<0.01 
was considered statistically significant 
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Table 18. Regression analysis of exercise induced alterations in research indices 
to risk factors. 
 
  Research Indices 
Variables  ΔvWf ΔsEsel ΔCPCs 
β .226 .419 .493 Age 
P .425 .193 .140 
β .603 .161 .099 BMI 
P .041 .582 .742 
R .168 .238 .230 BP 
β .568 .466 .492 
R .246 .127 .332 DM 
β .417 .701 .338 
β .376 .611 -.420 ↑lipidaemia 
P .243 .099 .250 
β .222 .212 .211 IHD 
P .455 .517 .528 
β .191 .185 .165 Smoker 
P .574 .623 .669 
R2  .527 .648 .391 
 
BP – Blood Pressure; BMI – Body Mass Index (Kg/m2); DM – Diabetes Mellitus; 
IHD – Ischaemic Heart Disease; CPC- Circulating Progenitor Cells; vWf – 
vonWillebrand factor; sEsel – soluble E-selectin; Δ indicates the change in research 
indices from baseline to peak exercise. Data refers to standardized β co-efficients. A 
P<0.01 was considered statistically significant. 
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Table 19. Study characteristics in relation to exercise test results 
 
Variable Negative test Positive test P-value 
N 9 11  
Age 72.7±6.23 67.7±8.66 0.45 
Male 6 (67%) 8 (72%) 0.59 
Diabetes 1 (11%) 1 (9%) 0.79 
Hypertension 8 (89%) 9 (82%) 0.40 
Hyperlipidaemia 6 (67%) 6 (54%) 0.34 
BMI (Kg/m2) 27.4±3.43 32.4±8.09 0.03 
Sinus rhythm 9 (100%) 10 (91%) 0.06 
Previous stroke 0 (0%) 1 (9%) 0.78 
Known CCF 3 (33%) 5 (45%) 0.34 
Smoking 1 (11%) 6 (54%) 0.001 
Heart rate    
At rest 72.4±18.2 68.9±16.0 0.94 
Peak exercise 146±12.9 144.1±23.5 0.07 
BP systolic (mmHg)    
 At rest 138.3±16.10 134.5±20.1 0.21 
Peak exercise 180±14.7 162.6±12.5 0.60 
CPC counts (mL-1)    
At rest 76 (34-156) 130 (86-180) 0.34 
Immediately after ETT 64 (41-168) 148 (104-168) 0.20 
30 min after ETT 78 (56-127) 124 (82-150) 0.16 
ΔCPC 10 (-10-19) 6 (-14-27) 0.82 
vWf (IU/dL)    
rest 108.4±34.1 123.7±18.9 0.13 
Immediately after ETT 133.7±32.3 129.6±13.7 0.04 
30 min after ETT 116.9±22.1 128.8±16.8 0.08 
ΔvWF 25.22±12.8 5.82±19.6 0.31 
sE-selectin (ng/mL)    
rest 25.1±9.2 24.1±9.4 0.82 
Immediately after ETT 24.3±8.2 23.1±8.0 0.40 
30 min after ETT 27.4±3.4 28.9±8.1 0.99 
ΔsE-selectin -0.78±5.8 -1.0±3.2 0.22 
CPC – Circulating Progenitor Cells; vWf – vonWillebrand factor; sE-selectin – 
soluble E-selectin; BMI – Body Mass Index; CCF – Congestive Cardiac Failure; BP – 
Blood Pressure; ETT – Exercise Tolerance Test; Δ – Change in value from pre-
exercise to peak exercise; Values are expressed as mean ± standard deviation (SD), 
Median (InterQuartile Range, IQR) or No. (%) as appropriate unless otherwise 
indicated. Analyses were performed using the χ2 test for categorical data or unpaired 
t-test for continuous parametric data. The Mann-Whitney U test was used for non-
parametric data. A p value < 0.05 was considered statistically significant 
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Diurnal Variation 
For this study, 13 patients were recruited (46% male, age 69.1±7.5 years) during the 
rehabilitation phase of a hospital admission with coronary artery disease. Median CPC 
counts showed a significant diurnal variation (table 20, figure 10, Friedman’s repeated 
measures ANOVA, p=0.011) being significantly higher at 12am compared to 12pm 
(150 [90-237] vs. 142 [38-167]; p=0.046) and 12pm compared to 6pm (150 [90-237] 
vs. 96 [79-188]; p=0.023). 
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Table 20 Circulating progenitor cell counts during the diurnal variation analysis. 
 
 Timepoint 
N=13 12pm 6pm 12am 6am 12pm (+24 hrs) P-value 
CPCs mL-1 142 (38-167) 96 (79-188) 150 (90-237) 124 (98-207) 154 (79-200) 0.011 
 
CPCs – Circulating Progenitor Cells; Values are expressed as median (InterQuartile Range, IQR). P-value refers to the results of Friedman’s 
repeated measures ANOVA. For significant differences (Tukey post hoc P<0.05): a12pm-6pm; b6pm-12am; c12am-6am; d6am-12pm (+24hours); 
e12pm-12am; f12pm-6am; g12pm-12pm (+24 hours); h6pm-6am; i6pm-12pm (+24 hours); j12am-12pm (+24 hours).
 
Figure 10 Diurnal variation in circulating progenitor cell counts 
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CPCs – Circulating Progenitor Cells; Values are expressed as median (InterQuartile 
Range)
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Temporal Decline 
To evaluate the effect of the delayed blood sample preparation of CPC recovery 
samples from a further 12 patients with chronic atrial fibrillation (58.3% male, mean 
age 69.9±7.9 years) were analysed sequentially at 4 hours and at 24 hours following 
venepuncture (figure 11). There were no significant changes in CPC numbers detected 
at 4 hours after sample collection, but there was a significant decline in CPC recovery 
observed when sample processing was delayed by 24 hours (P=0.019).
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Figure 11 Temporal decline in circulating progenitor cell counts. 
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3.3.4 Discussion 
Our results demonstrate that median CPC numbers appear to trend towards an 
increase (albeit not significant) following a single ‘one off’ exercise stimulus (to 
exhaustion) using the Bruce protocol regimen. However this increase is not sustained 
at 30 minutes post exercise. Our data also show that CPCs demonstrate a degree of 
diurnal variation with respect to the circadian clock, with an apparent peak in the 
evening and slightly lower levels throughout the remainder of the day. Finally, we 
show a significant decline in CPC recovery when sample processing was delayed by 
24 hours. 
 
In the exercise study, there was a notable increase in both systolic blood pressure and 
heart rate in all our patients. Oddly the rise in BP appeared to be greater amongst 
those with a negative test comared to those with a positive test. This latter observation 
was not significant despite an apparent 17mmHg difference, perhaps reflecting low 
numbers within each subgroup. Importantly, both of these parameters may have 
resulted in enhanced endothelial ‘shear stress’ that could have accounted for the 
observed changes in the various research indices tested. Indeed, a rise in both mean 
vWf and soluble E-selectin may reflect the impact of exercise upon the endothelium 
and/or acted as a signal to promote CPC release and recruitment into the endothelium. 
This endothelial ‘reaction’ to exercise has previously been demonstrated in several 
other small studies which have assessed sEsel, vWf flow-mediated dilatation and 
CECs respectively350, 353, 354. 
 
However, there are differential effects of moderate and extreme exercise on EPC 
levels. In healthy subjects, intensive and moderate exercise for 30 minutes, but not for 
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10 minutes, acutely increases circulating levels of EPCs355. Generally, EPC 
mobilisation seems to reflect the intensity of physical activity. For example, a brief 
exhaustive exercise increases levels of circulating EPCs by almost 4-fold267. 
However, extreme exercise may have a different effect, as no significant changes in 
EPC levels were observed in marathon runners, whilst CD34+ and CD133+ CPCs 
were significantly downregulated in parallel to VEGF levels356. 
 
Physical activity may differentially affect levels of various EPC subsets and an 
increase in CD133+KDR+ but not CD34+KDR+ EPCs was associated with the 
intensity of habitual exercise357. These indicate that data obtained for one population 
of circulating progenitors can not automatically be extended to all subsets. For 
example, more intensive daily physical rehabilitation up-regulates the number of 
CD34+133+ CPCs353. The present analysis suggests that exercise in short bursts may 
also enhance CPC mobilization, although this response is clearly not maintained after 
30 minutes. 
 
Our data suggesting a diurnal variation in CPCs is in agreement with findings from 
another small study investigating KDR+ EPCs358. It is plausible that the observed 
effects relate to relative dehydration given that consumption of fluids is generally 
lower in the early evening and overnight. However, this possibility is considered less 
likely given that the 6am sample – which follows the longest period of relative 
dehydration (overnight) – does not demonstrate the lowest counts. 
 
Similar diurnal patterns are seen with other cell lines (again in small studies) and, 
peripheral neutrophil, monocyte and lymphocyte numbers also appear to peak during 
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the evening rather than in the early morning359, 360. The explanation for these findings 
is unknown. Fluctuations in counts of various cell lines may be a consequence of 
alterations in the very stimuli that are known to promote their release. In the case of 
CPCs, this includes factors such as GM-colony stimulating factor (CSF), G-CSF and 
corticosteroids (amongst other factors) all of which have also been shown to express a 
degree of diurnal variation 361, 362. A further alternative possibility is that endothelial 
damage (and consequently repair) is greatest overnight, given that vascular events 
such as myocardial infarction, ischaemic stroke and sudden cardiac death also 
demonstrate marked circadian variation with a peak in the early morning hours 363, 364. 
 
In addition, the pattern of CPC diurnal variability, if present, may be more complex 
than is immediately apparent. Data from the 12pm (+24hr) sample counts were 
broadly similar to those seen at midnight the previous evening and are also slightly 
greater than those observed at 12pm the previous day (table 19). This observation is 
interesting and may imply that the suggestion of diurnal variation from statistical 
analysis may be due to small data samples with a broad spread. 
 
The significant decline in CPCs on serial sampling is also in keeping with other 
(small) studies from our research group assessing the temporal decline in CECs, 
where significant reductions were seen over a 24-hour period of cells being held ex-
vivo365. Again, there are several potential explanations for these findings, including 
progressive cellular destruction and cell clumping leading to alterations in both 
forward scatter and side scatter (essentially cell size and granularity) observed using 
flow cytometry. In both circumstances, such cells would have been excluded from our 
gating analysis. Alternatively, cells may adhere to the wall of the Vacutainer® tube or 
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the physical properties of CPCs could alter such that the fluorochromes used bind less 
avidly, leading to reduced capture of CPCs.  Cell clumping in the presence of EDTA 
is most commonly recognized with red cells or platelets and only extremely rarely 
occurs with lymphocytes366. Moreover the phenomenon of clumping is assumed to be 
more likely to occur during culture experiments (where EDTA and trypsin are 
required to dislodge adherent cells) rather than when cells are held in transit tubes. 
 
Of note, our blood samples were held at 4°C and stored away from the influence of 
direct sunlight. The blood sampling tube used is employed routinely in clinical 
practice worldwide and has a proven track record for reliable transport of samples 367, 
368. Indeed, blood samples may sit for several hours prior to clinical laboratory 
processing without undue influence on full blood count assessments369, 370. 
Lymphocyte counts in particular are considered very reliable even up to 3 days after 
blood sampling371. However, the cells assessed routinely under such circumstances 
are frequently occurring cells and not rare sub-populations such as CPCs.  Cellular 
destruction could, of course, occur due to alteration in the physiological properties of 
the suspension medium (whole blood) through the addition of K3 EDTA or even other 
contaminants. K3 EDTA does result in a small degree of shrinkage in red blood cells 
and slight increase in cell volume for other cells on standing 367, 368. Additionally, 
some of the effects seen with EDTA occur after a number of hours and could explain 
the temporal decline in cell counts.  K3 EDTA as a liquid anticoagulant does partially 
dilute the blood sample and has been shown to return blood counts of approximately 
1-2% less than with di-potassium (K2) EDTA, again introducing (albeit consistent) 
potential for error368, 372. 
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Finally, it is also possible that sequential insertion of large bore needles has the 
potential to strip cells from the vascular wall at the point of needle insertion. To 
overcome this many investigators routinely discard the first few mLs of blood drawn 
– particularly when measuring CECs. However for CPCs, this argument holds less 
strongly, given that the presumed origins of the majority of these cells is from direct 
bone-marrow release.   
 
The implications from these data are that analysis of CPCs should be performed 
promptly after blood sampling. In addition, samples should where possible be stored 
during transit from clinic to laboratory in a consistent physical environment, to ensure 
regulation of temperature and exposure to other physical parameters to ensure 
reproducibility and consistency of results. Similarly our data suggest that sampling 
time may also be important, with variable CPC counts across the circadian clock. 
 
Study Limitations 
This study has a number of limitations. The first relates to study design - in particular 
to the small sample sizes in each of the analyses. To enlarge the sample size is 
certainly feasible, although it should be noted that the diurnal variation experiment 
required a significant amount of goodwill from participants due to the frequency and 
timing of venepuncture. However, greater numbers in each individual experiment 
would certainly add to the value of the work and potentially remove uncertainty 
regarding some findings – for example table 19 documents an apparent sizeable 
difference in some of the parameters between the two groups (e.g. peak exercise BP, 
resting vWf etc.) without a significant P value. This likely represents broad spread of 
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data in cohorts with a small sample size (i.e. inadequate power). Such concerns may 
equally be applied to the diurnal and temporal decline experiments also. 
 
The application of statistical tests here and the apparent finding of significant 
differences may be considered chance – particularly given that the median values 
across the timepoints for the diurnal experiment are broadly similar. Again the broad 
spread of data that is inherent when measuring CPCs implies that larger sample 
numbers are required for further validation of these findings. In the diurnal 
experiment, repeating the measurements on the same series of patients over a period 
of several days may enhance validity, although logistics may prove limiting. 
 
Our analysis was not confined to a population of patients with a single pathology. 
This was a deliberate strategy given that results from such scientific data may require 
extrapolation to the broader population. It should however be noted that this approach 
does not allow for a detailed analysis of data on specific patient profiles. 
Consequently, such analyses were avoided due to inadequate statistical power. 
 
Finally, the antigenic definition of CPCs is highly variable across the literature, with 
no universally accepted profile as yet. Thus it is not possible to definitively 
extrapolate our (or others’) data and apply this to all progenitor cell populations. 
Finally, our study has analysed CPCs using only one laboratory technique and in 
particular has only considered cell counts and has not taken into account cell function 
– i.e. the potential for CPCs to reproduce and integrate into the endothelium. Such 
assessment is usually based on cell culture experiments, but is an important 
characteristic to define in CPCs. 
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 3.3.5 Conclusion 
Routine exercise stress testing does not affect significantly CPCs counts and usual 
physical activity prior blood sample collection is unlikely to affect their recovery. 
Peripheral CPC levels showed a degree of diurnal variation, whilst evidence of 
temporal decline in CPC counts was apparent at 24 hours. The implications from 
these data are that analysis of CPCs should be performed promptly after blood 
sampling. In addition, samples should where possible be stored during transit from 
clinic to laboratory in a consistent physical environment, to ensure regulation of 
temperature and exposure to other physical parameters to ensure reproducibility and 
consistency of results. Similarly, our data suggest that sampling time may also be 
important, with variable CPC counts across the circadian clock. Thus, various factors 
may affect accuracy of CPC enumeration. However, this interpretation must be 
considered with the knowledge that assessment of data with a broad spread in a small 
population can easily induce statistical error and thus further larger studies are 
required. 
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Section IV: Clinical Studies 
 
4.1 Cross-sectional Analysis 
 
Abstract 
Background The pathophysiological inter-relationships and underlying ‘drivers’ of the 
prothrombotic state in atrial fibrillation (AF) are poorly understood. There appears to 
be a complex series of alterations in a number of pathways all of which may 
ultimately contribute to thrombogenesis. The endothelium may be a central theme 
linking some of these parameters. We hypothesized that circulating progenitor cells 
(CPCs) numbers may be reduced amongst patients with more persistent forms of AF 
compared to paroxysmal AF or ‘disease controls’ in sinus rhythm. Secondly, we 
hypothesized that markers of endothelial damage/dysfunction (von Willebrand factor, 
soluble E-selectin), apoptosis (soluble Fas), soluble Fas ligand) and angiogenesis 
(vascular endothelial growth factor) would be reduced whilst serum markers of 
inflammation (interleukin-6) would be increased in the same groups. 
 
Results  135 consecutive patients with AF were recruited: 60 had permanent AF 
(mean age 69.6±8.4 years, 39 (65%) male), 22 persistent AF (mean age 66.2±10.3 
years, 16 (65%) male, 39 paroxysmal AF (mean age 70.2±8.8years, 24 (62%) male) 
and 14 had lone AF (mean age 46.7±11.8 years, 9 (64%) male). 33 ‘disease’ controls 
(mean age 67.9±9.6 years, 21 (64%) male) and 13 healthy volunteers (mean age 
50.9±9.4 years, 9 (69%) male) were also recruited. 
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Analysis of non-lone AF to the disease control group demonstrated a significantly 
lower level of sFas in the former (3.8 ng/mL (3.0-4.8) vs. 5.0 ng/mL (4.0-5.1) 
P<0.001), with the lowest levels of the marker observed in patients with persistent 
(3.6 ng/mL (3.0-4.6) or permanent AF (3.3 ng/mL (3.0-4.5). Patients with lone AF 
had similar levels of all the research indices to the healthy control arm, except for 
sFas ligand (275 (200-400) vs. 125 (100-250) ρg/mL) and the sFas:sFas ligand ratio 
(103.8 (78.9-127.3) vs. 56.2 (37.2-79.5)), both of which were significantly higher 
amongst the healthy controls (P=0.006 and P=0.014 respectively). Median CPC levels 
were significantly higher in lone AF compared to ‘non-lone AF’ (211/mL (120-361) 
vs. 85/mL (42-149), P<0.001). Lower levels of both sE-selectin (43.0 ng/mL (31.5-
67.5) vs. 68.0 ng/mL (44.0-75.0), P=0.042); and vWf (116.3 ± 23.5 IU/dL vs. 135.4 ± 
26.3 IU/dL, P=.013) were seen in lone compared to non-lone AF patients The 
presence/absence of AF was not predictive of any of the research indices tested. 
 
 
Conclusion This study has a number of limitations. Many of these relate to study 
design and statistical power. The latter despite our pre-specified recruitment numbers 
being broadly met, it was apparent that many analyses had a broader spread than 
anticipated. Despite this, it would appear that CPC counts and one index of apoptosis 
(sFas) appear to be abnormal in AF compared to healthy controls although these 
indices – as well as abnormalities of other markers including indices of endothelial 
damage/dysfunction, apoptosis, angiogenesis and inflammation – are probably more 
related to associated co-morbidities rather than AF per se. 
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4.1.1 Introduction 
Atrial fibrillation (AF) confers a ‘hypercoagulable’ or ‘prothrombotic’ state and 
consequent high risk of stroke and systemic thromboembolism. This is reflected by 
up-regulation of various blood indices including pro-thrombotic markers, platelet 
activation, blood stasis within the atria and ultimately by impairment of both cardiac 
and vascular endothelium373. Although the pathophysiological inter-relationships 
between endothelial/endocardial impairment and atrial electrical abnormalities are 
still elusive (i.e. cause or effect), endothelial damage/dysfunction in AF clearly 
represents a major potential driver of the ‘prothrombotic’ state, by virtue of 
interactions with the coagulation cascade at a number of levels373. 
 
Endothelial damage/dysfunction has been identified in many disease states many of 
which frequently associate with AF (e.g. hypertension, atherosclerosis, diabetes 
mellitus) and is often associated with worse cardiovascular outcomes374. However, 
altered endothelial function has also been shown to exist in AF even in the absence of 
co-morbidities. Indeed, high levels of plasma markers of endothelial 
damage/dysfunction, such as von Willebrand factor (vWf) and soluble E-selectin 
(sEsel) and abnormalities of flow mediated dilatation are consistently reported in 
patients with AF and importantly, may relate to both the pathogenesis of the 
arrhythmia and provide a central link for the various processes implicated in the 
hypercoagulable state373, 375 (section 1.2).  
 
The mature endothelium has limited regenerative capacity and it has been suggested 
that a specific subset of bone marrow-derived progenitors (circulating progenitor 
cells) might promote maintenance of endothelial integrity231, 232 (section 1.3). 
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Intriguingly, AF has been linked to the presence of systemic inflammation159, 166, 376  
and to up-regulation of angiogenic growth factors (e.g. vascular endothelial growth 
factor, VEGF) both of which also seem to be important in triggering release and/or 
recruitment of CPCs in other disease states344 (section 1.2.6). CPCs seem resistant to 
both apoptosis and oxidative stress and therefore (in adequate numbers) may 
potentially ameliorate the negative impact of such cardiovascular risk factors/co-
morbidities on endothelial health in AF. Conversely, CPC mobilization and function 
may also be impaired by various cardiovascular co-morbidities and thereby reflect 
another mechanism through which endothelial dysfunction in AF is enhanced344. Thus 
the balance of factors promoting endothelial repair (e.g. angiogenic factors) and 
damage (e.g. cardiovascular co-morbidities, inflammation) in AF is difficult to predict 
and detailed analysis has not yet been performed. 
 
The purpose of this study was to investigate the pattern CPCs in relation to markers 
endothelial damage/dysfunction (vWf, sEselectin), inflammation (IL-6), angiogenesis 
(VEGF) and apoptosis (sFas, sFas ligand) in patients with different temporal patterns 
of AF. 
 
4.1.2 Hypotheses 
These have been discussed in detail in section 2.1.3. 
 
4.1.3 Methods 
This has been described previously in section 2.2.1. Classification of temporal pattern 
of AF was as per internationally accepted criteria outlined in section 1.1.4 Patients 
below 55 years of age without established risk factors for AF were considered to have 
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lone AF. Reclassification was allowed if it later became apparent that the patient, for 
example, had paroxysmal, rather than a more persistent form of AF.  
 
Patients were compared to a cohort of disease-matched and healthy controls. These 
patients were recruited from general cardiology and hypertension clinics, or as 
attendees to pre-assessment clinics for minor operations e.g. hernia repair. Exclusion 
criteria have been discussed previously (section 2.2.1) 
 
Patients were treated according to established treatment protocols within the 
framework of national and international guidelines. The use of anticoagulants and 
anti-platelet agents was left to the discretion of the treating physician based upon 
assessment of individual patient’s thromboembolic risk (section 1.1.9). Where 
patients were treated with warfarin, the target International Normalized Ratio (INR) 
was 2.0-3.0. If possible and unless clinical risk dictated (e.g significant coronary 
artery disease) anti-platelet agents were discontinued in those patients prescribed 
warfarin. 
 
Laboratory 
Laboratory analyses were performed as described in section 2.4 and appendix. 
 
Statistical Methods 
This has been described previously in section 2.3. 
 164
 165
4.1.4 Results 
We recruited 135 consecutive patients with AF: 60 had permanent AF (mean age 
69.6±8.4 years, 39 (65%) male), 22 persistent AF (mean age 66.2±10.3 years, 16 
(65%) male, 39 paroxysmal AF (mean age 70.2±8.8years, 24 (62%) male) and 14 had 
lone AF (mean age 46.7±11.8 years, 9 (64%) male) (tables 21, 24). 33 ‘disease’ 
controls (mean age 67.9±9.6 years, 21 (64%) male) were recruited to allow for 
comparison against the non-lone AF patients (table 21) and 13 healthy volunteers 
(mean age 50.9±9.4 years, 9 (69%) male) were recruited as healthy controls to 
compare against the cohort of patients with lone AF (table 24). 
 
Cross-sectional analysis 
There were no significant differences in age, gender or major co-morbidities between 
non-lone AF patients and ‘disease controls’ except for a higher prevalence of 
coronary artery disease in the latter group (table 21). AF patients more often received 
warfarin, and the antiarrhythmic drugs digoxin and amiodarone, but were less often 
treated with anti-platelet agents. 
 
Analysis of the entire cohort of non-lone AF compared to the disease control group 
demonstrated a significantly lower level of sFas in the former (3.8 ng/mL (3.0-4.8) vs. 
5.0 ng/mL (4.0-5.1) P<0.001), with the lowest levels of the marker observed in 
patients with persistent (3.6 ng/mL (3.0-4.6) or permanent AF (3.3 ng/mL (3.0-4.5) 
(tables 22 & 23). No significant difference in levels of the other research indices was 
observed.
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Table 21. Demographic Data for AF Patients and Disease-matched Control Subjects 
 
 Variable Disease-matched Controls Paroxysmal AF Persistent AF Permanent AF P value 
 n 33 39 23 60  
Age (SD) 67.9 ± 9.6 70.2 ± 8.8 66.2 ± 10.3 69. 6± 8.4 .320 
Age > 75 (%) 10 (30) 16 (41) 4 (17) 22 (37) .289 
Male (%) 21 (64) 24 (62) 16 (65) 39 (65) .989 
B
a
s
e
l
i
n
e
 
D
a
t
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Body Mass Index (Kg/m2) 30.0 ± 7.2 28.2 ± 4.1 28.7 ± 6.1 29.0 ± 6.8 .782 
Smoking 13 (40) 11 (28) 9 (39) 22 (37) .588 
IHD (Angina / MI / PCI) 15 (46) 9 (23) 11 (48) 10 (17) .017 
Previous CVA 4 (12) 4 (10) 2 (9) 10 (17) .395 
CCF 2 (6) 4 (10)  2 (9) 17 (18) .106 
Hypertension 28 (85) 31 (80) 20 (87) 50 (83) .413 
Diabetes Mellitus 4 (12) 1 (3) 3 (13) 4 (7) .219 
Hyperlipidaemia 19 (58) 18 (46) 15 (65) 24 (40) .645 
R
i
s
k
 
F
a
c
t
o
r
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N
o
.
 
(
%
)
 
CHADS2 risk 1 (1-2) 2 (1-2) 1 (1-2) 2 (1-3) .181 
Antiplatelets 18 (55) 8 (21) 13 (57) 31 (52) .001 
Warfarin 2 (6) 20 (51) 23 (100) 25 (42) .000 
Beta-blocker 14 (42) 22 (56) 9 (39) 26 (45) .506 
Calcium-channel blocker 16 (48) 13 (33) 11 (48) 23 (38) .412 
Digitalis 0 (0) 2 (5) 4 (18) 18 (30) .000 
Flecainide 0 (0) 2 (5) 3 (14) 2 (3) .134 
Amiodarone 1 (3) 7 (18) 1 (4) 2 (3) .010 
ACE-i/ARB 21 (64) 24 (62) 15 (65) 35 (58) .997 
M
e
d
i
c
a
t
i
o
n
,
 
N
o
.
 
(
%
)
 
Statin 13 (39) 20 (51) 13 (57) 21 (34) .170 
Paroxysmal AF was defined as at least two electrocardiographically documented episodes of AF with interceding sinus rhythm. Persistent AF was defined as AF 
lasting >7 days without spontaneous reversion to sinus rhythm, suitable for and requiring pharmacologic or direct-current cardioversion to restore sinus rhythm. 
Permanent AF was defined as AF lasting for >1 year in a patient in whom cardioversion was considered to be inappropriate or who had previously been 
unsuccessful.  
Abbreviations: IHD – Ischaemic Heart Disease; MI – Myocardial Infarction; PCI – Percutaneous Coronary Intervention; ACE-I – Angiotensin Converting 
Enzyme inhibitor; ARB – Angiotensin-II Receptor Blocker; CCF – Congestive Cardiac Failure; CVA – Cerebrovascular Accident; CHADS2: 1 point is assigned 
for: Congestive cardiac failure, Age≥75 years, Diabetes mellitus, with prior Stroke or transient ischaemic attack being assigned 2 points.  
All Data expressed as Mean ± Standard Deviation (SD), No. (%) or Median (InterQuartile Range, IQR) unless otherwise stated. Comparisons between groups 
using the one-way analysis of variance or Kruskal-Wallis testing as appropriate. A p value < 0.05 was considered statistically significant. 
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Table 22. A comparison of Research Indices in all AF vs. Disease-matched controls 
 
 
Variable Disease-
matched 
Controls  
All AF* P value 
 n 33 122  
CPCs (cells/mL) 78 (30-149) 85 (42-149) .500 
vWf (IU/dL) 133.7 ± 23.7 135.4 ± 26.3 .737 
sEselectin (ng/mL) 68.0 (41.0-76.0) 68.0 (44.0-75.0) .871 
VEGF (ρg/mL) 60 (5-142.5) 70 (20-250) .211 
IL-6 (ρg/mL) 15 (10-18) 10 (2.25-20) .083 
sFas (ng/mL) 5.0 (4.0-5.1) 3.8 (3.0-4.8) <.001 
sFas ligand (ρg/mL) 200 (125-375) 250 (125-375) .473 Re
se
ar
ch
 In
di
ce
s 
sFas:sFas ligand 45.5 (30.6-94.4) 66.7 (34.5-125.0) .115 
*Lone AF excluded from this analysis due to absence of co-morbidities. 
 
CPC – Circulating Progenitor Cells; vWf – von Willebrand factor; IL-6 – InterLeukin-6; 
VEGF – Vascular Endothelial Growth Factor. All data expressed as mean ± standard 
deviation (SD), or median (InterQuartile Range, IQR) unless stated otherwise; P-value 
refers to the results of unpaired t-test or Mann-Whitney U test for parametric and non-
parametric data as appropriate. A P-value < 0.05 was considered statistically significant. 
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Table 23. A comparison of Research Indices by temporal pattern of AF 
 
 
Variable Disease-
matched 
Controls 
Paroxysmal AF Persistent AF Permanent AF P value 
 n 33 39 23 60  
CPCs (cells/mL) 78 (30-149) 90 (51-164) 85 (29-153) 82 (38-134) .754 
vWf (IU/dL) 133.7 ± 23.7 138.7 ± 22.7 136.6 ± 13.5 132.9 ± 31.5 .710 
sEselectin (ng/mL) 68.0 (41.0-76.0) 68.0 (52.0-73.0) 64.0 (39.5-76.0) 66.0 (39.5-82.5) .939 
VEGF (ρg/mL) 60 (5-142.5) 70 (5-140) 76.3 (20-290) 80 (18.8-297.5) .457 
IL-6 (ρg/mL) 15 (10-18) 10 (10-20) 15 (10-24) 10 (1-15) .069 
sFas (ng/mL) 5.0 (4.0-5.1) 4.5 (3.5-5.0) 3.6 (3.0-4.6) 3.3 (3.0-4.5) <.001 
sFas ligand (ρg/mL) 200 (125-375) 300 (125-500) 188 (119-188) 250 (125-400) .474 
R
e
s
e
a
r
c
h
 
I
n
d
i
c
e
s
 
sFas:sFas ligand 45.5 (30.6-94.4) 70.0 (36.4-110.0) 48.2 (31.9-123.9) 71.4 (31.8-
132.1) 
.373 
 
CPC – Circulating Progenitor Cells; vWf – von Willebrand factor; IL-6 – InterLeukin-6; VEGF – Vascular Endothelial Growth 
Factor. All data expressed as mean ± standard deviation (SD), or median (InterQuartile Range, IQR) unless stated otherwise; P-value 
refers to the results of one-way analysis of variance (ANOVA) or Kruskal-Wallis test for parametric and non-parametric data as 
appropriate. A P-value < 0.05 was considered statistically significant. 
 
 
Lone AF vs. Healthy Controls 
The healthy control group and lone AF groups were both comparable in baseline 
demographic parameters (table 24).  Patients with lone AF had similar levels of all the 
research indices to the healthy control arm, except for sFas ligand (275 (200-400) vs. 
125 (100-250) ρg/mL) and the sFas:sFas ligand ratio (103.8 (78.9-127.3) vs. 56.2 
(37.2-79.5)), both of which were significantly higher amongst the healthy 
controls(P=0.006 and P=0.014 respectively), (table 24). Median VEGF was 
approximately 50% higher in the lone AF group (132.5 (10-187.5) ρg/mL vs. 85 (53-
290) ρg/mL, however this did not reach statistical significance. There was no 
difference in levels of the other research indices between these two groups. 
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Table 24. Demography and Research Indices in Lone Atrial fibrillation Patients 
and Healthy Control Subjects. 
 
 Variable Healthy Controls Lone AF P value 
 n 13 14  
Age (SD) 50.9 ± 9.4 46.7 11.8 0.324 
Age > 75 (%) 0 (0) 0 (0) 1.000 
Male (%) 9 (69) 9 (64) 0.795 
Ba
se
lin
e 
D
at
a 
Body Mass Index 27.6 ± 5.9 25.1 ± 4.3 0.355 
Smoking 2 (15) 4 (29) 0.430 
IHD (Angina / MI / PCI) 0 (0) 0 (0) 1.000 
Previous CVA 0 (0) 0 (0) 1.000 
CCF 0 (0) 0 (0) 1.000 
Hypertension 0 (0) 0 (0) 1.000 
Diabetes Mellitus 0 (0) 0 (0) 1.000 
Hyperlipidaemia 0 (0) 0 (0) 1.000 Ri
sk
 F
ac
to
rs
 N
o.
 
(%
) 
CHADS2 0 (0) 0 (0) 1.000 
Antiplatelets 3 (16) 4 (28) 0.382 
Warfarin 1 (5) 2 (14) 0.094 
Beta-blocker 2 (11) 7 (50) 0.013 
Calcium-channel blocker 0 (0) 0 (0) 1.000 
Digitalis 0 (0) 0 (0) 1.000 
Flecainide 0 (0) 5 (36) 0.005 
Amiodarone 0 (0) 0 (0) 1.000 
ACE-i/ARB 0 (0) 1 (7) 0.244 M
ed
ic
at
io
n,
 N
o.
 (%
) 
Statin 0 (0) 0 (0) 1.000 
CPCs (cells/mL) 158 (75-336) 211 (120-361) 0.353 
vWf (IU/dL) 126.0 ± 32.6 116.3 ± 23.5 0.693 
sEselectin (ng/mL) 46.0 (26.0-64.0) 43.0 (31.5-67.5) 1.000 
VEGF (ρg/mL) 85 (53-290) 132.5 (10-187.5) 0.707 
IL-6 (ρg/mL) 10 (0-15) 15 (10-20.5) 0.083 
sFas (ng/mL) 2.8 (2.0-3.0) 3.1 (2.3-3.3) 0.214 
sFas ligand (ρg/mL) 275 (200-400) 125 (100-250) 0.006 Re
se
ar
ch
 In
di
ce
s 
sFas:sFas ligand 103.8 (78.9-127.3) 56.2 (37.2-79.5) 0.014 
 
CPC – Circulating Progenitor Cells; vWf – von Willebrand factor; IL-6 – 
InterLeukin-6; VEGF – Vascular Endothelial Growth Factor. All data expressed as 
mean ± standard deviation (SD), or median (InterQuartile Range, IQR) unless stated 
otherwise; P-value refers to the results of one-way analysis of variance (ANOVA) or 
Kruskal-Wallis test for parametric and non-parametric data as appropriate. A P-value 
< 0.05 was considered statistically significant. All data expressed as mean ± standard 
deviation (SD), or median (InterQuartile Range, IQR) unless stated otherwise; P-value 
refers to the results of unpaired t-test or Mann-Whitney U test as appropriate. A P-
value < 0.05 was considered statistically significant. 
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Lone vs. non-lone AF 
Median CPC levels were significantly higher in lone AF compared to ‘non-lone AF’ 
(211/mL (120-361) vs. 85/mL (42-149), P<0.001). Lower levels of both sE-selectin 
(43.0 ng/mL (31.5-67.5) vs. 68.0 ng/mL (44.0-75.0), P=0.042); and vWf (116.3 ± 23.5 
IU/dL vs. 135.4 ± 26.3 IU/dL, P=.013) were seen in lone compared to non-lone AF 
patients (table 25). 
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Table 25. Research Indices in Lone AF vs. non-lone AF. 
 
 Variable Non-lone AF Lone AF P value 
 n 122 14  
CPCs (cells/mL) 85 (30-149) 211 (120-361) <.001 
vWf (IU/dL) 135.4 ± 26.3 116.3 ± 23.5 .013 
sEselectin (ng/mL) 68.0 (44.0-75.0) 43.0 (31.5-67.5) .042 
VEGF (ρg/mL) 70 (20-250) 132.5 (10-187.5) .766 
IL-6 (ρg/mL) 10 (2.25-20) 15 (10-20.5) .296 
sFas (ng/mL) 3.8 (3.0-4.8) 3.1 (2.3-3.3) .001 
sFas ligand (ρg/mL) 250 (125-375) 125 (100-250) 0.24 Re
se
ar
ch
 In
di
ce
s 
sFas:sFas ligand 66.7 (34.5-125.0) 56.2 (37.2-79.5) .535 
 
CPC – Circulating Progenitor Cells; vWf – von Willebrand factor; IL-6 – 
InterLeukin-6; VEGF – Vascular Endothelial Growth Factor. All data expressed as 
mean ± standard deviation (SD), or median (InterQuartile Range, IQR) unless stated 
otherwise; P-value refers to the results of unpaired t-test or Mann-Whitney U test for 
parametric and non-parametric data as appropriate. A P-value < 0.05 was considered 
statistically significant. 
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Univariate and stepwise multiple regression analyses  
For the whole AF cohort (table 26), age correlated with vWf (r=0.174, p=0.045) and 
inversely with CPCs (r=-0.267, p=0.002). The presence of hypertension was 
associated with a lower CPC count (r=-0.293, p=0.001) and higher levels of 
sEselectin (r=0.209, p=0.022), and sFas (r=0.191, p=0.030). Of interest, the CPC 
count correlated with the CHADS2 stroke risk score (r=-0.345, p<0.001) and presence 
of congestive heart failure in AF (r=-0.180, p=0.049), despite small numbers of such 
patients. Additionally, CPC numbers significantly negatively correlated with sFas 
levels (r=-0.207, p=0.020). 
 
In the disease matched control group (table 27), hypertension correlated to VEGF (r=-
0.344, p=0.050), and smoking correlated to sFas (r=-0.385, p=0.027). There was a 
strong correlation between sFasL and the sFas:sFasL ratio (r=0.931, p<0.001). In the 
healthy controls in sinus rhythm group (table 28), age correlated to IL-6 (r=0.522, 
p=0.022), smoking correlated to CPCs (r=0.530, p=0.024) and sFasL (r=-0.153, 
p=0.002). There was also a correlation between sEselectin and VEGF (r=0.649, 
p=0.009) and sFas to the sFas:sFasL ratio (r=0.933, p<0.001). 
 
Following a stepwise multiple regression analysis of the entire cross-sectional cohort 
of patients, age (β=-0.272, P=0.014), hyperlipidaemia (β=0.369, P=0.001) and statin 
prescription (β=-0.260, P=0.014) emerged as significant predictors of CPCs. Age was 
also predictive of vWf (β=0.219, P=0.05). sE-selectin was predicted by both 
hypertension (β=0.354, P=0.019) and smoking (β=0.266, P=0.001). However, the 
presence/absence of AF was not predictive of any of the research indices tested (table 
29). 
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Table 26. Correlations of research indices to demographic data for all atrial 
fibrillation. 
 
Variables  vWf sEsel CPCs sFas sFasL Fas:FasL VEGF IL-6 
r .174 .113 -.267 .160 .026 -.041 .029 -.101 
Age 
p .045 .212 .002 .065 .770 .644 .749 .260 
r .093 -.009 -.147 .047 .014 -.019 .114 -.001 
IHD 
p .298 .921 .108 .595 .674 .832 .215 .989 
r .104 .209 -.293 .191 .108 .021 -.089 -.166 
HTN 
p .243 .022 .001 .030 .232 .818 .333 .067 
r -.056 .033 -.043 -.097 -.079 -.049 -.077 -.100 
CVA 
p .527 .721 .635 .272 .380 .587 .397 .271 
r -.009 .086 -.180 .100 -.048 -.063 .040 -.047 
CCF 
p .924 .355 .049 .261 .593 .486 .659 .607 
r -.067 .065 -.093 -.015 .070 .057 -.173 -.186 
DM 
p .451 .481 .312 .865 .438 .527 .058 .040 
r -.026 .180 .029 .050 -.038 -.058 -.234 -.171 ↑ Lipids 
p .769 .050 .749 .575 .674 .524 .010 .060 
r -.074 .093 .056 -.053 -.006 .008 .167 -.092 
BMI 
p .475 .383 .596 .609 .953 .941 .064 .385 
r .071 .134 -.345 .150 -.008 -.074 -.053 -.159 
CHADS2 
p .426 .147 .000 .091 .933 .412 .562 .080 
r .183 .087 -.017 .100 .198 .153 .166 .110 
Warfarin 
p .039 .350 .855 .262 .027 .090 .069 .231 
r .030 .169 .162 -.118 .060 .059 -.031 -.205 
Aspirin 
p .750 .085 .099 .214 .533 .539 .757 .035 
r -.076 .107 -.076 .007 -.077 -.082 -.122 -.031 
Statin 
p .407 .244 .407 .940 .389 .543 .182 .731 
r -.283 .134 -.283 .118 .076 .027 -.124 .066 ACE-i / 
ARB p .002 .150 .002 .185 .401 .768 .180 .473 
r .039 -.258 -.080 -.073 -.036 .001 -.017 .038 
Smoking 
p .663 .150 .386 .416 .695 .768 .852 .682 
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Table 26. Correlations of research indices to demographic data for all atrial 
fibrillation (continued). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables  sEsel CPCs sFas sFasL Fas:FasL VEGF IL-6 
r -.020 .086 -.047 .100 .095 .189 .051 
vWf 
p 826 .337 .588 .257 .283 .034 .572 
r  -.045 .018 .079 .085 .007 .049 
sEsel 
p  .630 .842 .384 .352 .939 .601 
r   -.207 -.020 .055 -.014 -.025 
CPCs 
p   .020 .823 .543 .880 .786 
r    .029 -.301 -.134 .043 
sFas 
p    .746 .000 .132 .626 
r     .029 .132 -.062 
sFasL 
p     .746 .146 .493 
r      .167 -.060 
Fas:FasL 
p      .064 .505 
r       .186 
VEGF 
p       .037 
IHD – Ischaemic heart disease; HTN – Hypertension; CVA – CerebroVascular 
Accident; CCF – Congestive Cardiac Failure; DM – Diabetes Mellitus; CHADS2: 
Stroke risk algorithm (see text); BMI – Body Mass Index; ARB / ACE-i: Angiotensin-
2 receptor blocker / Angiotensin converting enzyme inhibitor; vWf – vonWillebrand 
factor, sEsel – soluble E selectin; sFas – soluble Fas; sFasL – soluble Fas ligand; 
VEGF – Vascular Endothelial Growth Factor; IL-6 – Interleukin 6; CPC – Circulating 
Progenitor Cell. Data refers to Spearman correlation. 
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Table 27. Correlations of research indices to demographic data for disease-
matched controls in sinus rhythm. 
 
Variables  vWf sEsel CPCs sFas sFasL Fas:FasL VEGF IL-6 
r .108 -.170 -.207 -.003 -.111 -.097 .220 .186 
Age 
p .549 .353 .273 .986 .539 .592 .218 .301 
r -.080 -.003 .311 .104 .170 .051 .328 -.180 
IHD 
p .658 .985 .094 .553 .347 .777 .062 .315 
r .147 .225 .010 .122 .027 -.018 -.344 .227 
HTN 
p .416 .216 .957 .498 .883 .922 .050 .204 
r -.063 -.077 -.221 -.015 -.367 -.312 .029 .030 
CVA 
p .726 .675 .241 .934 .036 .077 .871 .868 
r .127 .112 N/A .238 -.114 -.133 -.047 .007 
CCF 
p .482 .540 N/A .182 .529 .459 .795 .970 
r .020 .062 .119 -.065 -.249 -.278 .157 -.025 
DM 
p .914 .737 .531 .721 .162 .117 .382 .890 
r .071 .073 .232 .154 -.107 -.203 .227 -.122 ↑ Lipids 
p .695 .693 .218 .391 .555 .257 .204 .498 
r .013 .055 -.236 -.136 -.013 .053 .255 -.055 
Warfarin 
p .941 .760 .209 .450 .941 .768 .152 .762 
r .208 -.212 -.132 -.029 -.333 -.345 .071 .187 
Aspirin 
p .246 .243 .486 .871 .058 .049 .695 .298 
r -.159 -.133 -.177 .040 .139 .132 -.154 -.185 
Statin 
p .469 .547 .455 .855 .526 .547 .482 .399 
r -.096 -.067 -.184 .078 .179 .159 -.220 .014 ACE-i / 
ARB p .595 .717 .331 .668 .319 .377 .219 .940 
r .195 .038 .228 -.385 -.265 -.199 -.128 -.030 
Smoking 
p .276 .836 .225 .027 .137 .267 .478 .868 
r .142 .027 .036 .021 -.325 -.295 .293 -.058 
BMI 
p .489 .898 .869 .918 .105 .144 .147 .777 
r  -.173 .070 -.049 -.179 -.137 -.209 .160 
vWf 
p  .344 .714 .786 .319 .446 .243 .373 
r   .041 -.170 .133 .180 .019 -.150 
sEsel 
p   .834 .352 .467 .323 .916 .413 
r    -.140 -.022 -.035 -.038 .191 
CPCs 
p    .462 .908 .854 .841 .312 
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Table 27. Correlations of research indices to demographic data for disease-
matched controls in sinus rhythm (continued). 
 
 
Variables  vWf sEsel CPCs sFas sFasL Fas:FasL VEGF IL-6 
r     .130 -.129 -.122 -.178 
sFas 
p     .472 .474 .499 .321 
r      .931 .243 -.436 
sFasL 
p      .000 .173 .011 
r       .276 -.315 
Fas:FasL 
p       .120 .074 
r        -.251 
VEGF 
p        .158 
IHD – Ischaemic heart disease; HTN – Hypertension; CVA – CerebroVascular 
Accident; CCF – Congestive Cardiac Failure; DM – Diabetes Mellitus; BMI – Body 
Mass Index; ARB / ACE-i: Angiotensin-2 receptor blocker / Angiotensin converting 
enzyme inhibitor; vWf – vonWillebrand factor, sEsel – soluble E selectin; sFas – 
soluble Fas; sFasL, soluble Fas ligand; VEGF – Vascular Endothelial Growth Factor; 
IL-6 – Interleukin 6; CPC – Circulating Progenitor Cell. Data refers to Spearman 
correlation. 
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Table 28. Correlations of research indices to demographic data for healthy 
controls in sinus rhythm  
 
 
Variables  vWf sEsel CPCs sFas sFasL Fas:FasL VEGF IL-6 
r .065 -.249 -.658 .147 .159 .294 .208 .522 
Age 
p .791 .353 .003 .648 .587 .442 .407 .022 
r .442 -.018 -.487 .114 .315 .800 .456 .081 
BMI 
p .150 .957 .109 .787 .447 .104 .136 .802 
r -.105 -.261 -.461 -.524 .035 N/A .130 .467 
Aspirin 
p .668 .329 .054 .081 .907 N/A .608 .044 
r -.157 -.082 .530 .088 -.153 -.274 -.308 -.180 
Smoking 
p .522 .762 .024 .785 .602 .476 .214 .462 
r  .069 -.232 -.124 .272 .433 .101 -.012 
vWf 
p  .799 .355 .702 .347 .244 .689 .961 
r   .083 .146 .057 -.679 .649 -.360 
sEsel 
p   .767 .687 .861 .094 .009 .170 
r    -.365 -.240 -.357 -.390 -.458 
CPCs 
p    .270 .429 .385 .122 .056 
r     .479 .227 .498 .146 
sFas 
p     .192 .557 .119 .651 
r      .933 .364 .498 
sFasL 
p      .000 .222 .119 
r       .263 .417 
Fas:FasL 
P       .528 .265 
        .000 
VEGF 
        .998 
BMI – Body Mass Index; vWf – vonWillebrand factor, sEsel – soluble E selectin; 
sFas – soluble Fas; sFasL, soluble Fas ligand; VEGF – Vascular Endothelial Growth 
Factor; IL-6 – Interleukin 6CPC – Circulating Progenitor Cell. Data refers to 
Spearman correlation. 
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Table 29. Multiple Linear Regression Analysis 
Variables  vWf sEsel sFas sFasL VEGF IL6 CPCs 
β* .219 -.030 .119 .202 .115 .061 -.272 
Age 
P .050 .787 .278 .087 .301 .595 .014 
β* .198 .354 .263 .154 -.094 -.011 -.155 
Hypertension 
P .194 .019 .063 .307 .538 .943 .305 
β* .032 .111 -.045 .081 .006 -.036 -.074 
Diabetes 
P .749 .261 .636 .434 .954 .727 .441 
β* .094 -.027 -.171 .008 -.112 -.147 -.049 
Stroke 
P .566 .866 .281 .963 .494 .388 .770 
β* .066 -.030 .051 -.014 .098 -.029 .005 
IHD 
P .435 .717 .534 .877 .255 .741 .950 
β* .107 .086 .081 .063 .209 -.062 -.117 
CCF 
P .389 .493 .498 .625 .099 .630 .311 
β* -.064 .132 .086 -.101 -.212 -.163 .369 ↑ lipidaemia 
P .567 .220 .421 .381 .066 .173 .001 
β* .047 -.075 -.030 .043 .054 .054 -.260 
Statin 
P .654 .456 .767 .687 .615 .629 .014 
β* .090 -.266 -.133 -.001 -.094 -.055 .060 
Smoking 
P .273 .001 .094 .986 .259 .520 .450 
β* -.007 .103 -.100 .043 .022 -.012 .043 
AF 
P .930 .210 .214 .619 .801 .894 .601 
R2  .075 .172 .171 .047 .109 .035 .192 
 
*Numbers are standardized β co-efficients. 
IHD – Ischaemic heart disease; CCF – Congestive Cardiac Failure; BMI – Body Mass 
Index; CHADS2: Stroke risk algorithm (see text); ARB / ACE-i: Angiotensin-2 
receptor blocker / Angiotensin converting enzyme inhibitor; AF – Atrial Fibrillation. 
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4.1.5 Discussion 
To our knowledge, this is the first study to assess both the relationship between the 
temporal pattern of AF and CPCs. We demonstrate similar levels of CPCs across our 
cohort of patients with AF and co-morbidities, but significantly suppressed levels 
compared to subjects with lone AF and healthy controls. Furthermore we report 
similar levels of IL-6 and VEGF amongst all our patients with AF and co-morbidities. 
Our analysis also confirms previously reported observations of enhanced endothelial 
damage/dysfunction (vWf), and endothelial activation (sEsel), in patients with non-
lone AF in comparison to both healthy control subjects in sinus rhythm and to lone 
AF (although levels of both indices were lower than that observed in AF with co-
morbidities). 
 
Finally, we have also investigated the relationship between AF and markers of Fas-
mediated apoptosis. We report a complex series of observations with significantly 
higher levels of sFas amongst disease-matched controls compared to all non-lone AF 
and to lone AF, but lower levels of both sFas ligand and the sFas:sFas ligand ratio in 
lone AF than in healthy controls. 
 
The present study suggests that both CPC counts and one index of apoptosis (sFas) 
are abnormal in (non-lone) AF compared to controls although these indices – as well 
as indices of endothelial damage/dysfunction, apoptosis, angiogenesis and 
inflammation – are probably more related to associated co-morbidities rather than to 
AF per se. We also confirm previously reported observations of enhanced endothelial 
damage/dysfunction (vWf), and endothelial activation (sEsel), in patients with AF in 
comparison to healthy control subjects in sinus rhythm and to lone AF. 
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 CPC counts were lowest amongst the subgroups of patients with AF who had various 
co-morbidities and amongst disease-matched controls, when compared to those 
patients with either lone AF or healthy controls where higher counts were seen. The 
reasons for the observed CPC reduction in non-lone AF patients (impaired 
mobilisation or increased consumption) in the presence of greater endothelial 
damage/dysfunction/ activation are unknown, but our findings are consistent with 
diminished levels of CPCs and other populations of progenitors with angiogenic 
potential in other cardiovascular disorders and risk factors231, 232. 
 
Generally, CPCs probably reflect the co-existence of co-morbid disorders rather than 
relating solely to the presence of AF. Importantly, these findings parallel increased 
levels of vWf, sEsel and IL-6 levels in both non-lone AF and in disease controls. 
Similarly, the higher levels of CPCs seen in healthy controls and in patients with lone-
AF mirror evidence of reduced endothelial damage (vWf) and endothelial activation 
(sEsel) in these subjects. This is contradictory to other research studies which have 
observed enhanced inflammation and coagulability in similar cohorts, but may simply 
be reflective of their younger age compared to other groups99, 171, 326. 
 
In keeping with previous studies we have shown raised levels of vWf amongst all 
patients with non-lone AF, with no significant difference based on temporal pattern99, 
326. We also note levels of vWf in lone AF to be similar to that seen in healthy 
controls – in keeping with data from the Framingham study where co-morbidities 
rather than AF was felt to be the primary mechanism for vWf release377. sEsel is an 
index of endothelial activation, not normally expressed by resting endothelial cells, 
 181
but detectable at low levels in normal healthy controls378. As with vWf, raised levels 
are seen amongst patients with AF, but there remains some debate as to whether this 
relates to the presence of co-morbidities or relates to arrhythmia itself379. In keeping 
with this data, we also report raised levels of sEsel in AF patients and controls with 
co-morbidities but not in healthy controls or lone AF. 
 
Regardless of whether endothelial ‘activation’ or ‘damage/dysfunction’ predominates, 
both processes have the potential to mediate thrombogenesis either directly by 
exposure of denuded endothelium to components of the coagulation cascade or 
through release of other regulatory molecules such as IL-6 or VEGF, both of which 
may also link to thrombogenesis373 and even CPC release171, 344. In the present 
analysis, we did not find any association between AF temporal pattern, nor the 
presence / absence of co-morbidities on levels of either marker. Again, this 
presumably relates to a complex series of interactions clouded by the presence of 
numerous co-morbidities. 
 
The Fas/Fas ligand pathway is one of a number of regulatory mechanisms through 
which programmed cell death (apoptosis) occurs380. Fas and its ligand are 
predominantly membrane bound and the apoptotic function of these molecules is well 
documented. Fas and its ligand are also found in soluble forms, but the precise 
function of these molecules remains unclear381. However, the ratio between these two 
molecules has been cited as a potential measure to assess cellular apoptosis382. In the 
present analysis, lower levels of  sFas were seen in non-lone AF compared to disease-
matched controls. sFas ligand levels and the sFas:sFas ligand ratio were both lower in 
lone AF compared to healthy controls, but levels of sFas were generally higher 
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amongst AF patients in the presence of co-morbidities. The relationship between AF 
and Fas-mediated apoptosis is therefore decidedly complex and it would appear that 
neither the temporal pattern of AF, nor the presence of the arrhythmia per se seem to 
have any influence on this process. The assumption therefore is that the various 
observed alterations in these markers likely reflect underlying co-morbid factors. 
 
Study limitations 
The cross-sectional nature of this study allows only for associations to be made rather 
than identification of cause and effect. The vast majority of patients with AF have a 
large number of co-morbidities. This in part, relates to the age of patients studied, 
where inevitably, other confounders such as ischaemic heart disease, hypertension, 
hyperlipidaemia are more likely to become apparent or at least become a target for 
therapeutic intervention. Also, AF may also occur as a consequence of many of these 
confounding variables and thus in a small study it is clearly not possible to establish 
the precise relationships between all variables. To accommodate for this, we recruited 
a number of patients with lone AF and also healthy control subjects. Both are difficult 
to recruit. The former because lone AF is a relatively rare entity; the latter because 
healthy controls are often not seen in a hospital setting where the majority of 
recruitable subjects are attending for treatment or investigation of important illness. 
 
Similarly, each of the various parameters discussed may also influence one or more of 
the indices researched in this study either directly (e.g. endothelial damage as a direct 
consequence of hypertension) or indirectly (e.g. secondary repair mechanisms 
triggered as a consequence of such damage) and may also link to one another (section 
1.2.6). It is therefore impossible to establish clear links. 
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Additionally, as there is no commonly accepted definition of circulating progenitors 
with angiogenic potential, it is possible that our results may not be applicable to all 
populations of angiogenic progenitors.. 
 
It was not possible to meet our pre-specified power calculation for every subtype of 
AF, although in some cases (e.g. permanent AF), the target was exceeded. This relates 
in part to reclassification of patients. For example, it became apparent that some 
patients initially assumed to have paroxysmal AF had in fact permanent AF. Also a 
number of patients, assumed to have persistent AF of recent onset were later felt so 
unlikely to maintain sinus rhythm (usually based on echocardiographuc appearances) 
and thus were only offered rate control. This strategy by default implies permanence 
of AF and thus again such patients were reclassified. This has inevitable implications 
when interpreting data with a broad spread in a relatively small sample and may 
explain why fluctuations in some indices (e.g. VEGF) although relatively profound in 
some of the analyses did not reach statistical significance. Similarly, the power 
calculation was based on anticipated variation in CPC numbers, as this was the main 
focus of the present work and thus may have been inadequate to allow full assessment 
of other parameters 
 
Further limitations may be applied to the application of multiple statistical analyses. 
Indeed, the concept of P<0.05 implying significance means a 5% (or 1 in 20) chance 
that the observed finding is due to chance alone. This work inevitably required 
numerous statistical comparisons. The greatest potential for error relates to univariate 
and multivariate comparisons where a large number of statistical comparisons are 
made. For this analysis a P<0.01 was considered significant. However, despite this 
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deliberate choice, 1 in 100 analyses may still relate to chance and thus caution needs 
to be applied to prevent over-interpretation. 
 
4.1.6 Conclusion 
CPC counts and indices of apoptosis (sFas) appear to be abnormal in AF compared to 
healthy controls although these indices – as well as abnormalities of other markers 
including indices of endothelial damage/dysfunction, apoptosis, angiogenesis and 
inflammation – are probably more related to associated co-morbidities rather than AF 
per se. This data continues to add to the complexity of the hypercoagulable state in 
AF. It is clear that there are pertubations of a number of physiological regulatory 
mechanisms and cellular pathways leading to endothelial damage, activation, 
inflammation, apoptosis, angiogenesis and ultimately activation of the coagulation 
cascade. 
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4.2 Effects of Rhythm Change 
 
Abstract 
Background: Atrial Fibrillation (AF) is associated with a high rate of stroke, which 
may relate to a hypercoagulable state. The purpose of this study was to investigate 
whether restoration of sinus rhythm altered indices that may be reflective of the 
hypercoagulable state. We hypothesized that restoration of sinus rhythm would 
improve plasma indices of endothelial damage (vonWillebrand factor, vWf, soluble 
Eselectin, sEsel), apoptosis (soluble Fas/Fas Ligand, sFas/sFasL), inflammation 
(Interleukin-6, IL-6) and angiogenesis (Circulating Progenitor Cells, CPCs). 
 
Methods: 22 consecutive patients (mean age 66.2 (10.3) years, 14 (64%) male) 
with persistent AF deemed suitable for direct current cardioversion (DCCV) were 
recruited. All patients were established on warfarin (target International Normalized 
Ratio, INR 2.0-3.0) for a minimum of 4 weeks prior to DCCV. Blood sampling was 
performed pre, immediately post and at 4-weeks post DCCV. Baseline results were 
compared to a cohort of 23 matched controls (mean age 67.1 (9.8) years, 16 (70%) 
male) who were known to maintain sinus rhythm. 
 
Results: Patients and controls were comparable in all major parameters aside 
from use of anti-arrhythmic drugs (P=0.049) and anticoagulants (P<0.001) for which 
there was significant excess amongst the DCCV cohort. Anti-platelet usage was 
significantly higher amongst the disease-matched control arm (P=0.001). There was 
no significant difference in baseline levels of vWf, CPCs, sE-selectin, IL-6, or 
sFas/sFas ligand ratio between either groups. Control subjects had modestly higher 
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levels of sFas (P=0.003), but not sFas ligand compared to the AF cohort. Patients with 
AF had almost a 2-fold higher median level of VEGF at baseline compared to the 
controls, but this difference did not reach statistical significance. 
 
Of the 22 patients who underwent cardioversion, there was a significant increase in 
median levels of CPCs (P=0.004) but no significant alteration in any of the other 
markers tested across the three timepoints. Despite an apparent rise in median VEGF 
levels of approximately 50% across the three timepoints, this was not a statistically 
significant. At discharge from hospital (2 hours following DCCV), 20 patients (91%) 
were in sinus rhythm. At 4 weeks, 17 patients (77%) continued to maintain sinus 
rhythm. Subsequent exploratory sub-group analysis was based on success at 4 weeks, 
and so the subjects with early relapse into AF were assumed to have failed 
cardioversion. Of the 17 patients who were successfully cardioverted into sinus 
rhythm, the increase in CPCs from baseline was significant (p=0.003), but not for 
those patients who relapsed back into AF (p=0.715). There was no significant change 
from baseline in any of the other markers studied. 
 
Conclusion: DCCV seems to lead to higher levels of CPCs with a rise seen 
immediately following the procedure. This appears to increase further at 4-weeks. 
This does not appear to be associated with any significant change in vWf, sE-selectin, 
VEGF, IL-6 or sFas/sFas ligand. The present analysis is in part agreement and in part 
contradictory to other available data and likely reflects the notorious difficulty in 
studying a diverse population where multiple co-morbidities are present. Nonetheless, 
the increase in CPCs with cardioversion success may reflect improved vascular health 
and this warrants exploration with a larger study with greater statistical power.
 187
4.2.1 Introduction 
AF tends to be progressive and recurrent with a trend from paroxysmal towards more 
persistent or permanent forms of the arrhythmia with time. Cardioversion is an 
established treatment for AF aimed at restoration of sinus rhythm. Although this may 
occur spontaneously, in many cases this requires the use of pharmacological agents or 
an R-wave synchronized direct current shock (DCCV) under sedation (section 1.1.6). 
With successful restoration and maintenance of sinus rhythm, the effects of the 
arrhythmia in driving the three components of Virchow’s triad are theoretically 
removed, potentially leading to lower thromboembolic risk. Although in practice, the 
high recurrence rate and delayed restoration of mechanical atrial systole have led to 
various guidelines recommending an extended period of anticoagulation5, 6 (section 
1.1.9). 
 
The purpose of this study was to investigate whether restoration of sinus rhythm 
altered indices that may be reflective of the hypercoagulable state or which may be 
implicated in the pathogenesis of AF.  
 
4.2.2 Hypotheses 
These have been detailed previously in section 2.1.3. In brief, we hypothesized that 
successful restoration of sinus rhythm would improve plasma indices of endothelial 
damage / dysfunction (vWf, sEsel), apoptosis (soluble Fas/Fas Ligand), inflammation 
(IL-6) and angiogenesis (CPCs). 
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4.2.3 Methods 
This has been described previously in section 2.2.2. In brief, 20 consecutive patients 
with persistent AF deemed suitable for DCCV. Persistent AF was defined as presence 
of AF on two 12-lead electrocardiograms (ECG) at least 7 days apart in patients 
where restoration of sinus rhythm was deemed attainable. Exclusion criteria are as 
previously described (section 2.2.2). 
 
All patients were established on warfarin (target International Normalized Ration, 
INR 2.0-3.0) for a minimum of 4 weeks prior to DCCV. All patients underwent 
synchronized DCCV under brief general anaesthetic (propofol), using a Medtronik 
Physio-Control LifePak 9 monopasic difibrillator (Redmond, USA). Paddles were 
placed in the antero-lateral position and up to a maximum of 4 sequential shocks were 
delivered (100J, 200J, 360J, 360J). 
 
Baseline results were compared to a cohort of age and sex-matched controls who had 
established cardiovascular risk factors, but who were known to maintain sinus 
rhythm. 
 
Laboratory  
Venous blood was drawn at baseline, immediately following DCCV and again at 4 
weeks as described in section 2.4. Analysis for CPCs and ELISAs was performed as 
described in the appendix. 
 
Power Calculation 
This has been described previously in section 2.3.1. 
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 Statistical Methods 
This has been described previously in section 2.3.2. 
 
4.2.4 Results 
22 consecutive patients (mean age 66.2 (10.3) years, 14 (64%) male) with persistent 
AF undergoing elective DCCV were recruited. A group of 23 age- and sex-matched 
control subjects (mean age 67.1 (9.8) years, 16 (70%) male) were used for baseline 
comparison as disease-matched controls (table 30). Patients and controls were 
comparable in all major parameters aside from use of anti-arrhythmic drugs (P=0.049) 
and anticoagulants (P<0.001) for which there was a significant excess amongst the 
DCCV cohort. Anti-platelet usage was significantly higher amongst the disease-
matched control arm (P=0.001). There was no significant difference in baseline levels 
of vWf, CPCs, sE-selectin, IL-6, or sFas/sFas ligand ratio between either group (table 
31). The controls however had modestly higher levels of sFas (P=0.003), but not sFas 
ligand compared to the AF cohort. Also patients with AF had almost a 2-fold higher 
median level of VEGF at baseline compared to the controls, but given a broad spread, 
this difference did not reach statistical significance. 
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Table 30. Demographic Data for AF patients and control subjects 
 
 Variable Controls AF P value 
 N 23 22  
Age (SD) 67.1 ± 9.8 66.2 ± 10.3 .753 
Age > 75 (%) 6 (26) 4 (18) .391 
Male (%) 16 (70) 14 (64) .758 
Ba
se
lin
e 
D
at
a 
Body Mass Index 30.5 ± 7.7 28.7 ± 6.1 .441 
Smoking 9 (39) 12 (55) .408 
IHD (Angina / MI / PCI) 11 (48) 4 (18) .057 
Previous CVA 2 (9) 1 (5) .517 
CCF 2 (9) 6 (27) .135 
Hypertension 20 (87) 17 (77) .459 
Diabetes Mellitus 3 (13) 0 (0) .233 
Hyperlipidaemia 15 (65) 10 (45) .236 Ri
sk
 F
ac
to
rs
 N
o.
 
(%
) 
CHADS2 1 (1-2) 1 (1-2) .615 
Antiplatelets 13 (57) 2 (9) .001 
Warfarin 1 (4) 22 (100) .000 
Beta-blocker 9 (39) 13 (59) .238 
Calcium-channel blocker 11 (48) 6 (27) .221 
Digitalis 0 (0) 4 (18) .049 
Flecainide 0 (0) 3 (14) .109 
Amiodarone 1 (4) 5 (23) .096 
ACE-i/ARB 15 (65) 15 (67) .586 M
ed
ic
at
io
n,
 N
o.
 (%
) 
Statin 13 (57) 14 (64) .763 
 
Abbreviations: IHD – Ischaemic Heart Disease; MI – Myocardial Infarction; PCI – 
Percutaneous Coronary Intervention; ACE-I – Angiotensin Converting Enzyme 
inhibitor; ARB – Angiotensin-II Receptor Blocker; CCF – Congestive Cardiac 
Failure; CVA – Cerebrovascular Accident; CHADS2: Stroke risk algorithm (see text). 
All Data expressed as Mean ± Standard Deviation (SD), No. (%) or Median 
(InterQuartile Range, IQR) unless otherwise stated. Comparisons between groups 
using the χ2 test for categorical data or unpaired t-test for continuous parametric data. 
The Mann-Whitney U test was used for non-parametric data. A p value < 0.05 was 
considered statistically significant. 
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Table 31. Baseline Research Indices 
 
 Variable Controls AF P value 
 n 23 22  
vWf (IU/dL) 139.8 ± 17.5 136.6 ± 13.5 .492 
sE-selectin (ng/mL) 64.0 (40.0-76.0) 64.0 (39.5-76.0) .674 
CPCs (cells/mL) 66 (30-187) 85 (29-153) .880 
VEGF (ρg/mL) 31 (0-125) 76.25 (20-290) .114 
IL-6 (ρg/mL) 15 (10-16) 15 (10-24.25) .766 
sFas (ng/mL) 5.0 (4.0-5.25) 3.6 (3.0-4.6) .003 
sFas Ligand 
(ρg/mL) 
200 (125-300) 188 (119-188) .945 
Re
se
ar
ch
 In
di
ce
s 
sFas/sFasL ratio 44.4 (30.0-70.0) 48.2 (31.9-
123.9) 
.488 
 
CPC – Circulating Progenitor Cells; vWf – von Willebrand factor; sEsel – soluble E 
selectin; IL-6 – InterLeukin-6, sFas – soluble Fas, sFasL – soluble Fas Ligand, VEGF 
– Vascular Endothelial Growth Factor. All data expressed as mean ± standard 
deviation (SD), or median (InterQuartile Range, IQR) unless stated otherwise; P-value 
refers to the results of unpaired t-test or Mann-Whitney U test as appropriate. A P-
value < 0.05 was considered statistically significant. 
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Table 32 illustrates the alteration in markers studied for the cohort of the 22 patients 
who underwent cardioversion at three time points –pre, immediately post and 4-weeks 
post DCCV. There was no significant alteration in levels of vWf, sE-selectin, IL-6, 
sFas, sFas ligand or the sFas:sFas ligand ratio. Despite an apparent rise in median 
VEGF levels of approximately 50% across the three timepoints, this was not a 
statistically significant change. There was a significant increase in median levels of 
CPCs (P=0.004) across all three timepoints (figure 12). 
 
At discharge from hospital (2 hours following DCCV), 20 patients (91%) were in 
sinus rhythm. At 4 weeks, 17 patients (77%) continued to maintain sinus rhythm. 
Subsequent exploratory sub-group analysis was based on success at 4 weeks, and so 
the subjects with early relapse into AF were assumed to have failed cardioversion 
(table 33). Of the 17 patients who were successfully cardioverted into sinus rhythm, 
the increase in CPCs from baseline was significant (p=0.003), but not for those 
patients who relapsed back into AF (p=0.715). There was no significant change from 
baseline in any of the other markers studied. 
 
Correlations and regression analysis was not performed as this was completed on the 
entire study population as part of the cross-sectional study (section 4.1). 
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Table 32. The Effects of Direct Current Cardioversion 
 
 Effects of DCCV  
Variable Pre Immediate post 4-weeks post P-
value 
Heart rate 75 ± 20 72 ± 15 76 ± 20 .508 
BPsystolic (mmHg) 134 ± 17 132 ± 17 134 ± 16 .830 
CPCs (/mL) 85 (29-153) 102 (78-195) 123 (70-215) .004a,b
vWf (IU/dL) 136.6 ± 13.5 137.9 ± 26.1 137.5 ± 21.3 .979 
sEsel (ng/mL) 64.0 (39.5-76.0) 64.0 (55.5-76.5) 68.0 (46.0-80.0) .706 
sFas (ng/mL) 3.6 (3.0-4.6) 3.5 (3.0-4.8) 4.5 (3.5-5.0) .156 
sFasL (ρg/mL) 188 (119-188) 200 (125-400) 300 (141-500) .635 
sFas:sFasL 48.2 (31.9-123.9) 50.0 (32.8-108.0) 70.5 (33.8-127.1) .944 
IL-6 (ρg/mL) 15 (10-24.25) 10 (0-17) 15 (10-22.5) .302 
VEGF (ρg/mL) 76.25 (20-290) 95 (27.5-136.25) 125 (62-232.5) .665 
 
CPC – Circulating Progenitor Cells; vWf – von Willebrand factor; sEsel – soluble E 
selectin; IL-6 – InterLeukin-6, sFas – soluble Fas, sFasL – soluble Fas Ligand, VEGF 
– Vascular Endothelial Growth Factor, BP – Blood Pressure; DCCV – Direct Current 
Cardioversion. All data expressed as mean ± standard deviation (SD) or median 
(InterQuartile Range, IQR) unless otherwise stated; P-value refers to the results of 
Friedman’s repeated measures ANOVA. A P <0.05 was considered statistically 
significant and where appropriate Tukey’s post hoc analysis applied: apre and 
immediate post; bpre and 4-weeks post; cimmediate post and 4-weeks post.
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Table 33. Effect of cardioversion success on research indices 
 
 Successful DCCV at 4-weeks Unsuccessful DCCV at 4-weeks 
Variable Baseline 4-weeks P-value  AF P-value 
n 17 5 
CPCs (/mL) 82.0 (17-116) 140 (66-205) .003 171 (46-269) 164 (50-284) .715 
vWf (IU/dL) 135.7 ± 15.3 133.9 ± 22.6 .462 138.2 ± 7.5 146.2 ± 16.4 .462 
sEsel (ng/mL 34.0 (25.0-37.0) 35.5 (25.0-40.0) .753 19.0 (16.0-37.5) 46.0 (26.0-82.0) .785 
sFas (ng/mL) 3.5 (3.0-4.5) 4.5 (3.3-4.8) .117 4.5 (3.2-4.8) 4.0 (3.6-5.0) .715 
sFasL 
(ρg/mL) 
187.5 (125.0-
400.0) 
325 (135-500) .551 175 (87.5-475) 175 (148-450) .686 
sFas:sFasL 48.6 (34.6-138.3) 78.9 (36-131) .605 40.0 (22.8-110.7) 42.9 (32-117) .686 
IL-6 (ρg/mL) 15.0 (7.5-22.75) 15 (10-20) .894 20 (5-65) 20 (5-38) .285 
VEGF 
(ρg/mL) 
120.0 (20.0-
342.5) 
132.5 (71.75-
257.5) 
.529 20.0 (10.0-895) 62 (35-512.5) .686 
 
CPC – Circulating Progenitor Cells; vWf – von Willebrand factor; sEsel – soluble E selectin; IL-6 – InterLeukin-6, sFas – soluble Fas, sFasL – 
soluble Fas Ligand, VEGF – Vascular Endothelial Growth Factor. All data expressed as mean ± standard deviation (SD) or median 
(InterQuartile Range, IQR) unless otherwise stated. Comparison from baseline values made using paired t-test or Wilcoxon test for parametric 
and non-parametric data respectively. 
 
Figure 12 Impact of Cardioversion on Circulating Progenitor Cells 
 
 
Scatter plot illustrating CPC counts for the entire cohort undergoing DC 
cardioversion. P-values from paired Wilcoxon test. P=0.004 using Friedman’s 
repeated measures ANOVA for entire cohort. 
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4.2.5 Discussion 
Although in theory, restoration of sinus rhythm offers the premise of reduced 
thromboemolic risk, the benefits of an aggressive cardioversion strategy have not 
translated into improvements in clinical outcome. The purported explanations for this 
have been discussed previously in section 1.1.6. 
 
A number of previous studies have assessed the effect of cardioversion on various 
parameters including atrial endocrine function, platelet activation, and numerous 
coagulation and endothelial parameters84, 154, 325, 383-387. Alterations in some indices 
have been cited as reflective of improved ‘vascular health’, but the data is not 
consistent and although modest improvements in some markers are seen, this does not 
apply across the board and in other series there is a detrimental effect (section 1.2.5). 
 
Our findings show a significant step-wise increase in CPCs following DCCV. 
Although an increase in CPCs also occurred in the DCCV failure group, this was a 
modest change and did not reach statistical significance. By week 4, there was a 
further significant rise in CPCs from baseline amongst those patients where DCCV 
had proven successful, but not in those where DCCV failed. 
 
Similar work from other research groups observing CD34+ cells following DCCV 
reported a downward trend in cell counts following DCCV success388. The argument 
from these and some other researchers is that endothelial damage is a potent stimulus 
for CD34+ cell release and therefore in response to removal of this stimulus, 
circulating CD34+ numbers decline389, 390. Of course, CD34+ cells are a mixed 
population of various lineages and therefore only limited comparisons with our work 
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(where cells have been more strategically gated, albeit still not pure endothelial 
progenitors) is possible (section 3.1). 
 
Although an increase in median VEGF levels across the entire cohort undergoing 
DCCV was observed, this did not reach statistical significance. This fluctuation was 
not observed in the subsequent subgroup analysis comparing those patients who 
maintained sinus rhythm at 4-weeks vs. those who reverted to AF (although the latter 
had VEGF levels approximately half of the former). This observation may therefore 
be a consequence of underpowering (although we exceded of our pre-specified power 
calculation) or be reflective of the rather broad spread in VEGF levels. 
 
There was also no clear fluctuation in levels of the other research indices tested 
following DCCV. This may be considered surprising, particularly as some may link to 
the hypercoagulable state in AF373, whilst others (i.e. VEGF) may be important in 
regulating CPC release344. Previous studies have observed alteration in levels of vWf 
in patients with AF and indeed alteration with DCCV325, but again this is not a 
consistent finding across the literature 377 and therefore may represent publication bias 
of a larger negative  study vs. a smaller later study with a chance finding. It is also 
plausible that failure to detect any difference was a result of low power. 
 
Other researchers have assessed the influence of DCCV on levels of sE-selectin and 
found no significant alterations in plasma levels325. In keeping with this, we too have 
seen no alteration in sE-selectin levels following DCCV regardless of outcome. This 
together with no change in vWf levels permits speculation that the observed 
fluctuation in CPCs peri-DCCV may not be a consequence of alterations in peripheral 
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stimuli such as endothelial damage/activation. It is therefore presumed that the major 
contributor to endothelial damage/dysfunction (and hence vWf / other molecule 
release) amongst this cohort was the presence of co-morbidities rather than the 
arrhythmia. This would be in keeping with data from Framingham and the cross-
sectional analysis previously performed (section 4.1). Although it is noteworthy that 
on multivariate analysis, a relationship between AF and CPCs was not defined (table 
29). Thus it is possible that the alterations in CPCs observed following DCCV are not 
a true finding and merely a reflection of bias due to small numbers of highly selected 
patients. 
 
In the present analysis, we observe similar levels of IL-6 amongst controls and 
patients undergoing DCCV, with little change in this serum marker of inflammation 
with cardioversion. Other studies have shown that markers of inflammation (e.g. hs-
CRP & IL-6) can predict DCCV success391-393. Although once again, there is some 
disparity amongst available data with others showing no association394. The 
explanation for this observation may be similar to that used to explain the lack of 
fluctuation in other markers tested in this study. Most importantly, the heterogeneous 
nature of our population and in particular the number of co-morbidities associated 
with these patients – such that rhythm disturbance is not the predominant means for 
IL-6 release in this series of patients. 
 
Significantly lower levels of sFas, but not sFas ligand, nor the ratio between the two 
were seen amongst the cohort of patients with persistent AF. Following DCCV, an 
upward trend in both median levels of sFas, sFas ligand and the ratio between the two 
was observed, although this did not reach significance either amongst those patients 
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who remained in sinus rhythm at 4 weeks or amongst those who reverted to AF. It is 
therefore assumed that cardioversion makes little or no impact on this mechanism for 
cellular apoptosis. This is perhaps not surprising given the complexity of the 
hypercoagulable state in AF, but given the increase in CPCs seen during the same 
timeframe, it could also be argued that lower Fas mediated apoptosis is unlikely to be 
the explanation for this observation and that the increase in CPCs likely reflects 
greater bone-marrow production / cellular release, for an as yet undefined stimulus. 
 
Study limitations 
The present study has a number of limitations. Once again, the first limitation relates 
to study design, which by virtue of the relatively small numbers included and large 
number of co-morbidities allows only for associations to be made rather than 
identification of cause and effect. Similar pitfalls also apply to the previous study and 
have already been discussed in detail (section 4.1.5). Such limitations are difficult to 
rectify, particularly as the number of patients referred for DCCV has dwindled in light 
of recent clinical trials, which have dramatically altered the perception of clinicians as 
to the effectiveness of a rhythm control strategy. Consequently, in our unit, the 
patients referred for DCCV are carefully selected and therefore may not be reflective 
of every patient deemed to have persistent AF or indeed those referred for 
cardioversion in other centres where application of guidelines may be less rigid. This 
may also explain the high cardioversion success rate seen at 4 weeks amongst the 
cohort of patient studied. 
 
In addition, the highly selected nature of the cohort of patients undergoing DCCV 
may infer bias. This is particularly notable when the observed alteration of CPCs in 
 - 200 - 
the present analysis is considered in light of the previous study (section 4.1.5, table 
29) where no association between AF and CPCs was evident on multivariate analysis. 
 
Although a series of controls were recruited for baseline comparison, these subjects 
were not followed longitudinally over the same time-course. Thus it is possible that 
observed alterations in the various markers tested simply reflects natural fluctuations 
in these parameters. Thus by studying small numbers of patients, we may have simply 
witnessed chance findings or conversely may have failed to detect a difference. 
 
As discussed previously (section 4.1.5 and above) there remain important limitations 
related to power. Although our power calculation was exceeded, this was based 
purported alteration in CPCs from data initially analysed in a different laboratory 
using a different series of patients and different equipment. We also supported this 
calculation with previous studies from our unit that had detected a difference in vWf 
using a similar sample size to ours (section 2.3.1). However, many of the parameters 
tested had a broad spread and thus even given this initial calculation, the present study 
would appear to be underpowered. It is also feasible that previous studies 
demonstrating alterations in a number of parameters with cardioversion were also 
underpowered as these observations have not always been evident in larger studies 
(section 4.2.5). 
 
Further limitations may be applied to the application of statistical analyses in 
subgroups as this will have a further detrimental effect on power and thus it is 
essential to acknowledge that such analyses were undertaken in an exploratory 
fashion. 
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4.2.6 Conclusion 
DCCV seems to lead to higher levels of CPCs with a rise seen immediately following 
the procedure, but this is sustained and even increases further at 4-weeks. This does 
not appear to be associated with any significant change in vWf, sE-selectin, VEGF, 
IL-6 or sFas/sFas ligand. The present analysis is in part agreement and in part 
contradictory to other available data and likely reflects the notorious difficulty in 
studying a diverse population where multiple co-morbidities are present. Nonetheless, 
the increase in CPCs with cardioversion success may reflect improved vascular health 
and warrants exploration with a larger study with greater statistical power. 
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4.3 Inflammation and Arrhythmia Burden 
 
Abstract 
Background: Atrial Fibrillation (AF) is associated with a high risk of stroke and is 
thought to confer a hyercoagulable state fulfilling all three components of Virchow’s 
triad (stasis, abnormalities of the endocardium and abnormalities of blood 
constituents). However, stroke risk is variable and underlying co-morbid factors seem 
to play a key role. In sustained forms of AF, the contribution of the arrhythmia to 
stroke appears clear and has been documented repeatedly in epidemiological studies. 
However, in paroxysmal AF, presently available data have yet to identify precisely 
what proportion of time spent in AF (i.e. arrhythmia burden, AFB) is of clinical 
relevance. We aimed to assess this relationship using surrogate blood markers for the 
hypercoagulable state associated with AF. 
 
Methods: 121 consecutive outpatients [mean age 74.7 ± 7.8 years; 73 (60.3%) 
male] with pacemakers capable of arrhythmia detection were recruited. AFB was 
assessed over a 1-month period and classified as AFB=0% (sinus rhythm), 0.1-10% 
(low), 10.1-50% (medium), >50% (high AFB), to broadly reflect the patterns of AF 
commonly encountered in clinical practice. 
 
Results: There was no statistically significant difference in age, gender, or co-
morbidities. Stroke risk scores (calculated from CHADS2) were similar in all groups. 
Rates of anticoagulation use were also comparable between groups except for the 
‘medium’ AFB group where a larger number of patients receiving warfarin were 
observed. There were no significant differences in indices of endothelial damage 
(vonWillebrand factor, vWf), endothelial activation (soluble E-selectin, sEsel) or 
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inflammation (high sensitivity C-reactive protein, hsCRP) across the groups. Median 
levels of Interleukin-6 (IL-6) reduced in a stepwise fashion between groups with 
increasing AF burden (P=0.476). A sub-analysis of the 58 patients with ‘true’ 
paroxysmal AF (that is, excluding those with sinus rhythm or persistent AF from the 
analysis) demonstrated that the median number of AF episodes per day was 0.1 (Inter 
Quartile Range (IQR) 0-2.1) and median duration of these episodes was 0.5 (IQR 0.2-
2.1) hours. 
 
Conclusion: Data from the present analysis are potentially of importance and of 
direct clinical relevance when considering patients with paroxysmal and pacemaker 
defined AF. Although our understanding regarding the complexity of the 
hypercoagulable state in AF remains incomplete, we report variable aberration of 
prothrombotic markers in this cohort of patients with AF. However, given no 
appreciable relationship between these prothrombotic markers and AFB, it is it is 
plausible that these abnormalities do in fact relate primarily to underlying risk factors, 
and that such patients should be anticoagulated if risk factors dictate. Thus, AFB 
should probably not directly influence the decision to anticoagulate, but rather the 
presence of AF combined with clinical risk scoring algorithms should remain the 
predominant tool for stroke risk assessment. However, these findings must be 
interpreted with caution: the population studied was highly selected and data may not 
be applicable to the general population. Similarly, the data points had a broad spread 
and even though the pre-specified power calculation was met, it is clear that for some 
analyses to be interpreted, greater numbers still are required. 
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4.3.1 Introduction 
Although the diagnosis of AF often follows the report of symptoms from the patient, 
frequently, this is not the case and AF is an asymptomatic incidental finding (section 
1.1.3). Therefore, the true prevalence of this arrhythmia relates to how hard the 
clinician looks – in many cases, AF may only be detected on 24-hour (or longer) 
periods of ambulatory monitoring.  This claim is strongly supported by the literature 
where up to 70% of AF episodes detected by trans-telephonic transmission are found 
to be asymptomatic395. 
 
In patients with symptomatic paroxysmal AF, many also have frequent bouts of 
asymptomatic arrhythmia396, 397. This can lull both the patient and clinician into a false 
sense of security and may even prompt premature discontinuation of anticoagulation 
for those patients believed to be maintaining sinus rhythm. This may, in part, explain 
the higher rate of stroke seen in the ‘rhythm control’ arm of recent clinical trials398 
(section 1.1.6). Thus, some clinicians routinely continue long-term anticoagulation for 
all AF patients deemed at significant stroke risk even if the arrhythmia is deemed 
‘cured’, as only limited data exists to establish what frequency/duration of AF 
episodes (that is, AF arrhythmia burden) is of clinical significance399. 
 
The purpose of this study was to investigate whether a greater proportion of time 
spent in AF (that is, AF arrhythmia burden (AFB)) led to more extensive 
abnormalities of surrogate markers for enhanced coagulability. 
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4.3.2 Hypotheses 
These have been detailed previously in section 2.1.3. In brief, we tested the 
hypothesis that in paroxysmal AF, the arrhythmia burden may influence the extent of 
systemic inflammation (IL-6 and hsCRP), endothelial damage (vonWillebrand factor 
(vWf)) and endothelial activation (soluble E-selectin (sE-selectin)). 
 
4.3.3 Methods 
The present study required access to a large cohort of patients with permanent 
pacemakers incorporating advanced AF detection algorithms (Vitatron ‘T70’ or 
Selection 9000 – see Device Characteristics, below). This required collaboration with 
another unit (Eastbourne District General Hospital) as our hospital only had access to 
limited numbers of suitable patients. Consecutive outpatients aged 18-85 were 
identified as those who had previous documented evidence of paroxysmal AF with at 
least two episodes within the last three months. Anti-arrhythmic therapy had been 
stable in all patients for at least five half-lives prior to study entry. Exclusion criteria 
have been discussed previously (section 2.2.3). 
 
Pacemaker interrogation was performed at baseline to establish the ‘AF burden’ 
(AFB).  The pacemaker Holter memory was then cleared. Following completion of 
the recruitment phase of the study, the pacemaker was interrogated and the AFB 
calculated once again.  Patient groups were categorized on the basis of pacemaker 
interrogation as follows: sinus rhythm only [that is, AFB=0], ‘low’ AFB [0.1-10% 
time in AF], ‘moderate’ AFB [10.1-50% time in AF] and ‘high’ AFB [>50% time in 
AF].  These AFB groupings were selected to reflect commonly encountered 
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presentations of paroxysmal AF – i.e. patients with only occasional arrhythmia, those 
with regular episodes of AF and those with frequent recurrence of AF.  
 
Device Characteristics 
The Vitatron ‘T70’ or Selection 9000 pacemakers are dual chamber pacemakers with 
sophisticated algorithms for AF detection and prevention, and incorporate advanced 
AF detection and therapy algorithms. These devices have software tailored to detect 
the common mechanisms through which episodes of paroxysmal AF are initiated – by 
premature atrial complexes (PAC), by bradycardia or immediate reinitiation of AF400. 
AF detection is based upon atrial rate, whereby atrial tachyarrhythmias are detected 
when the median atrial cycle length is less than the programmed AT or AF detection 
interval and when the atrioventricular ratio is greater than 1:1 for a predefined number 
of cycles.  Anti-AF pacing is then provided either in response to ‘triggers‘ or by 
continuous overdrive atrial pacing.  This study used the diagnostic capacity of these 
devices to determine AF burden, rather than their therapeutic functions.  The 
algorithms for AF prevention therefore remained stable for the duration of the study. 
 
Laboratory  
Venous blood was drawn both at baseline and again at 4 weeks as described in section 
2.4 and processed according to protocols in 2.4.4. As blood samples were obtained 
from patients in another unit some distance away it was not possible to analyses 
samples for CPCs. 
 
Statistical Methods 
This has been described previously in section 2.3.2. 
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 Power Calculation 
This has been described previously in section 2.3.1. 
 
4.3.4 Results  
121 patients [mean age 74.7 ± 7.8 years; 73 (60.3%) male] were recruited. There was 
no statistically significant difference in age, gender, or co-morbidities. Stroke risk 
scores (calculated from CHADS2) were similar in all groups [table 34]. Rates of 
anticoagulation use were also comparable between groups except for the ‘medium’ 
AFB group where a larger number of patients receiving warfarin were observed. The 
use of anticoagulation in the sinus rhythm group reflects the design of the study where 
all patients included were documented to have AF at some point. 
 
There were no significant differences in indices of endothelial damage (vWf), 
endothelial activation (sE-selectin) or inflammation (hsCRP) across the 4 patient 
groups [table 35]. Median levels of IL-6 reduced in a stepwise fashion between 
groups with increasing AF burden. This change however, did not reach statistical 
significance (P=0.476). A sub-analysis of the 58 patients with ‘true’ paroxysmal AF 
(that is, excluding those with sinus rhythm or persistent AF from the analysis) 
demonstrated that the median number of AF episodes per day was 0.1 (Inter Quartile 
Range (IQR) 0-2.1) and median duration of these episodes was 0.5 (IQR 0.2-2.1) 
hours. 
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Table 34. Baseline Characteristics of Subjects in relation to Atrial Fibrillation 
Burden 
 Sinus rhythm 
[AFB=0] 
AFB 
0.1-10% 
AFB 
10.1-50% 
AFB 
>50% 
P-
value 
N 38 34 24 25  
Age 76.1 ± 8.4 73.4 ± 8.2 73.2 ± 7.4 75.7 ± 6.8 .317 
Male 22 (57.9) 18 (52.9) 15 (62.5) 15 (60.0) .897 
AF Burden / % 0 ± 0 2.7 ± 3.3 32.5 ± 13.9 99.2 ± 4.20 .000 
Hypertension 19 (50.0) 20 (58.8) 14 (58.3) 21 (84.0) .055 
LAd / cm 3.83 ± .67 4.1 ± .89 4.2 ± .55 4.4 ± .50 .182 
LVFS / % 33.6 ± 9.4 35.6 ± 7.5 34.1 ± 7.6 30.4 ± 14.3 .575 
Diabetes 5 (13.2) 3 (8.8) 0 (0) 4 (16.0) .249 
Hyperlipidaemia 14 (36.8) 17 (50) 11 (45.8) 14 (56.0) .446 
CAD 11 (28.9) 6 (17.6) 3 (12.5) 10 (40.0) .119 
Prior stroke 6 (15.8) 5 (14.7) 3 (12.5) 2 (8.0) .820 
CHADS2 score 1.87 (1.45) 1.88 (1.49) 1.50 (1.22) 2.12 (1.01) .299 
Anticoagulation 16 (42.1) 16 (47.1) 21 (87.5) 14 (56.0) .004 
Smoker 6 (15.8) 1 (2.9) 1 (4.2) 1 (4.0) .187 
Statin use 22 (57.9) 16 (47.1) 17 (70.8) 15 (60.0) .409 
ARB/ACE-i 14 (36.8) 17 (50.0) 9 (37.5) 17 (68.0) .199 
 
AFB: atrial fibrillation burden; LVFS: Left ventricular fractional shortening from M-
mode in parasternal long-axis plane; LAd: Left atrial diameter measured in 
parasternal long-axis plane; CHADS2: Stroke risk algorithm score (see text); ARB: 
Angiotensin-2 Receptor Blocker; ACE-i: Angiotensin converting enzyme inhibitor. 
 
Values are expressed as mean ± standard deviation or No. (%) unless otherwise 
indicated. Analyses were performed using the χ2 test for categorical data or one-way 
analysis of variance for continuous data. Tukey’s post hoc analysis was performed 
where appropriate. A p value < 0.05 was considered statistically significant. 
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Table 35. Endothelial, inflammatory and coagulation indices, in relation to Atrial 
Fibrillation Burden 
 Sinus rhythm
[AFB=0] 
AFB 
0.1-10% 
AFB 
10.1-50% 
AFB 
>50% 
P-
value 
vWf 
(IU/dL) 
133.2 (14.3) 136.3 (18.3) 132.0 (26.9) 139.5 (19.1) .518 
Sol E-selectin 
(ng/mL) 
56.0 (38.0-
68.0) 
68.0 (50.0-
74.0) 
64.0 (30.0-
76.0) 
68.0 (45.0-
84.0) 
.296 
Il-6 
(ρg/mL) 
15.6 (7.0-
60.0) 
11.0 (5.1-
33.3) 
10.0 (5.0-
38.0) 
9.0 (4.0-
30.0) 
.476 
hsCRP 
(μg/mL) 
2.4 (3.3) 3.0 (3.8) 2.5 (3.8) 2.5 (3.0) .329 
 
All data are mean (SD) or median (IQR) as appropriate.  AFB, atrial fibrillation burden; 
vWf, von Willebrand factor, IL-6, interleukin-6; CRP, C-reactive protein; sol, soluble. 
Analysis by oneway ANOVA or Kruskall-Wallis for parametric and non-parametric 
data respectively 
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No correlations were observed between levels of sE-selectin and vWF (r = -0.015, P = 
0.886) or between hsCRP and IL-6 (r = -0.021, P = 0.835) [table 36]. A positive 
correlation was observed between levels of sE-selectin and both hsCRP (r =0.296, P = 
0.003) and IL-6 (r = 0.306, P = 0.003). 
 
Following a step-wise multiple linear regression analysis, age emerged as a significant 
predictor of vWf (β = 0.354, P=0.010). Left ventricular ejection fraction was 
predictive of sE-selectin (β=0.335, P=0.020). Anticoagulation was a predictor of vWf 
levels (β=0.387, P=0.005) [table 37]. 
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Table 36. Correlations between research indices 
Variables  sEsel IL-6 vWf 
hsCRP R .296 -.021 .139 
 P .003 .835 .144 
sEsel R .306 .007 
 P 
 
.003 .946 
IL-6 R -.129 
 P 
  
.186 
 
vWf – von Willebrand factor; IL-6 – interleukin-6; CRP – high sensitivity C-reactive 
protein; sEsel – soluble E Selectin.Correlations relate to Spearman’s method 
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Table 37.  Multiple Linear Regression Analysis 
Variables  vWf hsCRP sEsel IL-6 
β* .039 .157 .044 .266 Arrhythmia 
burden (%) P .877 .581 .751 .376 
β* .354 .018 -.281 .028 
Age 
P .010 .899 .105 .856 
β* -.173 -.257 .108 .269 
Gender 
P .217 .103 .455 .107 
β* -.190 -.062 -.067 .023 
Hypertension 
P .169 .681 .765 .890 
β* .063 -.028 .000 -.087
Diabetes 
P .621 .843 .998 .554 
β* .009 -.043 -.172 -.036
Stroke 
P .946 .762 .457 .816 
β* .374 -.540 .338 .058 
CHADS2 
P .321 .188 .361 .896 
β* .140 .027 .020 -.207
ARB / ACE-i 
P .293 .850 .893 .837 
β* -.060 .122 .052 -.145
IHD 
P .663 .412 .710 .365 
β* .004 .135 .335 .072 
LVFS 
P .975 .332 .020 .626 
β* .158 .184 -.064 .003 
↑ lipidaemia 
P .223 .197 .678 .982 
β* .387 -.165 .018 .048 
Warfarin 
P .005 .258 .897 .763 
R2  .251 .105 .199 .115 
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Table 34.  Multiple Linear Regression Analysis (continued) 
 
Variables  vWf hsCRP sEsel IL-6 
β* .226 -.033 .096 .125 
Smoking 
P .090 .974 .495 .416 
β* .142 .167 -.126 .115 
Statin 
P .292 .868 .416 .456 
β* .128 -.140 .195 .036 
LA diameter 
P .322 .320 .183 .812 
* Numbers are standardized β co-efficients 
LA – Left atrium; LVFS – Left ventricular fractional shortening; IHD – Ischaemic 
heart disease; CHADS2: Stroke risk algorithm (see text); ARB / ACE-i: Angiotensin-
2 receptor blocker / Angiotensin converting enzyme inhibitor.   
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4.3.5 Discussion 
Our analysis shows no significant inter-group difference in indices of inflammation, 
endothelial damage or endothelial activation. These findings may support the notion 
that the abnormalities of the prothrombotic state seen in AF may simply be reflective 
of underlying co-morbidities174, rather than being reflective of the presence or absence 
of AF per se. Indeed, it is relatively uncommon to encounter patients with AF who do 
not have at least one (and usually multiple) co-morbidities (section 1.1.2). 
Importantly, such conditions tend to be predominantly of a ‘vascular’ nature (e.g. 
hypertension) and consequently may have the potential to drive low-grade systemic 
inflammation, generate endothelial damage and promote platelet activation and 
therefore may, in their own right, lead to a state of enhanced coagulability46, 159 
(section 1.2.2). Also, this study could be of importance in defining the role of 
pacemaker-detected AF (and burden) in clinical practice as this concept has not been 
adequately explored. 
 
The body of literature available addressing arrhythmia burden in paroxysmal AF and 
risk of stroke is limited. Nonetheless, there are ample available data to conclude that 
paroxysmal AF should be considered as an important clinical entity398, 399. The data 
investigating AFB to stroke risk is particularly sparse and it is therefore not possible 
from the presently available literature to conclude precisely what AFB increases the 
stroke risk in paroxysmal AF to levels seen with sustained forms of AF. The absence 
of significant inter-group differences in surrogate markers of the hypercoagulable 
state seen in our analysis, adds further weight to the concept that arrhythmia burden 
alone is unhelpful in establishing stroke risk and that the decision to anticoagulate 
should therefore be based upon assessment of clinical risk factors. 
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Inflammatory molecules, in particular IL-6 may be important in linking inflammation 
and thrombogenesis in AF by enhancing platelet production of and sensitivity to 
thrombin169 and stimulating transcription of fibrinogen170. IL-6 is also linked to 
endothelial activation171 offering a further plausible link with activation of the 
coagulation cascade as the process of endothelial damage may occur as a consequence 
of thrombosis and thereby enhance availability of molecules such as tissue factor 
(TF). It is interesting that IL-6 seemed to trend downwards in this study amongst 
patients with increasing AFB, particularly given that other studies have suggested the 
converse to be true – amongst patients with increasing temporal patterns of AF (i.e. 
paroxysmal vs. persistent vs permanent) – see section 1.2.6. 
 
Nonetheless, another important link between inflammation and thrombogenesis is 
provided by study of E-selectin. This glycoprotein is expressed solely on endothelial 
cells and only following activation by inflammatory cytokines (e.g. IL-1β, TNF-α) or 
endotoxin401, 402. Expression of E-selectin is transitory and appears to mediate 
leukocyte adhesion thereby promoting or reflecting localized inflammation403. E-
selectin may therefore reflect either endothelial damage or activation and may also 
link inflammation and thrombogenesis in AF375. Thus there would appear to be an 
intimate relationship between AF, inflammation, endothelial damage and activation of 
the coagulation cascade (section 1.2.2). 
 
The general lack of correlation between the various markers and clinical 
characteristics of the patients studied is interesting but perhaps not surprising. To 
interpret this, one must consider that previous studies have also demonstrated 
diversity in the strength of association between clinical risk factors and various blood 
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markers tested46, 159. In addition it is important to note that some markers reflect more 
than one pathophysiological process. Thus, there may be subtle and diverse 
differences in the molecular mechanisms that result in release of each molecule, and a 
process that (for example) drives the release of vWf may only minimally alter levels 
of sE-selectin and vice versa. Similar arguments may also apply to hsCRP and IL-6, 
although despite this, modest correlations were seen between these two markers. 
Additionally weak correlations were also observed between IL-6 and sE-selectin, and 
hsCRP and sE-selectin. The implication therefore is that low-grade systemic 
inflammation may ‘drive’ or even be a consequence of endothelial 
damage/dysfunction – a concept that has already been suggested (section 1.2.6). 
Similarly, it could be concluded that inflammation (or even endothelial damage) could 
lead to platelet activation and such claims would be in keeping with existing data 
suggesting a complex and intimate relationship between the various vascular risk 
factors, AF and the hypercoagulable state46, 159.  In addition, there was no correlation 
between vWf and frequency of AF episodes nor with median episode duration. Again 
this may suggest that patient baseline characteristics are an essential component of the 
hypercoagulable state. 
 
On multiple linear regression analysis, age appeared to be predictive of endothelial 
damage (vWf). There also appeared to be a relationship between anticoagulation and 
vWf, which is difficult to explain. However, patients receiving anticoagulation are in 
fact older with a higher AF burden and more co-morbidities, each of which could 
potentially mediate vWf release through greater degrees of endothelial damage or 
dysfunction. Alternatively, these findings could relate to chance given that numerous 
parmeters were assessed.. 
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 Study limitations 
The main limitation of this study is its cross-sectional design and that the present 
analysis does not include a matched cohort of ‘healthy control’ subjects in sinus 
rhythm to act as a baseline comparator. However, each of the markers assessed in this 
study have already been extensively investigated in patients with AF and aberrancies 
of each have been consistently reported compared to healthy control subjects. 
However, many of these aforementioned studies are of variable size and quality and 
therefore precise relationships between markers and AF remains open to debate. 
Indeed, as previously discussed in section 4.1.5 and section 4.2.5, there are notable 
inconsistencies amongst the published literature. 
 
This study is also relatively small sized but we are in fulfilment of our prespecified 
power calculation. Nonetheless, some of the markers tested had a wide range and thus 
a power calculation based on vWf and IL-6 may not apply universally to all markers 
tested as each will have different characteristics and laboratory assays may differ. 
 
The patient cohort considered here is highly selected – each had a permanent 
pacemaker and thus may not only have a different spectrum of ill health or co-
morbidities to the general population with AF, they may also have been followed up 
in a different manner too. Some may remain under active follow-up in a cardiology 
clinic, whilst others may remain under follow-up with a pacing clinic where the 
pacemaker is interrogated periodically for function and battery life. Either option may 
imply key differences between this cohort and other patients with paroxysmal AF. 
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It would be also be difficult to generalize these observations to all paroxysmal AF 
patients, given the wide spectrum of this disorder and given the importance of "the 
state of AF" as a risk factor for thrombotic events, especially in the presence of co-
morbidities404. Also there remains an important distinction between ‘device-defined 
AF’ and paroxysmal AF in the traditional sense as the former is based upon a series of 
algorithms. 
 
Finally, the half-life of many of the markers studied is considerably shorter than the 1 
month period over which AFB was assessed. Thus the influence of AF on the research 
indices may be lessened, particularly in cases with a very low AFB. This 
consideration would be difficult to overcome given the broad range of AFB observed 
amongst the cohort of patients studied. 
 
4.3.6 Conclusion 
Data from the present analysis are of particular importance and of direct clinical 
relevance when considering patients with paroxysmal and pacemaker defined AF. 
Although our understanding regarding the complexity of the hypercoagulable state in 
AF remains incomplete, we again report variable aberration of prothrombotic markers 
in this cohort of patients with AF. However, given no appreciable relationship 
between these prothrombotic markers and AFB, it is it is plausible that these 
abnormalities do in fact relate primarily to underlying risk factors, and that such 
patients should be anticoagulated if risk factors dictate. Thus, AFB should probably 
not directly influence the decision to anticoagulate, but rather the presence of AF 
combined with clinical risk scoring algorithms should remain the predominant tool for 
stroke risk assessment. 
 - 219 - 
Section V: Conclusion 
 
5.1 Summary of Findings 
The main objective of this work was to further dissect the complex hypercoagulable 
state that seems to be associated with AF and establish novel mechanisms that may 
link and drive underlying processes such as inflammation and angiogenesis. This 
work has involved several comprehensive literature reviews, each of which has 
already been published in peer-reviewed scientific journals.   
 
5.1.1 Literature appraisal 
The first of the literature reviews (section 1.1) investigated the importance of AF as a 
clinical entity and outlined comprehensively the management of this arrhythmia, 
which at times can be particularly challenging and often requires specialist opinion 
and/or intervention. In particular this review emphasized the clinical sequelae of AF, 
the most important and evident being stroke. In section 1.1.9, the review continues to 
offer a literature appraisal of thromboprophylaxis by both antiplatelet agents (namely 
aspirin) and Vitamin K antagonists (warfarin). This review emphasises that a 
thromboprophylaxis decision is not always clear-cut and that individual assessment 
with reference to the published literature is essential to provide the most appropriate 
management strategy to our patients.  
 
The second literature review (section 1.2) focussed on the hypercoagulable state in 
AF and in particular considered how, through very complex mechanisms and 
interactions, this arrhythmia is able to satisfy all three components of Virchow’s triad 
for thrombogenesis. As previously discussed, stasis remains the most evident and 
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obvious component of Virchow’s triad during periods of AF (section 1.2.4). However, 
it is clear that a broad spectrum of abnormalities do in fact exist ranging from 
evidence of vessel wall (endocardial / endothelial) disruption to aberrancies of various 
blood constituents (sections 1.2.3 & 1.2.5). The latter range in diversity from those 
seemingly connected directly to AF and the coagulation cascade to factors that have 
may provide a link between various mechanistic processes. Although not fully 
understood, in section 1.2.6, the review has discussed in detail various processes that 
may be involved in driving the thrombogenic tendency. Such a comprehensive review 
has not been published previously and it is hoped that this will provide a framework 
for other investigators to build upon. 
 
The final literature review (section 1.3) has assessed the relevance of EPCs within 
cardiovascular medicine and discussed the data supporting these rare cells as 
important identifiers of patients at high cardiovascular risk. More importantly, this 
review discusses the purported role for these cells in replenishing the endothelium – a 
vital organ and which is implicated in the pathophysiology of numerous 
cardiovascular diseases, including one that may be central to thrombogenesis in AF. 
 
EPCs have evolved in definition since first being characterized in early experiments. 
This has had inevitable consequences as many studies discussed in this review have 
used differing antigenic definitions and thus cells assessed by one research group are 
not necessarily the same as those assessed in other experiments. Additionally, many 
of the published studies have been on small highly selected groups of patients or have 
been conducted in vitro. Thus inconsistencies within some of the published literature 
are to be anticipated. Nonetheless, EPCs are still considered an important 
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physiological tool for endothelial regeneration and strong, consistent correlations with 
outcome continue to ignite excitement about their potential as a therapeutic tool.  
 
5.1.2 Laboratory Studies 
In section 3.1, the phenotypic definition of EPCs has been discussed, as has the 
concept of ‘antigenic shift’ whereby the surface markers of EPCs changes over time 
and with cellular maturation (table 12). This, of course, presents a significant problem 
to researchers and choosing which subpopulation of EPCs to investigate can be 
challenging. Particularly given the angiogenic potential of cells also alters as they 
mature221-224. Thus investigating a more mature population of cells (which by this 
point have become highly selected and some of which may have already become 
integrated into the endothelium), may not allow for assessment of the true capacity of 
EPCs for neoangiogenesis. Importantly, given the heterogeneity of the EPC 
population, a robust definition still does not yet exist225. The lack of universal 
agreement on the definition of true EPCs and the difficulty in reliably identifying a 
subpopulation with an evolving phenotype was recognized early in this work. In 
response to this observation, we opted to change nomenclature from EPC to CPC for 
the remainder of the study (section 3.1.2). 
 
In section 3.2, the two main laboratory techniques for enumerating CPCs were 
compared and contrasted. Both processes have a steep learning curve and require 
meticulous attention to detail. Cell culture in addition requires a sterile working 
environment, utilized effectively to minimize contamination and growth of bacteria 
and yeasts. Despite this, reproducible results for either technique were achievable. We 
however report very little correlation between the two modalities and observed 
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frequent inconsistencies in various parameters during cell culture: (1) the size of EC-
CFUs and proportion of single cells fluctuate significantly, even on the same culture 
plate; (2) the ability of CPCs to migrate towards one another to form EC-CFUs varies; 
and (3) the rate of CPC differentiation and proliferation may affect the number of EC-
CFUs, despite similarities in CPC counts on separate plates. In contrast, we 
considered that the count of differentiated cultured CPCs by flow cytometry with 
specific mature endothelial markers was a potentially more objective alternative. It 
was on that basis, we continued the remainder of the study using only flow cytometry. 
Naturally, this may have limitations given that one important aspect of CPC biology is 
the ability of these cells to replicate and differentiate. This functional aspect of CPCs 
cannot be assessed by flow cytometry, which allows only assessment of cell counts at 
a static time point rather than allowing dynamic assessment. Also, the lack of 
universal agreement on EPC/CPC definition by either flow, or cell culture implies that 
one cannot be certain that the two subsets are comparable or complimentary when 
assessed simultaneously. One potential way to overcome this may have been to count 
CPCs and perform a cell sort using the flow cytometer at baseline. These cells could 
then be plated and undergo cell culture for later characterization. However, this was 
not possible with the available equipment within our laboratory. Also, cell culture 
may have been influenced by the conjugation of antibodies and additional processing 
steps. 
 
Although much has been learnt about the endothelium and about CPCs, there remain 
some startling gaps in our knowledge. In section 3.3, we sought to define further some 
of the basic (patho) physiological properties of the group of CPCs that were to be 
studied in the remainder of the project. In particular, we investigated the influence of 
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exercise treadmill testing (ETT) on peripheral CPC levels, diurnal variation of CPC 
counts and also the rate of temporal decline in CPCs once held in blood transit tubes 
ex-vivo. The latter two components were considered of fundamental importance when 
assessing CPCs in the laboratory. 
 
Exercise led to significant increases in systolic blood pressure, heart rate, vWF and 
sE-selectin levels, but no significant influence on CPC counts were observed (section 
3.3.3). An exploratory subgroup analysis assessed patients with a negative ETT vs. 
those unable complete the protocol (positive or inconclusive ETT). The cohort with a 
positive ETT had higher median CPC counts across all three time-points, although the 
ΔCPC (from rest to peak exercise) were similar. None of these differences reached 
statistical significance – possibly due to being underpowered. There were no major 
differences in sE-selectin or Vwf levels across the three timepoints, although patients 
with a positive test had borderline significantly lower vWf levels immediately after 
the test. 
 
Median CPC counts showed significant diurnal variation (P=0.011), being 
significantly higher at 12am compared to 12pm (P=0.046) and 12pm compared to 
6pm (P=0.023). Delayed sample preparation by 4 hours did not significantly affect the 
number of CPCs detected, compared to baseline, but there was a significant decline in 
CPC recovery observed when sample processing was delayed by 24 hours (P=0.019). 
 
These initial results were used to help standardize our assessment of CPCs during the 
remainder of the project. It was felt that this was of particular importance given the 
rarity of CPCs and thus essential to ensure that all patients, sampling, techniques and 
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measurement errors were consistent. In all cases, patients were asked to have been 
resting for at least 30 minutes prior to blood sampling, venepuncture was, where 
possible, completed at comparable time points and blood processing completed 
promptly. 
 
5.1.3 Cross-sectional analysis 
The cross-sectional study presented in section 4.1 was designed to allow analysis of 
patients with AF (classified by temporal pattern, section 1.1.4) and both healthy and 
disease-matched controls in sinus rhythm and aimed to establish association between 
CPCs, endothelial damage/activation and other processes that may link to the 
hypercoagulable state – namely inflammation, angiogenesis and apoptosis and to 
further explore whether previously reported aberrations in these and similar 
parameters may be a consequence of AF or due to associated co-morbidities (section 
1.2.5). 
 
In this study (section 4.1.5), comparison of all non-lone AF to the disease control 
group demonstrated a significantly lower level of sFas in the former (P<0.001), with 
the lowest levels of the marker observed in patients with persistent or permanent AF. 
Patients with lone AF had similar levels of all the research indices to the healthy 
control arm, except for sFas ligand and the sFas:sFas ligand ratio, both of which were 
significantly higher amongst the healthy controls (P=0.006 and P=0.014 respectively). 
 
Median CPC levels were significantly higher in lone AF compared to ‘non-lone AF’ 
(P<0.001). Lower levels of both sE-selectin (P=0.042); and vWf (P=.013) were seen 
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in lone compared to non-lone AF patients The presence/absence of AF was not 
predictive of any of the research indices tested. 
 
This study therefore suggests that CPC counts and one index of apoptosis (sFas) 
appear to be abnormal in AF compared to healthy controls, although these indices – as 
well as abnormalities of other markers indirectly assessing endothelial 
damage/dysfunction, apoptosis, angiogenesis and inflammation – are probably more 
related to associated co-morbidities than to AF or indeed the temporal pattern of the 
arrhythmia per se. However, these preliminary conclusions need to be considered in 
light of a number of limitations. Many of these relate to study design, the application 
of statistical analyses and power. The latter, despite our pre-specified recruitment 
numbers being broadly met, it was clear that many analyses had a broader spread than 
was initially anticipated. 
 
There are numerous reports of increased vWf and sE-selectin amongst patients with 
AF with no relationship to the temporal pattern of the arrhythmia99, 326, 377, 379. The 
data from this analysis would be in keeping with this assessment. However, we also 
report that levels of vWf and sE-selectin in lone AF are similar to levels seen in 
healthy controls (and lower than levels seen in non-lone AF) and this raises the 
possibility that the predominant driver of vWf / sE-selectin release is in fact co-
morbidities rather than the rhythm disturbance. This finding is in contrast with 
previous work from our research group where elevated levels of vWf were seen in 
lone AF326, but is in agreement with data from the much larger Framingham study377. 
These two seemingly contradictory observations may relate to ‘publication bias’ – a 
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small study with a positive finding has a better chance of being published and 
therefore it may be prudent to accept the stronger Framingham study as more reliable. 
 
There are presently no other significant studies assessing CPCs in AF and therefore 
the findings in the present analysis reporting suppressed levels of CPCs amongst the 
subgroups of patients with AF who had various co-morbidities and amongst disease-
matched controls compared to those patients with lone AF or healthy controls where 
higher levels were seen are novel. The lack of difference in CPC numbers between 
temporal subtypes of AF observed in this study is similar to that seen with the other 
endothelial markers studied. 
 
Importantly, the differential CPC numbers observed between those with and without 
co-morbidities raises the possibility that CPCs may somehow be implicated in the 
hypercoagulable state (note that the patients with lone AF did by definition have a 
CHADS2 score of 0). This of course may simply reflect the known utility of CPCs to 
reflect vascular health – but such implications can be drawn from other studied 
markers also. It is, tempting to speculate that with enhanced endothelial 
damage/activation in the presence of AF and co-morbidities, reduced CPC numbers 
simply reflects consumption. Investigating which of these options is the most 
plausible is difficult, in part due to significant confounders and in part due to diversity 
of the progenitor cell population. 
 
Previous investigators have also reported that levels of various inflammatory 
cytokines are related to the temporal pattern of AF (sections 1.2.5 and 1.2.6), although 
again, the data is not consistent and there are some discrepancies between studies and 
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between the various molecules tested159. In this analysis, we found no alteration in IL-
6 based on temporal pattern of AF and interestingly found levels in lone AF and in 
healthy controls to be similar to levels seen in non-lone AF, suggesting in this cohort 
at least that IL-6 mediated inflammation was not an important mechanism. 
 
There are numerous plausible explanations for these findings and the discrepancies in 
IL-6 / vWf / sE-selectin data. It is important to note that patients considered to have 
lone AF are highly selected, younger and have no co-morbidities aside from rhythm 
disturbance and therefore, the research indices measured are more likely to reflect the 
arrhythmia. One must also consider the notion that ‘lone AF’ is perhaps a misnomer. 
Indeed, it is a particularly rare entity and if these patients are kept under follow-up 
then it is likely many of them will develop a number of co-morbidities over time. It 
may therefore be argued that at least some are ‘pre’ diabetic or ‘pre’ hypertensive and 
that their co-morbidities have not yet become clinically detectable. Also, some of 
these patients had paroxysmal AF and were in sinus rhythm at the time of blood 
sampling – potentially masking the effects of the arrhythmia on the parameters 
measured. 
  
In addition, section 1.1.2 documents some of the vast array of co-morbidities that 
frequently associate with AF and many of these were not assessed or corrected for in 
this analysis and it is possible that these parameters act as significant confounders 
thereby driving release of various molecules. 
 
In summary, this data adds to the complexity of the hypercoagulable state and now 
permits us to consider the possibility that aberrations in CPCs may also be implicated. 
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However, the precise link between these various pathways is not clear and it is not 
possible to identify cause or effect, nor exclude the interactions from various co-
morbidities. 
 
5.1.4 Longitudinal study 
The cross-sectional study presented in section 4.2 was designed to allow analysis of 
patients with persistent AF undergoing elective DCCV and allow comparison with a 
cohort of disease-matched controls in sinus rhythm. The aim of this study was to try 
and establish whether AF may directly influence the parameters that have already 
been considered as part of the longitudinal study. Analysis of a cohort of patients 
undergoing DCCV allows for intra-individual assessment over a period of time during 
which attempts were made to re-establish sinus rhythm. Such an approach potentially 
allows for more accurate assessment of whether the change in rhythm was of direct 
relevance to the various research parameters. 
 
Our results indicate that there was no significant difference in baseline levels of vWf, 
CPCs, sE-selectin, IL-6, VEGF or sFas/sFas ligand ratio between the cohort with 
persistent AF undergoing DCCV and the disease-matched controls in sinus rhythm. 
The latter group however had modestly higher levels of sFas, but not sFas ligand. 
Also patients with persistent AF had an almost 2-fold higher level of VEGF at 
baseline, although this did not reach statistical significance. 
 
For the persistent AF group, there was a significant increase in median levels of CPCs 
across the peri-DCCV period (P=0.022). Althoguh there was an increase in VEGF 
across all three timepoints this was not significant and there was no change in the 
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other research parameters. Of the 17 (77%) patients who successfully maintained 
sinus rhythm at 4 weeks, the increase in CPCs from baseline was significant 
(p=0.003), but not for those patients who relapsed back into AF (p=0.715). There was 
no significant change from baseline in any of the other markers studied. 
 
Previous research has investigated various parameters peri-DCCV (section 4.2.5) and 
has reported variable response of vWf, VEGF and IL-6. In studies where 
improvements in these indices are seen, investigators have cited their findings as 
reflective of improved vascular health following restoration of sinus rhythm. However 
results are not consistent across the literature with a number of conflicting outcomes. 
Other research groups have investigated CPCs (albeit using an alternative definition) 
peri-DCCV and demonstrated that the number of these cells trends downwards 
following successful restoration of sinus rhythm. This is in contrast to our analysis 
where the opposite effect is seen, but this is not mirrored by improvements in the 
other research indices studied and therefore the interpretation of these findings 
remains open to debate. 
 
It is possible that the increase in CPCs may reflect improved vascular health of 
patients maintaining sinus rhythm. However, section 4.1 has already considered 
various parameters including CPCs and analysed results according to AF temporal 
pattern and the presence / absence of co-morbidities. This study was highly suggestive 
that it was factors other than arrhythmia that led to alterations in CPCs and other 
markers. It therefore seems less plausible that rhythm change in this analysis was the 
sole cause for alteration in CPC counts. 
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As discussed previously (section 5.1.3), it is likely that similar limitations to those 
discussed in the longitudinal study also apply to this analysis including difficulty in 
assessing patients with a broad spectrum of co-morbidities, and various concerns that 
relate to CPC definition.. This includes the highly selected nature of these patients 
where the diagnosis of persistent AF and suitability for cardioversion was based upon 
history and clinician perception of cardioversion potential. 
 
Also, the study design meant that patients undergoing DCCV only had a comparator 
group at baseline and therefore there was only a limited control group. Further 
strength may have been added by also following the control group for serial sampling 
over the 4-week period with repeat blood sampling. 
 
In summary therefore, DCCV seems to lead to higher levels of CPCs with a rise seen 
immediately following the procedure. This appears to increase further at 4-weeks, but 
does not appear to be associated with any significant change in vWf, sE-selectin, 
VEGF, IL-6 or sFas/sFas ligand. The present analysis is in part agreement and in part 
contradictory to other available data and likely reflects the notorious difficulty in 
studying a diverse population where multiple co-morbidities are present. Nonetheless, 
the increase in CPCs with DCCV success may reflect improved vascular health and 
this warrants exploration with a larger study with greater statistical power. 
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5.1.5 Arrhythmia burden study 
The AF arrhythmia burden study is presented in section 4.3. As discussed previously, 
it is unclear from the literature what AF episode frequency / duration is of clinical 
significance. Essentially this study was designed to try and establish whether indices 
implicated in the hypercoagulable state were altered to a similar extent when analysed 
in subgroups with different AFBs ranging from predominantly sinus rhythm to 
predominantly AF. It was unfortunately not possible to assess these patients for CPCs 
as they had to be recruited in collaboration with another centre some distance away. 
Thus we only had the ability to store and process frozen serum. 
 
Based on an analysis comparing sinus rhythm to low (1-10%), medium (10.1-50%) 
and high (>50%) AF arrhythmia burden, our data show no significant differences in 
indices vWf, sEsel or hsCRP across the groups of patients . Median levels of IL-6 
reduced in a stepwise fashion between groups with increasing AF burden, but this was 
not a significant finding (P=0.476). 
 
The body of literature available addressing arrhythmia burden in paroxysmal AF and 
risk of stroke is particularly sparse and it is therefore not possible to conclude 
precisely what AFB increases the stroke risk in paroxysmal AF to levels seen with 
sustained forms of AF. Nonetheless, there are ample available data to conclude that 
paroxysmal AF should be considered as an important clinical entity (sections 1.1.9 
and 4.3.6)398, 399. 
 
Data from the present analysis are potentially of importance and of direct clinical 
relevance when considering patients with paroxysmal and pacemaker defined AF. 
 - 232 - 
Although our understanding regarding the complexity of the hypercoagulable state in 
AF remains incomplete, we report variable aberration of prothrombotic markers in 
this cohort of patients with AF. However, given no appreciable relationship between 
these prothrombotic markers and AFB, it is it is plausible that these abnormalities do 
in fact relate primarily to underlying risk factors, and that such patients should be 
anticoagulated if risk factors dictate. This point adds further weight to the concept that 
arrhythmia burden alone is unhelpful in establishing stroke risk and that the presence 
of AF combined with clinical risk scoring algorithms should remain the predominant 
tool for stroke risk assessment and hence the decision to anticoagulate. However, 
these findings must be interpreted with caution: the population studied was highly 
selected and data may not therefore be applicable to the general population or even 
those patients with non-pacemaker defined paroxysmal AF. Similarly, even though 
the pre-specified power calculation was met, it is clear that for some analyses to be 
interpreted with full confidence, greater numbers still are required. 
 - 233 - 
5.2 Study Limitations 
All studies can be improved and hindsight lends an ideal opportunity to identify 
methodological flaws. If this research was to be reproduced, several alterations should 
be considered and these are discussed in detail: 
 
a) Definition of AF 
The classification of patients according to the temporal pattern of AF is an important 
consideration. Although this method is somewhat arbitrary, given the trend in AF 
towards recurrence (and thereby more persistent forms of AF) it was felt that labelling 
patients based upon the chronicity of AF was the most pragmatic solution to allow for 
assessment of AF ‘severity’. It is of course, fully acknowledged that such a strategy 
may have no bearing on thromboembolic risk and the reasons for this have been 
explored in depth previously (sections 1.1.9, 1.2.2 and 4.3.5). 
 
In the present study, the temporal pattern of AF was based on established international 
guidelines and nomenclature7. However, this is somewhat arbitrary and depends on a 
number of factors – in particular the expertise and experience of the treating 
cardiologist and upon patient age. For example, patients who are younger are more 
likely to be thought to have persistent AF and thus be offered cardioversion, whereas 
more elderly patients are more likely to be assumed to have permanent AF and 
thereby be offered only a rate control strategy. Although this would seem entirely 
reasonable based upon the relative merits of each strategy and success of each 
strategy (section 1.1.6), this does allow for early introduction of recruitment bias. 
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This is particularly evident in this analysis where patients with persistent AF were 
younger with less co-morbidity and this is perhaps reflected in the obviously high 
immediate success rates seen for cardioversion. If further studies based upon AF 
temporal pattern are to be conducted, then it may be important to consider a highly 
aggressive cardioversion strategy from the outset, with patients only characterized as 
having permanent or paroxysmal AF if cardioversion fails or if there is evidence to 
support these diagnoses from an early stage (e.g. Holter study). However, given data 
from clinical trials suggesting that aggressive rhythm control strategies may be 
inferior for many patients, such an approach would require careful consultation and 
consideration of ethical matters. 
 
An alternative approach may be to consider an animal model of AFto help further 
understand some of the more basic concepts of the hypercoagulable state in a 
controlled fashion. This has been done successfully in the past using advanced pacing 
techniques. Although this is somewhat artificial and detached from a ‘real-world’ 
assessment, such an approach would allow for assessment of the direct influence of 
the arrhythmia on various parameters being tested and potentially allow for removal 
of confounding factors by greater standardization. Again this would require careful 
ethical consultation. 
 
Similarly the definition of lone AF may be open to debate. In most studies lone AF is 
considered to be AF in persons below the age of 55 years with a structurally normal 
heart and without any com-morbidities. AF by this definition is a rare entity and it is 
therefore extremely difficult to recruit such persons, many of whom tend to have 
paroxysmal forms of the arrhythmia. The potential sequelae of this are that some 
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patients with lone AF will inevitably be in sinus rhythm at the time of recruitment and 
indeed may predominantly be in sinus rhythm with only have sporadic bouts of AF. 
Also, there are some doubts as to whether lone AF is ever truly ‘lone’ - as many will 
develop co-morbidities such as hypertension or diabetes mellitus  if they are followed 
up. Thus they may be considered pre-hypertensive. or pre-diabetic, potentially 
skewing any analysis of these patients on the basis that they are otherwise healthy. 
 
b) Mode of patient recruitment 
Each of the patients in this study was carefully recruited from a pool of patients 
attending our AF outpatient clinic. This strategy again induces recruitment bias for a 
number of reasons. Firstly, patients referred into this clinic represent those where AF 
has been detected. This may have been an incidental finding when the patient attended 
a doctor for other matters – but this automatically implies co-morbid illness. 
Alternatively, AF may have been the primary problem – i.e. the patient had reported 
symptoms related to AF. In either situation, the patients recruited become less 
representative of the general population as they have been pre-selected. Additionally, 
few units within the UK have a dedicated AF clinic or a particular interest/expertise. 
Again, this implies bias – as provision of a particular service means that patients are 
more likely to be referred or specialist advice sought. Additionally, due to the highly 
specialized nature of our AF clinic, patients may be managed in a slightly different 
manner compared to elsewhere in secondary care. Recruitment in a multi-centre 
fashion may help avoid the inevitable bias of recruiting solely from a specialized 
centre. 
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c) Study design 
The studies within this thesis were designed to test the hypotheses (section 2.1.3) in as 
logical a manner as possible. However, the very design and even conduct of these 
studies may be a source of bias and limitations. For example, the cross-sectional study 
(section 4.1) offers a comparison of patients with differing temporal patterns of AF. 
This definition of AF can be somewhat arbitrary this has already been discussed as a 
limitation above. However, were the study to be conducted by another researcher, 
some patients may have been classified as having an alternative temporal form of AF 
as this is a particularly subjective diagnosis. 
 
Also the cross-sectional design, did not allow for patients to be matched – i.e. patients 
were recruited consecutively and classified as appropriate, but this did not necessarily 
lead to similar proportions of patients with various co-morbidities in each group. This 
is difficult to correct for, aside from boosting recruitment to a higher level. 
 
Similar concerns can be applied to the longitdunal study (section 4.2). Also, in this 
study, patients undergoing cardioversion only had a control group at the first 
timepoint. Where sequential measurements were taken, this had to be compared back 
to the samples taken at baseline – i.e. each patient was his/her own control. This does 
not allow consideration of other parameters that may have influenced biomarker 
levels (e.g. time or assay varation) and therefore to perform serial ampling on the 
control group would have improved the study. 
 
In the arrhythmia burden study (section 4.3), the group of patients considered to have 
sinus rhythm had had previously documented bouts of AF (although none during the 
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study period) and therefore may not be considered pure controls. Also patients being 
recruited in another centre, prevented us from running samples on the flow cytometer 
for CPCs and this therefore limits the ability to fully mate findings from this study 
with the remainder of this thesis. 
 
d) Power / Statistical Analyses 
For each study, hypotheses were to be tested by recruitment of patients to a level pre-
specified from a detailed power calculation. In each case, this was based upon data 
from previously published studies and/or pilot data from our own or related research 
groups. However, these calculations were primarily based on data for CPCs and not 
necessarily for other markers. This was not entirely unreasonable, as similar markers 
run in the department previously had not required patient numbers hugely different to 
those calculated here. Although the power calculation was broadly met in each study, 
it is clear that the data spread for the markers studied was broad. This is clearly 
obvious in some analyses (e.g. VEGF section 4.2) where a trend is clearly apparent 
and the P value remains well above 0.05. Thus if the study were to be repeated, larger 
patient numbers would be recommended. 
 
In each study, established statistical analyses were applied. In all cases, the test used 
was appropriate for the data being handled (e.g. median, interquartile range and non-
paramteric tests were applied to non-parametric data and so on). Nonetheless, in some 
analyses, especially correlations and multiple regression, large numbers of statistical 
comparisons were made, thereby increasing the probability of finding a positive 
association by chance alone. This was in part accounted for by reducing the P-vaue 
considered as significant to less than 0.01 for these particular analyses. However, 
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even with this change 1 in 100 tests is likely to prove ‘significant’ by chance. It is 
therefore essential to consider these analyses as illustrative only. If more detailed 
association is required, entering fewer variables into the equation may improve 
accuracy. 
 
e) Substitute indices for hypercoagulability 
The present analysis used a number of laboratory indices in assessment of endothelial 
function, inflammation and hypercoagulability. The interaction and importance of 
each of these processes in terms thrombogenesis has been discussed in detail in 
section 1.2 but remains particularly complex and poorly understood. Moreover, it is 
not clear whether each index directly relates to clinical outcome (i.e. stroke) in AF. Of 
course, such links are now harder to establish given that based on trial evidence 
various interventions (e.g. anticoagulation) are offered to reduce event rates. 
 
Of the many indices tested, each plays a subtle and discrete role which may not fully 
depict the process each molecule represents. For example, IL-6 release only reflects 
one molecular pathway in an inflammatory response where there is release of 
numerous pro-inflammatory molecules and cytokines, including other interleukins 
and CRP. However, the relative function, activity and interaction of each molecule 
has not yet been fully defined. Thus it is plausible that the complexity of the various 
pathways is lost by over-simplification of measurement of individual assays. 
Moreover, each assay reflects concentration of each molecule rather than functionality 
and the former does not necessarily imply the latter. Such considerations also apply to 
markers that represent endothelial function and activation of the coagulation cascade. 
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The design of the present study was to explore various interactions at the molecular 
level and thereby help guide future research directions which are discussed in detail in 
the next section. To overcome limitations based upon assessment of only a handful of 
indices which do not necessarily reflect all elements of a given process is difficult. 
However as various interactions become detangled and more defined this will no 
doubt become a less daunting task. 
 
To use hard clinical endpoints (e.g. stroke) in a population patients with numerous co-
morbidities requires very large patient numbers and long duration of follow-up in 
order to observe an adequate event rate. Even then, cause and effect remains difficult 
to define and this is plainly obvious in the diversity of stroke-risk algorithms that are 
available some of which have been based on evidence from large studies (section 1.1). 
 
f) Circulating Progenitor Cells 
A number of pitfalls need to be discussed when considering CPCs. The first relates to 
cellular definition. Our understanding of cellular and endothelial rejuvenation remains 
incompletely understood. Although CPCs are thought to play a significant role, their 
precise origin, function and antigen expression remains a matter of debate. The 
complex flux in the latter that seems to occur during cellular maturation until ultimate 
integration within the endothelium has further hampered research efforts. Thus 
individual research groups have used a varied definition for CPCs and thus could be 
measuring cells of entirely diverse functionality. 
 
The method used to detect CPCs is also important. In this thesis we have discussed 
the relative merits of flow cytometry vs. cell culture. On the basis of early laboratory 
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work, our experiments continued without cell culture given significant concern about 
the accuracy of data collected. However, the major advantage of cell culture is the 
ability to assess cellular functionality. 
 
Both techniques have a number of common pitfalls. Sample processing in both 
techniques requires a number of wash stages, which has the potential to lose cells – 
this is of vital importance when measuring cells as rare as CPCs. Additionally, cells 
may lyse during centrifugation or pipetting again leading to aberrant results. In cell 
culture, it is possible to culture cells other than CPCs, although these should not show 
the characteristic morphology, migration and staining characteristics. In flow 
cytometry, sample error may be introduced by inadequate washout from the previous 
sample (which we were careful to avoid). Similarly delays in processing, cell fixation 
with paraformaldehyde etc. may lead to alteration in cellular characteristics. Again, 
we were careful to minimize such events to enhance reproducibility. 
 
Naturally, other limitations are evident. Some relate to laboratory methodology 
regarding ELISA analysis, although each assay was rigorously tested within the 
department to ensure reproducibility. Other considerations must include use of 
statistical analyses which can only imply association, and not cause and effect.  
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5.3 Future Research Directions 
Given the rising prevalence of AF and the strong association of this arrhythmia with 
stroke, research into both the mechanisms of AF and the pathophysiological 
interactions leading to stroke must remain high on the research agenda. However, it 
has become very clear through the conduct of this study that investigating AF as a 
clinical entity is particularly challenging. The reasons for this have already been 
explored in depth, but primarily relate to difficulties in examining data, which may (or 
may not) relate to one or more of the many co-morbidities that frequently co-exist 
with AF. Thus it is imperative that future research be driven by sound hypotheses and 
a methodical approach. Avenues that may merit exploration in future research are 
discussed in brief: 
 
a) Use of biomarkers in refining stroke risk 
The concept of stroke risk stratification to target populations deemed at significant 
risk of thromboembolic events has been discussed in detail in section 1.1. Although 
numerous schema are available, none is ideal with significant discrepancies in terms 
of patient categorization. This is most evident amongst patients categorized likely to 
be categorized as either low- or high-risk for stroke. This potentially can have serious 
implications – excessive anticoagulation in low risk patients can cause harm through 
increased bleeding events, whilst inadequate anticoagulation amongst high-risk 
patients can result in inadequate stroke prophylaxis often by the use of antiplatelet 
agents when anticoagulation (or novel agents) would be more appropriate. 
 
Many stroke-risk schema follow a common theme and primarily base assessment 
upon clinical parameters (e.g. age, blood pressure, diabetes etc.), although some also 
 - 242 - 
consider imaging modalities such as echocardiography or brain imaging. The use of 
biomarkers to refine stroke risk schema has also been discussed and is an area of 
active research405. A number of indices have been considered useful in this setting and 
include vWf and D-dimer, both of which appear to complement existing stroke risk 
stratification schema116, 124, 125. vWf, have limited evidence for . The latter however is 
usually modulated by warfarin and therefore may not be ideal for use in the setting of 
patients already receiving anticoagulation406. Given the spectrum of biomarker 
abnormalities evident in AF – particularly AF with co-morbidities (i.e. those known to 
be at enhanced stroke risk) – the quest to identify a biomarker to reliably indicate 
those patients at greatest stroke risk is an important one and should continue in 
earnest. Of course, any marker used must be robust with an assay that is easy to 
implement in healthcare laboratories. This would ideally be studied in the setting of a 
large trial such that the markers tested can be linked to clinical endpoints (stroke). 
 
b) Atrial fibrillation arrhythmia burden. 
One major concern for clinicians when dealing with patients who exhibit paroxysmal 
AF, relates to thromboembolic risk. Indeed, it is not clear from the available literature 
exactly what frequency / duration of AF episodes puts a given individual at significant 
stroke risk to merit anticoagulation. Similar considerations also apply in patients with 
permanent pacemakers where very brief episodes of AF are sometimes identified at 
routine pacemaker interrogation and there is only limited evidence in the literature 
assessing the clinical importance of this entity. Part of this thesis has investigated such 
considerations and finds no relationship between the prothrombotic indices tested and 
arrhythmia burden. However, it is not possible to directly extrapolate this data in to 
clinical management. 
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 Certainly this topic requires further research and is presently the subject of a number 
of clinical trials407, 408. The recently reported TRENDS study assessed AF burden 
defined by algorithms within existing implantable devices (pacemakers, defibrillators 
etc.) against thromboembolic events collated in a prospective manner408. The 
investigators conclude that the risk of events was low in patients with device defined 
AF compared to AF diagnosed in a more traditional manner, but that greater AF 
burden did correlate to increased risk of embolic events. In a similar study which is 
still in the recruitment phase, investigators are assessing the potential for remote 
device monitoring in AF detection and consequent initiation of early 
anticoagulation407. It is hoped that these trials will further our understanding and help 
identify the importance of the arrhythmia burden in a clinical context. 
 
c) Modulation of stroke risk with antiarrhythmic drugs 
Early trials assessing rate vs. rhythm control in sustained forms of AF did not 
demonstrate any difference in stroke event rates between the two arms, although in 
AFFIRM, there was a trend towards higher mortality and significantly more 
arrhythmic events and hospitalizations in the rhythm control arm (section 1.1)10. Thus 
in many patients rate control may be considered superior. In paroxysmal AF, the 
management strategy is rhythm management (i.e. maintenance of sinus rhythm) by 
default. This is usually achieved through the prescription of various antiarrhythmic 
agents, or ablation, but despite these AF can (and frequently does) recur. In patients 
where long-term maintenance of sinus rhythm is achieved, the stasis component to 
Virchow’s triad is removed. Similarly coagulation abnormalities due directly to AF 
could also be moderated. There is some clinical evidence to support this notion. A 
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post-hoc analysis of a recent trial investigating dronedarone (a novel antiarrhythmic) 
vs. placebo reported a significant 34% reduction in stroke risk amongst those taking 
the treatment409. Thus further research assessing the impact of successful rhythm 
control on stroke rates should be encouraged. 
 
In addition, there are other avenues that merit exploration in particular the impact of 
patients who have undergone AF ablation and are known to be successfully 
maintaining sinus rhythm. Such a cohort could be readily compared pre- and post-
ablation using a number of laboratory assays and thereby help clarify whether various 
abnormalities truly relate to AF or to co-morbidities. Additionally, these patients 
should be followed prospectively to assess for event rates. This is particularly 
important, as long-term maintenance of sinus rhythm following various ablation 
techniques is still unknown given the relative youth of these procedures. 
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5.4 Conclusion 
It is clear that AF satisfies all 3 components of Virchow’s triad for thrombogenesis. 
Although stasis is the most evident feature of this arrhythmia, it is no longer accepted 
that this is the only means through which thrombogenesis occurs. Research has 
demonstrated aberrancies of various pathways, which may be implicated in 
thrombogenesis either directly, or indirectly. However, the endothelium seems to be a 
central link through which these processes interact. The present study has implicated a 
possible link for CPCs in this process. It has, however, not been possible to establish 
cause or effect and formal documentation of the precise interaction of various 
processes involved in thrombogenesis remains elusive. 
 
Finally, the present analysis has established that of the laboratory indices tested in 
paroxysmal AF, are unhelpful in trying to establish what AF arrhythmia burden is of 
enhanced thrombogenic risk and concludes that clinical risk stratification should 
remain the primary tool for assessing stroke risk in any given individual. 
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Appendix 
 
a) vWf ELISA 
 
Brief Method: 
1. Coat microtitre plate with 100 μl of a dilution of primary antisera (35 μl in 20ml 
pH 9.6 coating buffer) at room temperature for >60 minutes or overnight in the 
fridge. 
2. Wash 3x, add 100 μl  1/40 serum or plasma in pbs/tween, or neat tissue culture 
fluid, incubate for >60 minutes at room temperature. 
3. Wash 3x, add 100 μl peroxidase-labelled conjugate (35 μl in 20ml PBS) for >45 
minutes at room temperature. 
4. Wash, add 100 μl substrate (OPD, hydrogen peroxide, citrate buffer). The colour 
develops almost immediately. 
5. Stop with 100 μl acid. Read at 492 nm 
 
Expected values: 
In citrated normal plasma in the region of 100 + 30 IU/dL stable atherosclerosis 
typically 130 + 35 IU/dL, acute coronary syndromes often 150 + 40. Data generally of 
normal distribution. 
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b) VEGF ELISA 
 
Brief Method: 
1. Coat microtitre plate with 112 μl of primary antisera l in 20 ml PBS buffer for 2 
plates overnight in the fridge. 
2. Wash, block with 100 μl /well of 5% Marvel (1g in 20mls PBS-T for 2 plates) for 
1 hour at room temperature. 
3. Wash, add 100 μl of neat plasma, or neat tissue culture fluid, and recombinant 
standards for 2 hours at room temperature. Standards are double diluted down the 
plate. Use fresh tips for each sample. 
4. Wash, add 112 μl of biotinylated anti-human VEGF antibody in 20 ml PBS tween 
for 90 minutes at room temperature. 
5. Wash, add Streptavidin (100μl/well) for 45 minutes at room temperature. 
6. Wash, add 100 μl substrate (Solutions A and B). Blue colour develops well with 
in 20 to 30 minutes 
7. Stop with 50 μl/well acid. Colour goes yellow. Read at 450 nm.  
 
Expected values: 
Data usually not normally distributed. Controls generally have median values of about 
30-50 ρg/ml (but IQR may be over 200 ρg/ml) Patients’ median values generally 100 
to over 200 ρg/ml. Again, wide IQRs. 
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c) soluble E-selectin ELISA 
 
Brief Method: 
1. Coat microtitre plate with 100 μl of capture polyclonal antiserum in pH 9.6 
buffer in the fridge (4oC) overnight or 1.5 hours at room temperature. 
2. Wash, add 100 μl serum/plasma (diluted 1/5 [20% plasma: 80% blue or pbs-
tween buffer] on the plate) or standards (top ‘prepared’ 50 ng/mL) for 1.5 hours at 
room temperature. Also, prepare a sample of the ‘Universal’ plasma. 
3. Wash, add 100 μl detection antibody (one vial in 20 mls PBS/Tween for two 
plates) for 1.5 hours at room temperature 
4. Wash, add 100 μl Streptavidin-HRP conjugate (diluted 1/200 in PBS/Tween, 
i.e. 100 μl plus 20 mls) for a minimum of 20 minutes at room temperature in the dark 
5. Wash, add 100μl substrate (made up from equal volumes of reagents A and 
B). It should go blue. Wait 3 – 5 minutes. The key definition is a clear gradation of 
blue colour from the top to the blank. 
6. Stop with 75μl Acid. It will go yellow. Read at 450 nm. 
 
Expected Values: 
About 20-40ng/mL. The Universal is about 40 ng/mL. 
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d) soluble Fas Ligand ELISA 
 
Brief Method: 
1. Coat microtitre plate with 100μl of primary antisera (56μl of reconstituted primary 
antibody in 10ml PBS for 1 plate) room temperature (working concentration 
2μg/ml). 
2. Wash, block with 200μl /well of 5% Marvel (2.5g in 50mls PBS-T for 2 plates) 
for 1 hour at room temperature. 
3. Wash, add 100µl serum and 100 µl recombinant standards for 2 hours at room 
temperature. 
4. Wash with PBS-T and add 56μl of reconstituted secondary Ab in 10ml PBS-T  
then incubate for 2 hours at room temperature (working concentration 50ng/ml). 
5. Wash, add 100ul/well of streptavidin-HRP (50ul strep-HRP in 10mls of PBS-T 
for 1 plate) and incubate for 20 minutes at room temperature (avoid direct light). 
6. Wash, add 100μl substrate solution 5 mls Colour regent A + 5 mls B for 1 plate. 
Colour will develop in less than 5 minutes. 
7. Stop with 75μl/well acid. Read at 450 nm 
 
Expected values: 
Data usually not normally distributed. Controls generally have median values of about 
5mcg/ml Patients’ median values generally lower. 
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e) soluble Fas ELISA 
 
Brief Method: 
1. Coat microtitre plate with 100μl of primary antisera (56μl of reconstituted primary 
Ab in 10ml PBS for 1 plate) room temperature (working concentration 1μg/ml). 
2. Wash, block with 200μl /well of 5% Marvel (2.5g in 50mls PBS-T for 2 plates) 
for 1 hours at RT. 
3. Wash, add 100µL serum (or EDTA plasma) diluted to 1 in 5 (by adding 20µL of 
sample to 80µL PBS-T) and recombinant standards for 2 hours at RT.  
4. Wash with PBS-T, add 100μl 56μl of reconstituted secondary Ab in 10ml PBS-T 
for 2 hours at RT (working concentration 50ng/ml). 
5. Wash, add 100ul/well of streptavidin-HRP (50ul strep-HRP in 10mls of PBS-T 
for 1 plate) and incubate for 20 minutes at RT (avoid direct light). 
6. Wash, add 100μl substrate solution 5 mls Colour regent A + 5 mls B for 1 plate. 
Colour will develop in less than 5 minutes. 
7. Stop with 50μl/well acid. Read at 450 nm 
 
Expected values: 
Data usually not normally distributed. Controls generally have median values of about 
5mcg/ml Patients’ median values generally lower. 
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f) Interleukin-6 ELISA 
 
Brief method: 
1. Coat microtitre plate with 100μL capture antibody (4g/mL murine monoclonal 
anti-human IL-6) and leave overnight at room temperature 
2. Wash 3 times with PBS-tween 
3. Add 100μL undiluted sample plasma to each well and leave for one hour at 
room temperature. 
4. Wash 3 times with PBS-tween 
5. Add 100μL detection antibody (50ng/mL biotinylated anti-human IL-6) to 
each well and incubate for 2 hours at room temperature 
6. Wash 3 times with PBS-tween 
7. Dilute 100μL streptavidin/HRP in just over 20mLs PBS-tween. Add 100μL to 
each well and incubate for 20 minutes at room temperature 
8. Wash 3 times with PBS-tween 
9. Mix 10.5mL reagent A with 10.5mL reagent B. Add 100μL to each well. 
Reaction will take about 30 minutes at room temperature 
10. Stop with 50μL 1M hydrochloric acid. Read at 450nm OD 
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